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Coronaviruses (CoV) primarily infect the upper respiratory and gastrointestinal tract of birds and 
mammals making them an important class of infections for agriculture, industry and human 
health. In 2003 an endemic of severe acute respiratory syndrome (SARS) resulted in 
approximately 8000 infections with a 10% mortality rate. This discovery added to four 
coronaviruses previously documented as being able to infect and cause disease in humans; OC43-
CoV, KHU1-CoV, 229E-CoV and NL63-CoV. In 2012 Middle East respiratory syndrome coronavirus 
(MERS-CoV) emerged. Both SARS-CoV and MERS-CoV are thought to have originated from 
coronaviruses found in bats which were transmitted to man through different intermediate 
vectors. More recently, SARS-CoV-2 (commonly referred to as CoVid-19) emerged in December 
2019 resulting in a world-wide pandemic. The coronavirus N protein is a ~45kDa protein found 
associated with the genome of the virus. Despite a common function in RNA binding CoV N 
proteins are antigenically distinct making them useful as diagnostic antigens for tests of 
seroconversion. To assess the MERS-CoV N protein as a diagnostic antigen a soluble full length 
His-tagged N protein was expressed using E. coli. Recombinant N protein was purified to 
homogeneity by IMAC chromatography and was observed as a single species of the predicted 
molecular weight with minimum breakdown. When used as a capture antigen in ELISA tests with 
a number of human CoV positive sera, recombinant MERS-CoV N protein was shown to react 
strongly with MERS-CoV positive sera but not with sera from other CoV infections. Similar data 
was obtained by western blot. These data suggest recombinant MERS-CoV N protein is a suitable 
antigen for serosurveillance. The expression of a number of other CoV N proteins to provide a mini 
array of N proteins for tests of a variety of human sera for their history of coronavirus infection 
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DISORDER PLOT WITH THE FALSE POSITIVE RATE THRESHOLD SET TO 5.0%, AGAIN THE AREA OF DISORDER BEING FOCUSED ON 
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TWO BANDS INDICATED THE 200BP DELETION WAS SUCCESSFUL (~1000BP AND ~800BP) THE GEL MOLECULAR SIZES MAY BE 
BETTER ASSESSED WITH A MORE DILUTE LOADING AND/OR LONGER RUNNING OF THE GEL FOR A GREATER RESOLUTION. ....... 151 
FIGURE 40: GEL ELECTROPHORESIS SHOWING FIVE CONSTRUCTS AFTER A DOUBLE ENZYME DIGEST USING NCO1 AND XHO1. 
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6= IBV AND LANE 7=ΔIBV. BANDS DENOTED BY THE LETTER A SHOW THE LARGER HIS-TAGGED VECTOR PTRIEX1 (5301BP) 
AND BANDS SHOWN BY THE LETTER B ARE THE VIRAL-SPECIFIC INSERTS, LANE 6 AND 7 SHOW THE ~200BP DELETION LOST BY THE 
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LANES 12 AND 13 229E-COV, LANES 14 AND 15 IBV, LANES 16 AND 17 ΔIBV AND LANES 18 AND 19 A CELL ONLY CONTROL. 
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FIGURE 43: ELISA RESULTS SHOWING KNOWN POSITIVE HUMAN SERA AGAINST RECOMBINANT NL63-COV PROTEIN. SERA USED IS 
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SERIES. AS SUCH 1= 1:50, 2=1:100, 3=1:200, 4=1:400, 5=1:800, 6=1:1,600, 7=1:3,200 AND 8=1:6,400. ERROR BARS 
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COLOUR CODED; MERS-COV IN BLUE, OC43-COV IN GREEN, NL63-COV IN PURPLE, 229E-COV IN YELLOW AND SARS-COV 
IN RED. THE DILUTION SERIES STARTED WITH THE STOCK SERA BEING DILUTED 1:50 AND FOLLOWED A TWO-FOLD DILUTION 
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NOT SHOWN DUE TO LACK OF REPEATS. THIS SHOWS THERE TO BE STRONG POSITIVE REACTION TO THE MERS-COV POSITIVE 
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YELLOW AND IBV IN GREY. THE DILUTION SERIES STARTED WITH THE STOCK SERA BEING DILUTED 1:50 AND FOLLOWED A TWO-
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The original first draft of the abstract that I summited alongside my poster for the International 
Union of Microbiological Societies in 2014 included the following sentence “without the proof-
reading ability of DNA polymerase, RNA viruses have an increased mutation rate. This, added to a 
large and unpredictable natural reservoir, means that it is likely that new, potentially epidemic or 
pandemic, coronaviruses may emerge in the future.” 
Indeed, post writing this thesis, a novel coronavirus outbreak (SARS-CoV-2, more commonly 
referred to as Covid-19) emerged in December 2019 (Velavan and Meyer 2020). The virus epi‐
centred in Hubei Province of the People’s Republic of China and rapidly spread, resulting in a 
devastating worldwide pandemic.  
The outbreak has meant a change to my current job role as Deputy Head of Science at a secondary 
school. As I am now adjusting to setting distance learning and am currently shielding, as per 
government advice, due to having underlying health conditions. It is for this reason that 
throughout the body of text only the 6 human coronaviruses known at the time of writing are 
largely mentioned.  
The latest report from the world health organisation (WHO) published in December 2020 stated 
that there were 2,566 laboratory-confirmed cases of infection with MERS-CoV, including 882 
deaths giving it a 34.4% fatality rate (WHO 2020). WHO reported SARS-CoV cases as totalling 
8,422 including 916 deaths (fatality rate 10.9%) (WHO 2020). At the time of writing, August 2021, 
Covid-19’s case numbers are estimated to be 207,784,507 resulting in 4,370,424 deaths (fatality 
rate 2.1 %) (WHO 2021). Due to increased understanding of the virus and the implementation of 
various disease transmission prevention strategies, alongside the introduction of vaccination 
programs incidences of new cases and deaths continue to decrease (WHO 2021). Clearly 
understanding coronaviruses in greater detail and working on vaccines, treatments and 
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 Coronaviruses introduction  
Coronaviruses (CoV) are Baltimore group four enveloped viruses with a positive-sense 
ribonucleic acid (RNA) genome. Coronaviruses are of the order Nidovirales, the family 
Coronaviridae and the subfamily Coronavirinae. Coronavirinae consists of four genera; 
Alphacoronavirus, Betacoronavirus, Gammacoronavirus and Deltacoronavirus. The genomic size 
of coronaviruses ranges from 26 kilobases to 32 kilobases, which is the largest of any RNA virus. 
The virions are spherical and approximately 70-120nm in diameter (Graham, Donaldson et al. 
2013). The name coronavirus is derived from the Latin word “corona”, meaning crown or halo, 
and refers to the characteristic appearance of virions under transmission electron microscopy 
(TEM), cryo-electron microscopy (cryo-EM), scanning electron microscopy (SEM) or atomic force 
microscopy (AFM). The projections seen are created by the viral spike (S) glycoproteins, as shown 
in Figure 1. S proteins are homotrimeric single-pass transmembrane (TM) proteins and it is these 
proteins that determine host tropism. Alongside the spike proteins; envelope (E), membrane (M) 
and nucleocapsid (N) proteins all contribute to the overall structure of coronaviruses (de Groot 
2011) (King 2012).  
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1.1.1 Structure and proteins 
 
Figure 1: The basic structure of a coronavirus virion including the four main structural proteins; spike 
(S), envelope (E), membrane (M), nucleocapsid (N) (Peiris, Guan et al. 2004). 
 
 
 S (spike) protein (~180kD) (Graham, Donaldson et al. 2013) 
The spike glycoprotein shown in Figure 1 contains a receptor-binding domain (RBD) used to 
facilitate viral entry into a cell. The RBD is the principle determinant of host range and yet it is 
poorly conserved among viruses; allowing host receptor usage to vary, as shown in Table 1 
(Graham, Donaldson et al. 2013). The S glycoprotein has two subunit domains; the amino-terminal 
S1 domain, where the RBD is located and the carboxy-terminal S2 domain containing the putative 
fusion peptide, two heptad repeat domains and a TM domain (Graham and Baric 2010). S proteins 
can bind to sialic acid (9-O-acetyl neuraminic acid) on the host cell surface which gives the virus 
haemagglutinating ability (Huang, Dong et al. 2015) and antibodies against S protein are 
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Table 1: The coronaviruses used in this study along with their receptor. Table adapted from 
Journal of Virology (Graham and Baric 2010) APN= aminopeptidase N (aka CD13), ACE2= 
angiotensin converting enzyme 2, DC-SIGN= Dendritic Cell-Specific Intercellular adhesion 
molecule-3-Grabbing Non-integrin, DC-SIGNR= dendritic cell-specific ICAM-grabbing non-
integrin, ICAM= intercellular adhesion molecule, LSECtin= liver and lymph node sinusoidal 
endothelial cell C-type lectin, DPP4= dipeptidyl peptidase 4 and CD26= cluster of 
differentiation 26 
 
 HE (Haemagglutinin-Esterase) protein (65kD) 
HE proteins are unique to the Betacoronaviruses subgroup (Huang, Dong et al. 2015). HE is a 
diamer and has been shown to be unessential for replication (Popova and Zhang 2002). The 
protein is used to create a reversible attachment to O-acetylated sialic acids on the host cell by 
acting initially as a lectin and later as a receptor-destroying enzyme (RDEs) in order to facilitate 
the release of viral progeny (Huang, Dong et al. 2015). Antibodies against HE protein can also 
neutralize the virus (Kasai, Morita et al. 1998).  
 M (membrane) protein (22-25kD) (Ujike and Taguchi 2015) 
The M protein is the most abundant protein in the virus envelope (Ujike and Taguchi 2015). It 
consists of a short, glycosylated N-terminal ectodomain made up of three TM domains (referred 
to as tm1, tm2 and tm3 regions) and a long C-terminal cytoplasmic tail domain. The protein 
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provides the virion some rigidity and helps the nucleocapsid to attach to the membranes of 
internal structures such as the Golgi apparatus (Ujike and Taguchi 2015). 
 E (envelope) protein (9-12kD) (Wilson, McKinlay et al. 2004) 
Found on the viral membrane the envelope protein is found around the nucleus and at the cell 
surface in infected cells. The E protein is important in virion assembly and morphogenesis. It has 
also been shown to have ion channel activity with immunopathological consequences (Verdiá-
Báguenaa, Nieto-Torresb et al. 2012) 
 N (nucleocapsid) protein (42-50 kD) (Zuwała, Golda et al. 2015) 
The main viral protein that this study is interest in is the N protein. The CoV N protein is usually 
phosphorylated. However, using the prokaryote Escherichia coli (E. coli) as an expression system 
results in limited eukaryotic post-translational modifications; meaning that phosphorylation will 
not occur (Khow and Suntrarachun 2012). The size of the N protein varies depending on virus and 
phosphorylation, see Table 2. The difference in expected molecular weight and observed 
molecular weight may be account for by the possible addition of a 6x polyhistidine tag. The 6x 
polyhistidine tag is often used to purify the recombinant proteins and has a molecular weight of 
0.8kDa (Terpe 2003).  The N protein is one of the most abundant viral proteins produced in an 
infected cell. It is a multifunctional protein with roles in replication, transcription and translation 
(Berry, Manasse et al. 2012). It has been shown to act as a viral suppressor of RNA silencing in 
mammalian cells (Cui, Wang et al. 2015), and can also induce apoptosis and reorganise actin in 
infected cells (Surjit, Liu et al. 2004).  
As is typical of positive strand RNA viruses, coronaviruses do not incorporate the RNA polymerase 
into the virus particle; rather the polymerase is expressed after infection by using the positive 
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Table 2: The FASTA format sequence of the coronaviruses used in this study alongside their 
predicted and referenced molecular weights. Predicted molecular weights generated using 






Coronavirus genes are arranged in the order 5’-rep1a-rep1b-S-E-M-N-3’. Some also contain the 
additional haemagglutinin esterase gene, as shown in KHU1-CoV and OC43-CoV in figure 2 (Kazi 
2005). The replicase gene (rep) accounts for approximately two thirds of the genome and includes 
the two open reading frames (ORFs) ORF1a and ORF1b. Orf1a encodes a polyprotein of ~450-
500kD and Orf1b a polyprotein of ~750-800kD. Translation of the entire rep region occurs using 
a -1 ribosomal frameshift signal located at the ORF1a/ORF1b junction. Orf1a encodes a 3C-like 
protease (3CIpro) similar to picornavirus 3C proteinases (Hegyi and Ziebuhr 2002). The CoV 
replicase also includes a series of domains with enzymatic activities including a large RNA-
dependant RNA polymerase (RdRp) (Gorbalenya, Enjuanes et al. 2006). 
 
Figure 2: Schematic of the coding potential of six human coronavirus (HCoV) genomes and an 
avian coronavirus IBV (which will later be used as an experimental control). Colour coding 
indicates genes in red, coding sequences (CDS) in blue, mature peptides/open reading frames 
(ORFs) in yellow. Image created using Geneious version 8.0.5 (http://www.geneious.com 
(Kearse, Moir et al. 2012)). All sequences used were sourced from the National Centre for 
Biotechnology Information (NCBI) website (http://www.ncbi.nlm.nih.gov) (229E-CoV = 
NC_002645.1, KHU1-CoV = NC_006577.2, IBV= NC_001451.1, MERS-CoV= NC_019843.3, NL63-





Once the viral particle enters the cell it is uncoated, and the genome is deposited in the cytoplasm. 
The Coronavirus genome has a 5’ methylated cap and a 3’ polyadenylated tail (Bouvet, Debarnot 
et al. 2010). This allows the RNA to attach to ribosomes for translation. As with all positive-
stranded RNA viruses, replication of CoV genomes is mediated through the continuous synthesis 
of full-length negative stranded-RNA. This becomes the template for the synthesis of progeny 
virus genomes. The RNA-dependent RNA polymerase (RdRp) template switch allows for the 
production of 3′-coterminal nested set of subgenomic mRNAs (sgmRNAs) which are translated 
into virion structural proteins (SP) or to non-structural accessory proteins (NSP). There are up to 
16 NPS which aid the replication process alongside the recruitment of host proteins (Wu and 
Brian 2010). Replication occurs within double-membrane vesicles (DMVs) (Angelini, 
Akhlaghpour et al. 2013). The viral N protein has also been shown to co-localize with the 
replication complex in DMVs and is thought to play a role in transcription. Studies have shown 
that only background levels of CoV RNA synthesis occurs in the absence of N protein (Almazan 
2004). N proteins are important for viral replication, in the case of mouse hepatitis virus (MHV), 
a commonly used animal model for human coronaviruses, it has been shown the that N protein 
interacts with nsp3 a component of the replication/transcription complexes (RTCs) via two 
distinct regions, failure to do so results in impaired stimulation of genomic RNA and viral mRNA 
leading to decreased MHV replication and progeny production (Cong, Ulasli et al. 2020) 
1.1.4 Mutation 
RNA polymerase does not have the same proof-reading capability as DNA polymerase and, as 
such, it is prone to a high error rate during RNA replication. The large size of the coronavirus 
genome means that there can be several mutations in each progeny virus; these can be deletions, 
additions or substitutions. Recombination events also occur, which is unusual in non-segmented 
RNA viruses, but may be as a result of the discontinuous mode of RNA replication that occurs. Both 
these facts allow for the rapid evolution of the virus and can result in the introduction of new 
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strains.  Although the mutation rates of coronaviruses are relatively high it is worth noting that 
CoVs express a 3′-to-5′ exoribonuclease in non-structural protein 14 (nsp14-ExoN) which has 
been shown to have an RNA proofreading function, one study showed that ExoN negative strains 
of SARS-CoV had a 16-fold increase in mutation rates, so some proofing is in place (Smith, Blanc 
et al. 2013). 
1.1.5  Pathology 
CoVs primarily cause upper respiratory tract infections in humans and fowls, and enteric 
infections in porcine and bovine species. HCoV infections have also been known to cause 
respiratory, enteric, hepatic, renal and even central nervous system problems (Rousset, Moscovici 
et al. 1984) (L Enjuanes 2008). Alongside Rhinoviruses, Coronaviruses are believed to cause a 
significant percentage of all common colds in human adults; with some estimates as high as 30% 
(Mesel-Lemoine 2012).  The severity and location of a CoV infection varies depending on strain. 
229E-CoV and NL63-CoV target epithelial cells and both can lead to respiratory infections and 
bronchiolitis. OC43-CoV is known to target the lower respiratory tract and can result in 
pneumonia alongside the common cold.  
Animal Alphacoronaviruses include transmissible gastroenteritis coronavirus (TGEV), an 
enteropathogenic CoV that infects lung cells and the villus epithelial cells of the small intestine in 
pigs. Other Alphacoronaviruses include porcine respiratory CoV (PRCV) (Cox, Hooyberghs et al. 
1990), porcine epidemic diarrhoea virus (PEDV) (Utiger 1995), canine coronavirus (CCoV) (Erles, 
Toomey et al. 2003) and feline coronavirus (FCoV) (Holzworth 1963).  
Betacoronaviruses include murine CoVs. MHV has a high mortality rate and causes a progressive 
demyelinating encephalitis in mice. As such, it is often used as a murine model for multiple 
sclerosis. Commonly used laboratory strains infect the liver and brain and so are also used as 
animal models for hepatitis and encephalitis. KHU1-CoV is another Betacoronavirus which infects 
human alveolar cells. Severe acute respiratory syndrome corona virus (SARS-CoV) has been 
classified as a Betacoronavirus sub-group B and causes severe acute respiratory disease, 
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pneumonia, diarrhoea and can prove to be fatal. The Middle East respiratory syndrome 
coronavirus (MERS-CoV) is another Betacoronavirus (sub-group c) which leads to acute 
respiratory disease, kidney failure, multiple organ dysfunction and can cause fatalities.  
Gammacoronaviruses include infectious bronchitis virus (IBV) which infects ciliated epithelia of 
the nose and trachea in chickens. It also targets their urogenital tract. 
1.1.6  Immune response 
The immune response is a complex, vast and multifarious system which is hard to view in its 
entirety. CoV infections have several known affects upon the host including up regulation of genes 
involved in inflammation, coagulation and the stress response. Inflammation response includes 
the up-regulation of interleukin 8 (IL-8). IL-8 induces chemotaxis in target cells, namely 
neutrophils, directing them towards the site of infection. IL-8 is also known to promote 
angiogenesis, the formation of new blood vessels from pre-existing vessels. Studies have shown a 
positive a correlation between the IL-8 levels and disease severity (Yoshikawa, Hill et al. 2009). 
Interferon gamma (IFN-γ) is also released by the host in response to CoV infections. IFN- γ 
promotes the differentiation of Th1 cells into cytotoxic CD8+ T-cells which can destroy infected 
cells. When a cell becomes infected several cellular transcription factors become activated, such 
as interferon regulatory transcription factor 3 (IRF-3) and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB). These, in turn, activate the production of type I IFNs which 
bind to the IFN-α/β receptor (IFNAR) and initiate the Janus kinase and signal transducer and 
activator of transcription (JAK/STAT) pathway, causing activated transcription factors to 
translocate to the nucleus. The transcription factors activate genes containing interferon-
stimulated response element (ISRE) in their promoters. These genes, once activated, enable the 
cell to enter a state that resists viral infection and can prevent virus replication (Garcia-Sastre and 
Biron 2006). Although the immune response is activated with the intention of being beneficial 
towards the host, many of these responses are general in their effects once initiated and collateral 
damage on non-infected cells can prove detrimental to the host.  
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More recently a number of studies have focused on antibody response to SARS-CoV-2 in order to 
try to ascertain whether the type and levels of patient antibodies can predict susceptibility to 
secondary infection and/or indicate immunity. Papers discussing the antibody response to SARS-
CoV-2 published between 01/01/2020 and 26/06/2020 were comprehensively evaluated in a 
systematic review (Post, Eddy et al. 2020). The review included 150 papers. The studies were said 
to be of variable quality and had heterogeneity of methods, participants, outcome measured and 
assays used and lacked the characterisation of longer-termed patterns. As such, large, cross-
national cohort studies using appropriate statistical analysis and standardised serological assays 
and clinical classifications remain needed. That being said, the review found that IgM was 
consistently detected before IgG in included studies, with peak titres detected at weeks two to five 
and declining over a further three to five weeks post-symptom onset, varying on the patient group. 
IgG titres peaked around weeks three to seven post-symptom onset then plateaued, generally 
continuing for at least eight weeks. Neutralising antibodies were detectable within seven to fifteen 
days following disease onset, increasing until days 14–22 before levelling and then decreasing. 
Titres of neutralising antibodies were lower in asymptomatic or clinically mild disease cases. 
Convalescent plasma has been used to source specific and potent neutralising antibodies; cross-
reactivity but limited cross-neutralisation with other human coronaviridae was reported. The 





 Human coronaviruses 
1.2.1 Brief overview 
For many years, only two human coronaviruses were known; 229E-CoV and OC43-CoV. The 
discovery of SARS-CoV in 2003 added a third and by the end of 2004 three independent research 
laboratories reported the discovery of a fourth. It was named NL63-CoV (van der Hoek, Pyrc et al. 
2004). In 2005, a fifth HCoV was discovered in Hong Kong, called KHU1-CoV (Vabret, Dina et al. 
2006). In September 2012, a sixth human coronavirus was discovered and initially referred to as 
Novel Coronavirus 2012. It would later be called Middle East Respiratory Syndrome Coronavirus 
(MERS-CoV) (Zaki, van Boheemen et al. 2012). More recently, SARS-CoV-2 (commonly referred to 
as Covid-19) emerged in December 2019 resulting in a world-wide pandemic (Velavan and Meyer 
2020). 
1.2.2 Evolution   
Bat coronaviruses are thought to be the gene source of Alphacoronavirus and Betacoronavirus, 
and avian coronaviruses as the gene source of Gammacoronavirus and Deltacoronavirus (Woo, 
Lau et al. 2012). The most recent common ancestor of Alphacoronavirus has been placed as 
~2,400 BC, Betacoronavirus ~3,300 BC, Gammacoronavirus ~2,800 BC and Deltacoronavirus 
~3,000 BC (Woo, Lau et al. 2012).  
The virus continues to evolve. More recently identified strains of non-human coronavirus include 
a porcine enteric alphacoronavirus, swine acute diarrhoea syndrome coronavirus (SADS-CoV), 
similar to bat HKU2, responsible for the death of 25,000 piglets in China in 2016-17  (Gong, Li et 
al. 2017, Zhao, He et al. 2018). And following a coronavirus (FRCoV) being identified in ferrets 
(Mustela putorius furo) in 2006 (Wise, Kiupel et al. 2006), a 2017 study has identified ferret enteric 




1.2.3 Severe Acute Respiratory Syndrome (SARS) 
In 2003, following the outbreak of SARS-CoV which had begun the previous year in Asia, the World 
Health Organization issued a press release stating that the causative agent had been identified as 
a novel coronavirus by a number of laboratories (WHO 2003). The epidemic resulted in over 8,000 
infections, about 10% of which resulted in death (Li, Li et al. 2005). Angiotensin-converting 
enzyme 2 (ACE 2) was shown to be the cellular receptor for SARS-CoV (Li, Li et al. 2005). Once 
infected, a patient’s first symptom was that of a fever; with temperatures being equal to, or 
exceeding, 38oC (Xu 2003). Days 2-7 included flu-like symptoms such as chills, headache, muscle 
aches, sore throat, malaise, mucus etc. Various cohort studies have been conducted looking at the 
frequency of each symptom and the results of four of these are detailed in Appendix one. This 
developed into an upper respiratory tract infection resulting in a dry cough and shortness of 
breath. In some cases, as the infection progressed, pneumonia could be confirmed using a chest 
X-ray. The infection, if it develops further, results in respiratory failure and acute respiratory 
distress syndrome (ARDS) which can be fatal. The incubation of SARS-CoV is ~ 2–10 days. The 
body produces immunoglobulin M (IgM) as an antibody response during the acute phase of 
infection (~3 -12 weeks), IgG is produced later and peaks at week 12 (Xu 2003).  SARS-CoV is 
thought to have originated in bats and spread through an intermediate animal known as a masked 





1.2.4 Middle East Respiratory Syndrome (MERS)  
The Middle East Respiratory Syndrome coronavirus (MERS-CoV) is a Betacoronavirus which was 
first reported on 24th September 2012 on Program for Monitoring Emerging Diseases (ProMED-
mail) by Egyptian virologist Dr. Ali Mohamed Zaki in Jeddah (Zaki, van Boheemen et al. 2012). The 
largest outbreak of the disease occurring outside of the Middle East arose on the 20th May 2015 
when a 68-year-old man was diagnosed with the disease in Korea (Lee 2015). The patient in 
question had recently returned from visiting Bahrain, Saudi Arabia and Qatar and it is thought 
that he picked up the virus whilst in the Middle East (Lee 2015). As shown in the epicurve in Figure 
3, there was a second large outbreak of the virus in Korea. There have been 185 laboratory 
confirmed cases of MERS-CoV in Korea resulting in 36 deaths, there was also one case reported in 
China when a patient travelled there from Korea (Park, Perera et al. 2015)(WHO 2017).  As of 
March 27th 2020 WHO has been notified of 2494 laboratory-confirmed cases of infection with 
MERS-CoV, including at least 858 related deaths, giving MERS a 34.4% mortality rate (WHO 2020). 
Fortunately sustained human-to-human transmission has not been well documented (Timothy M. 
Uyeki 2016). A total of 27 countries have reported cases of MERS-CoV. Bahrain, Iran, Jordan, 
Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates (UAE), and Yemen have all 
reported cases within the Arabian Peninsula. Travel-associated cases seen outside of this area 
have occurred in; Algeria, Austria, China, Egypt, France, Germany, Greece, Italy, Malaysia, 
Netherlands, Philippines, Republic of Korea, Thailand, Tunisia, Turkey, the United Kingdom (UK), 
and the United States of America (USA) as shown in a map produced in 2017 in Figure 3, although 
new cases have been reported since the image was produced these have all occurred in countries 




 Figure 3: Middle East respiratory syndrome coronavirus map and epicurve: A global map 
showing the locations of the 1936 reported MERS-CoV cases up to 2017, colour coded by 




 Signs and symptoms 
In MERS-CoV infections, sufferers present with serious respiratory illness (fever, cough, shortness 
of breath and breathing difficulties). Pneumonia is common. Some patients also develop 
gastrointestinal symptoms, including diarrhoea and kidney failure. In people with immune 
deficiencies the disease may have an atypical presentation. Unlike most respiratory viruses MERS-
CoV has a strong tropism for non-ciliated bronchial epithelial cells (Kindler, Jonsdottir et al. 2013). 
The virus has been shown to evade innate immune responses and to antagonise IFN production 
in infected cells (Raj, Mou et al. 2013). It was initially thought that MERS-CoV would use the same 
receptor as SARS-CoV (ACE2) (Li, Moore et al. 2003). However, studies showed that this was not 
the case and instead dipeptyl peptidase 4 (DPP4) acted as the cellular receptor (Müller 2012).  
 Origin 
It is not certain whether the emergence of MERS-CoV occurred as a result of a single zoonotic 
event with subsequent human-to-human transmission, or if the fact that there are multiple 
geographic sites of infection is a result of multiple zoonotic events from a common unknown 
source. A study by led by Professor Ziad Memish estimated perhaps as many as 7 separate 
zoonotic transmissions may have occurred (Cotten, Watson et al. 2013).  
 Natural reservoir 
1.2.4.3.1 Bats  
The original source of the virus is thought to be bats. Bats have a widespread geographical 
distribution, are capable of flight and are the second largest group of mammals, behind rodents. 
These factors facilitate their role as natural viral reservoirs. Analysis has shown MERS-CoV to have 
sequence homology with both bat HKU4-CoV and HKU5-CoV, carried by the genera 
Tylonycteris and Pipistrellus respectively (Memish, Mishra et al. 2013). However, the study was 
not without problems as the collection of samples and cold chain transport was compromised. In 
the study 1003 bats were sampled from the Middle East, only one of which proved positive for 
MERS-CoV. This indicated that an intermediate vector was likely to be required to facilitate the 
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spread of the virus. This is similar to the progression of the SARS-CoV whereby Rhinolophid bats 
were identified at the viral reservoir and civets the intermediate vector (Lau, Woo et al. 2005). 
229E-CoV is also believed to have a bat origin in Hipposideros caffer rubber bats (Pfefferle, Oppong 
et al. 2009, Drexler, Corman et al. 2014) as does NL63-CoV in Perimyotis subflavus bats (Huynh, Li 
et al. 2012). 
1.2.4.3.2 Camels 
Further investigative studies suggested that dromedary camels were likely to be the intermediate 
vector (Alagaili, Briese et al. 2014). In December 2013, a study conducted in the Middle East 
showed no evidence of previous MERS-CoV infection in sheep, goat, cattle or chickens; however, 
90% of camels (280 out of 310 sampled) tested positive for previous exposure (Hemida, Perera 
et al. 2013). Between 2016 and 2018, one study collected a total of 4027 nasal swabs and 3267 
serum samples from dromedary camels in Egypt, Senegal, Tunisia, Uganda, Jordan, Saudi Arabia, 
and Iraq  (Kandeil, Gomaa et al. 2019). The study used RT-PCR and detected MERS-CoV RNA in 
nasal swab samples from Egypt, Senegal, Tunisia, and Saudi Arabia. Samples from all counties 
showed antibodies in microneutralization assays. Positive PCR samples were partially sequenced, 
and a phylogenetic tree was constructed. The study’s results indicate the widespread distribution 
of the virus in camels, however the study highlighted the need for a systematic active surveillance 
and longitudinal studies for MERS-CoV to better understand the epidemiology of the disease and 
dynamics of viral infection (Kandeil, Gomaa et al. 2019). Ancestor analysis suggests that the jump 
of MERS-CoV from bats to camels may have occurred approximately 20 years ago in Africa, with 
the camels then being imported into to Arabian Peninsula (Corman, Ithete et al. 2014). Although 
camels do not often present with clinical signs of infection (Chu, Poon et al. 2014) more recent 
serological studies further backdated the presence of MERS-CoV antibodies in camels, suggesting 
that MERS-CoV has been present in dromedary camels for at least three decades in the Middle 
East and North and East Africa (de Wit, van Doremalen et al. 2016).  
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1.2.4.3.3 Other animals potentially susceptible  
In vitro testing has been conducted in several studies in order to assess permissiveness of selected 
cell culture models, with the aim of identifying other potential other intermediate host species of 
MERS-CoV. One study looked at livestock, primate, rodent, insectivore and bat cell line 
susceptibility and saw efficient viral replication (>9.3 log10) virus RNA genome (equivalents/mL 
of cell culture supernatant) in goat kidney and lung cells, alpaca kidney cells and in dromedary 
umbilical cord cells (Eckerle, Corman et al. 2014). However, the same study found that the virus 
did not replicate in sheep, cow, rodent, or insect cells; even though all cell lines tested expressed 
the receptor DPP4 (Eckerle, Corman et al. 2014). Another animal study showed rhesus macaques 
(Macaca mulatta) were susceptible to infection but that hamsters, ferrets and mice were not (van 
Doremalen, Miazgowicz et al. 2014). The DPP4 recognizing RBD  is found in the S1 N-terminal of 
the S protein and consists of ~240 residues spanning aa 367-606 (Hu, Ge et al. 2015). The study 
predicted that camels, goats, sheep, and cows could all potentially be used as intermediate host 
reservoir species for MERS-CoV (van Doremalen 2014). Horse DPP4 receptors have also shown 
to be permissive to infection (Barlan, Zhao et al. 2014). To summarise, published results have 
shown that MERS-CoV is able to infect and replicate in cell lines derived from humans, non-human 
primates (NHP), bat, swine, goat, horse, rabbit, civet, and camel cell lines, but not from mice, 
hamster, dog, ferret, and cat cell lines (Chan, Chan et al. 2013, Eckerle, Corman et al. 2014, van 
Doremalen, Miazgowicz et al. 2014, Haagmans, van den Brand et al. 2015). This count have 
potential agricultural implications and may affect disease outbreaks and spread in the future. 
1.2.5 Diagnosis 
Diagnostic testing of suspected cases during dangerous emerging coronavirus outbreaks can 
prove beneficial in containing the outbreak and can also provide information on the disease 
source and progression. Methods of detecting HCoV infections include isolating the virus by 
culture, visualization of the virions using TEM and detection of current or prior infection using 
serological techniques. Tissue culture and cell line selection is difficult when culturing the virus, 
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especially in relation to a previously unknown strain. TEM can be beneficial in that it does not 
require any reagents specific to the virus; however, it is not specific and may not be able to identify 
a virus past the family level (Goldsmith and Miller 2009). Presently the most used diagnostic 
techniques are based around the polymerase chain reaction (PCR), whereby specific or broadly 
covering primers can be used to detect viral presence. Real-time reverse transcriptase PCR (RT-
PCR) can be used for rapid identification of MERS-CoV from patient samples (Corman, Eckerle et 
al. 2012). The primers used are called ‘UpE’ (targets elements upstream of the E gene) and ‘1A’ 
(targets the ORF1a gene). However, there are some technical difficulties in using PCR based 
methods, mainly that the tests are conducted on patient samples with potentially live virus. This 
clearly has health and safety implications for any health care professional collecting samples and 
any laboratory worker conducting the screening. Detection rates by early quantitative RT-PCR 
(qRT-PCR) assays are often low as they rely on samples being taken during viral shedding and 
correct sample handling. Specificity can also be dubious as there is a chance for cross-
contamination in laboratories processing multiple samples (Yam, Chan et al. 2003) (Patrick 2006). 
On 17th July 2015 emergency use authorization was given to a commercially developed RealStar 
MERS-CoV RT-PCR Kit U.S. (Altona Diagnostics GmbH, Hamburg, Germany) (Timothy M. Uyeki 
2016) for the detection of MERS-CoV infection. Using immunofluorescence assays (IFA) has also 
been investigated, however antibodies against Betacoronaviruses have been found to cross-react, 
which limits the use of the procedure in diagnostics (Corman, Muller et al. 2012). There remains 
a lack of a readily available, rapid, simple and accurate test for the detection of MERS-CoV. This 
may be in part due to the limited availability of clinical specimens and MERS-CoV isolates from 
infected patients. Paired acute and convalescent serum samples would be needed in order to 
develop serological tests to confirm MERS-CoV infection in cases when viral shedding is not 
detectable and for population surveillance of both exposure and immunity to MERS-CoV infection. 
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 Serological assays:  
Diagnostic screening can also be conducted with the use of serological tests; using either virus-
derived antigen or recombinant structural coronavirus proteins. These assays can be beneficial in 
that antibodies remain present and detectable over a long period; allowing transmission patterns 
to be assessed, the origin to be traced and allowing for the detection of asymptomatic infections. 
However serological testing can still be problematic. Validation of results relies on numerous 
previously highly characterised positive and negative sera samples (Meyer, Drosten et al. 2014). 
Gaining samples from patients can prove difficult for both logistical and ethical reasons. There are 
two main points to consider when serological testing takes place: 
• Assay sensitivity: this is the number of positive samples that can be correctly identified 
• Assay specificity: this is the number of negative samples that can be correctly identified. 
This is an important factor to consider in order to avoid false positive diagnoses. 
High seroprevalence of antibodies against coronaviruses responsible for the common cold, as well 
as cross-reactive against conserved regions of immunogenic coronavirus proteins, can result in 
false positive results. WHO advise the use of a viral neutralization test (VNT) to exclude any 
serological cross-reactions with other human or animal coronaviruses (WHO 2004). 
 Virus based serological assays: 
These include immunofluorescence assays (IFAs), enzyme-linked immunosorbent assays 
(ELISAs) and Western-blot (WB) assays. The main disadvantage for virus-based serological assays 
is the necessity for the laboratories to be biosafety level three (BSL 3). IFAs rely on subjective 
interpretation of fluorescence staining patterns and are therefore hard to standardise. The 
process is also not appropriate for high-throughput screening. Also, ELISAs can only be effective 




 Recombinant protein-based assays: 
The main advantage of using recombinant proteins as the base of an assay, as opposed to live 
virus, is the fact they negate the need for a BSL 3 laboratory. The general premise for these types 
of assays is that a single immunogenic viral gene is cloned into either a eukaryotic or prokaryotic 
plasmid to allow it to be expressed in either mammalian, insect, or bacterial cell culture. One 
downside of recombinant protein-based assays is the technical skill and time required for the 
various processes including; cloning, transfection, optimisation of expression and protein 
purification. There are two immunodominant proteins which are potential targets for screening 
in relation to coronavirus infection; the N and the S proteins. 
• N protein: is the smaller of the two and its lack of glycosylation sites make it relatively 
easy to express and purify in large quantity from bacteria (Qiu, Shi et al. 2005). Although N protein 
has been noted as having high sensitivity it has also been reported as having cross-reactivity 
against other HCoVs when used in protein-based assays (Qiu, Shi et al. 2005) (Maache, Komurian-
Pradel et al. 2006) (Che, Qiu et al. 2005). 
• S protein:  The majority of neutralizing antibodies are directed against the S protein 
(Buchholz, Bukreyev et al. 2004). The S protein can also be more useful when screening 
convalescent sera, as antibodies directed against it occur later in infection than those against the 
N protein (Tan, Goh et al. 2004, Woo 2005). However, there are technical difficulties in using 
bacteria to express the full-length protein and so often only fragments are used to conduct ELISAs 
and WB assays with, which may impair sensitivity and specificity (Meyer, Drosten et al. 2014). 
 Cross-reactivity and cross-neutralization amongst coronaviruses 
When a coronavirus has been established in the population cross-reaction of antibodies can occur 
between immunogenic proteins of viruses that are closely related. Any common epitopes can go 
on to elicit, or re-activate, cross-neutralizing antibodies (Bradburne 1970). This function of the 
immune system is beneficial for the host; however, it can prove problematic in serological 
surveillance because it can lead to false positives. It is for this reason that a confirmation assay 
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such as a viral neutralization test (VNT) is sometimes recommended. However, this can prove 
labour-intensive and is not ideal in an outbreak situation when rapid detection plays a pivotal role 
in containing the disease. 
1.2.6 Animal screening 
If a viral outbreak has a zoonotic origin, the testing of livestock and wild animals can allow the 
animal reservoir and potential animal vector to be identified (Guan, Zheng et al. 2003, Hemida, 
Perera et al. 2013). This can allow human intervention to contain the virus by interrupting the 
chain of transmission. Studies can be impractical logistically and can also be complicated by the 
fact that animals may harbour unidentified coronaviruses that may cause a cross-reaction to any 
antigen being screened (Meyer, Drosten et al. 2014). 
1.2.7 Therapeutic drugs 
To date there are no commercially approved vaccines against, or therapeutic treatments for, 
MERS-CoV(Lu 2020). Although vaccines are undergoing clinical trials the drug development 
process generally takes over 10 years, making it impractical to develop novel anti-coronavirus 
drugs to treat an outbreak (Coleman, Sisk et al. 2016).   
Alongside those mentioned in section 1.2.7.2, other therapeutics being research include 
substances derived from medicinal plants. One study investigated 15 such extracts for their anti-
IBV properties prior and during infection and found the three most effective to be derived from 
M. piperita, T. vulgaris and D. canadense (Lelesius, Karpovaite et al. 2019) 
 Animal models  
Before human clinical trials can take place for any potential countermeasure to MERS-CoV, proof 
of concept data must be obtained from in vivo studies of experimentally infected animals. However 
there is a lack of a small animal model that is naturally susceptible to MERS-CoV infection, as the 
virus does not infect mice, hamsters and ferrets (van Doremalen and Munster 2015). Transgenic 
mice expressing human DPP4 have been engineered to overcome this (Hao, Lv et al. 2019). Due 
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to the presence of receptors in their nasal epithelium, rabbits are also being investigated as 
potential hosts for MERS-CoV. A study showed high levels of viral RNA shedding from rabbits’ 
noses following virus inoculation, however the rabbits did not develop clinical manifestations of 
the disease and produced only limited amounts of infectious virus from the nose. The was no 
transmission of the virus by contact or airborne routes observed in rabbits, limiting their use in 
MERS-CoV vaccine research (Widagdo, Okba et al. 2019). Due to the lack of availability of 
dromedaries, and the high cost of obtaining them in the United States, Alpacas are being 
investigated as a suitable proxy for camels (Crameri, Durr et al. 2016). The final problem with 
current animal models is the limited access to clinical samples and recent virus isolates to use 
upon them.  
 Potential therapeutic countermeasures 
MERS-CoV S2 contains two heptad repeat regions needed for S protein-mediated membrane 
fusion, HR1 and HR2, it is therefore assumed that peptides that mimic these may prove beneficial 
in interfering with the viral-membrane fusion process (Wang, Hua et al. 2019). mABs targeting 
the RBD of the S protein have been shown to block viral attachment (Zhou, Yang et al. 2019). Heavy 
chain variable domain antibodies isolated from camelids, called nanobodies, have been used as 
therapeutics to block the RBD/receptor interaction (Zhao, He et al. 2018). A 2019 study showed 
that three peptides derived from the HR2 region in spike protein of BatCoV HKU4 exhibited 
potent inhibitory activity against MERS-CoV S-mediated cell-cell fusion and viral infection; 
making them another possible candidate for further development as antiviral agents 
against MERS-CoV infection  (Xia, Lan et al. 2019). 
Potential therapeutic drugs for MERS-CoV are shown in Table 3, these include repurposed food 
and drug agency (FDA) and European Medicines Agency (EMA) approved drugs that have 
nonspecific properties but that show efficacy against MERS-CoV in vitro. One study screened a 
library of over 1000 FDA-approved drugs in order to test for inhibition of coronavirus replication. 
Abelson (Abl) kinase inhibitors, including the anticancer drug imatinib, were shown to inhibit 
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both SARS-CoV and MERS-CoV in vitro by inhibiting Abelson tyrosine-protein kinase 2 (Abl2) and 
disrupting fusion of the virions at endosomal membranes (Coleman, Sisk et al. 2016). Another 
study screened FDA-approved drugs using a split-protein-based cell-cell fusion assay and found 
that Nafamostat, a serine protease inhibitor currently used to treat pancreatitis and disseminated 
intra-vascular coagulation (DIC), was found to be a potent inhibitor of S-mediated membrane 
fusion due to its ability to inhibit transmembrane protease serine 2 (TMPRSS2) (Yamamoto, 
Matsuyama et al. 2016). Investigating libraries of previously approved drugs could facilitate a 
rapid response to outbreaks and help curtail some of the delay in development and manufacturing 








NIAID Rocky Mountain 
Laboratories, Hamilton, 
MT, USA 
Ribavirin + IFN 
Polymerase + 
Immunomodulator 
Active in cell 
culture and NHP 
Approved for hepatitis C 
virus, compassionate use for 
MERS-CoV (Falzarano, de Wit 
et al. 2013) (Al-Tawfiq, 
Momattin et al. 2014, Omrani, 
Saad et al. 2014) 
University of Hong 
Kong, Hong Kong 
Interferon B1b Immunomodulator 
Active in cell 
culture 
Preclinical development 
(Chan, Yao et al. 2015) 
Hemispherix 
Biopharma, 
Philadelphia, PA, USA 
Alferon N Immunomodulator 
Active in cell 
culture 
Approved for human 
papillomavirus, orphan drug 
designation granted by the 
European Medicines Agency 
(Agency 2016) 
Romark Laboratories, 




Active in cell 
culture 
Approved for cryptosporidia 
and giardia, in clinical trials 
for influenza virus 
(Stockman, Bellamy et al. 
2006) 
AbbVie, North Chicago, 
IL, USA 
Lopinavir Protease 
Active in cell 
culture, NHP 
models 
Approved for HIV (Chan, Yao 
et al. 2015) 
BioCryst 
Pharmaceuticals, 
Durham, NC, USA 
BCX4430 Polymerase 




Clinical trial for Ebola virus 
(Warren, Wells et al. 2014) 
Sarafianos Laboratory, 
Columbia, MO, USA 
SSYA10–001 Helicase 
Active in cell 
culture 
Broadly active against 
coronaviruses (Adedeji, Singh 
et al. 2014, Wycoff, Maclean 
et al. 2015) 
Planet Biotechnology, 




Active in cell 
culture 
Preclinical development 
(Wycoff, Maclean et al. 2015) 
New York Blood 
Center, New York, NY, 
USA 
HR2P-M2 Spike/fusion 
Active in mouse 
models 
Preclinical development 
(Channappanavar, Lu et al. 
2015) 
Loyola University, 
Chicago, Stritch School 






Active in cell 
culture 
Preclinical development 
(Kilianski, Mielech et al. 
2013) 
University of Maryland, 





NIAID; University of 










Multiple screening efforts (de 
Wilde, Jochmans et al. 2014, 
Dyall, Coleman et al. 2014) 
Table 3: MERS-CoV small molecule and biologics treatment candidates. NIAID=National Institute 
of Allergy and Infectious Diseases, IFN= interferon, NHP=nonhuman primate, DPP4= dipeptidyl 
peptidase-4, PLpro= papain-like protease, 3CLpro= 3C-like protease, NCATS= National Centre 
for Advancing Translational Sciences, NIAID= National Institute of Allergy and Infectious Disease 
and FDA= US Food and Drug Administration. Table sourced from CDC: Emerging Infectious 




As well as using drugs as a treatment strategy, immunotherapeutics are also being studied. 
Immunotherapeutics work by altering the hosts’ immune response either by stimulating, reducing 
or enhancing it. Immunotherapeutics often have less side effects than therapeutic drugs and have 
the advantage of being less likely to cause microbial resistance (Masihi 2001). Current 
immunotherapeutics under investigation for MERS-CoV consist of convalescent plasma as well as 
monoclonal or polyclonal antibody therapies, most of these have specific neutralizing activity 
against the spike protein, as seen in Table 4. Monoclonal antibodies can be isolated either from 
fully human convalescent blood or from transgenic animals which have the advantage of being 
able to be manufactured on a large scale with a high safety profile (Timothy M. Uyeki 2016). One 
study, shown in Figure 5, uses a transchromosomal (Tc) bovine production system to produce 
fully human polyclonal MERS-CoV immunoglobulin G (IgG) antibodies (Luke, Wu et al. 2016). In 
the study a γ-irradiated whole killed virus vaccine (Jordan strain) or a clade B spike protein 
nanoparticle vaccine (Al-Hasa strain) was used to infect two sets of Tc cows. The resulting Tc sera 
produced high ELISA and neutralising antibody titres in vitro. Two bovine human Tc IgG were 
purified; SAB-300 was produced after Jordan strain vaccination and SAB-301 from the Al-Hasa 
strain. SAB-301 was selected for in vivo and preclinical studies. SAB-301 was administered to 
transgenic Ad5-hDPP4 receptor-transduced mice, as a single dose either 12, 24 or 48 hours after 
MERS-CoV infection using the Erasmus Medical Centre 2012 strain. This rapidly resulted in viral 
lung titres near or below the limit of detection. The system could provide a means to rapidly 
produce a therapeutic to prevent and/or treat MERS-CoV infection and other emerging infectious 
diseases (Luke, Wu et al. 2016). Antibodies such as anti-C5aR1 antibody (Ab), can also be used to 
target the complement over-activation-induced immunopathogenesis resulting from a MERS-CoV 
infection (Jiang, Li et al. 2019). Fully human monoclonal antibodies usually have good safety 
profiles however problems may arise in the development of immunotherapeutics such as the risk 
of antibody-dependent enhancement of disease as well as the potential generation of escape 















available and has been 
used for the treatment 
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(Corti, Zhao et al. 2015)  
Table 4: current MERS-CoV immunotherapeutic treatment candidates (MG= immunoglobulin, 
Ad5-DPP4= adenovirus 4 virus expressed dipeptidyl peptidase-4, NHP= nonhuman primate, 
DPP4= dipeptidyl peptidase-4 /CD26, dipeptidyl peptidase-4 and VLP= virus-like particle). Table 
sourced from CDC: Emerging Infectious Diseases (Timothy M. Uyeki 2016) 
A 2019 study reported that using a combination of a MERS-CoV HR2 peptide mimic (HR2P-M2) 
alongside an RBD-targeting neutralising mAB (m336) worked more efficiently than either 




 Physical prevention 
Preventative strategies are being researched too. In the 2003 SARS-CoV outbreak, civet cats, the 
suspected reservoir of the virus, were culled to prevent further spread of the disease. Culling of 
camels in the Middle East would be culturally impractical as they are important for a variety of 
reasons including food, milk, transport and racing purposes (Timothy M. Uyeki 2016). 
Theoretically MERS-CoV infection could be prevented by vaccination, pre- or post-exposure 
antiviral chemoprophylaxis, or passive immunoprophylaxis of people deemed to be high risk. 
 Vaccines  
1.2.8.2.1 Human vaccination 
Animal data has shown that full protection against MERS-CoV requires both humoral and cellular 
immune responses, which are mainly induced by the S and N proteins. Although the N protein is 
more highly conserved, the crucial role of the S protein in viral entry makes it the main focus of 
vaccine research (Zhao, He et al. 2018). Candidate vaccines were reviewed during a symposium 
joint hosted by the International Vaccine Institute (ITI) and WHO in June 2018, the vaccines 
reviewed all targeted the full-length S protein but varied in vaccine approach including; live-
attenuated, inactivated, VLP, and viral-vectored. At the time of writing, most of the potential MER-
CoV vaccines shown in Table 5 are currently undergoing animal model analysis.  
Vaccine development is not without complication, all vaccines must pay attention to ongoing 
assessment of antigenic evolution of circulating MERS-CoV strains in order to be effective 
(Agnihothram, Gopal et al. 2014). Another consideration is the potential for causing antibody-
dependent enhancement of the disease upon virus challenge. A study using transgenic mice 
observed “pulmonary Th2-immunopathology, associated with eosinophilic infiltration and 
increased pro-inflammatory cytokines in the lung”  after immunization with an inactivated MERS-
CoV vaccine followed by a wild-type MERS-CoV challenge, similar observations have been seen in 
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a SARS murine model (Tseng, Sbrana et al. 2012); leading to an increase in focus on creating a 
vaccine which targets more discrete portions of the MERS-CoV S protein (Jiang, Li et al. 2019). 
A team at the University of Madrid in Spain has successfully engineered a mutant virus lacking the 
structural E proteins. The mutant was proven to be replication competent and propagation 
defective therefore making it potentially a safe and promising vaccine candidate (Almazan, 
DeDiego et al. 2013). A human phase I clinical trial was started in January 2016 testing the safety 
of GLS-5300 (a DNA plasmid vaccine that expresses the MERS-CoV spike glycoprotein). The study 
is examining the results of GLS-5300 when administered at one of three dose levels following a 
three-injection vaccination regimen followed by electroporation. The study is also assessing 
immune responses over a 1 year period with respect to the generation of antibody and cellular 
responses (Trials.gov. 2016). Results are expected to be published in November 2020.   
Source Vaccine 2016 status 
Novavax, Gaithersburg, MD, USA 
Spike protein trimer in 
40 nm particle; likely 
adjuvanted 
Mouse immunogenicity shown (Arabi, 
Arifi et al. 2014) 
NIAID/Vaccine Research Centre, 
Bethesda, MD, USA 
Two candidate vaccine 
approaches: DNA spike 
prime-S1 protein boost 
and S1 prime-S1 boost 
Mouse and NHP immunogenicity 
shown; NHP2 (macaque-radiological 
efficacy shown) (Wang, Shi et al. 2015) 
GeneOne Life Science, Seoul, 
South Korea; Inovio 
Pharmaceuticals, Plymouth 
Meeting, PA, USA 
DNA expressing spike; 
electroporation device 
Mouse, NHP, and camel 
immunogenicity shown; 
NHP2 (viremia, lung pathology) 
(Muthumani, Falzarano et al. 2015) 
phase I study started (Trials.gov. 
2016) 
Greffex, Aurora, CO, USA 
Fully deleted adenovirus 
packaging vector 
Mouse immunogenicity (Greffex 2014) 
Erasmus University Rotterdam, 
the Netherlands; University of 
Marburg, Marburg, Germany; 
Ludwig-Maximilians University, 
Munich, Germany 
MVA vectored spike 
protein 
Mouse immunogenicity and protection 
shown; clinical trials in planning stage 
(Song, Fux et al. 2013, Volz, Kupke et 
al. 2015)  
New York Blood Centre, New 
York, NY, USA; Shanghai Medical 
College, Shanghai, China 
Spike receptor-binding 
domain subunit vaccine 
Recombinant protein containing the 
377–588 aa fragment of the S1 subunit 
(Wang, Shi et al. 2015) 
Table 5: Human vaccine candidates for MERS-CoV targeting spike protein (NHP= non -human 
primate, MVA= modified vaccinia Ankara and S1= portion of spike protein with the receptor 




1.2.8.2.2 Camel vaccination 
Interrupting the transmission from dromedary camels to human is clearly an important 
countermeasure in preventing the spread of the disease (Adney, Wang et al. 2019). That being 
said, culling camels, similar to how badgers were culled to try and prevent the spread of bovine 
TB in the UK (Blowey, Gray et al. 2017) is impractical for the reasons mentioned in section 1.2.8.1. 
However, prevention of camel-to-camel MERS-CoV transmission and reduction of spread from 
dromedaries to humans, remains worth investigating. An animal vaccination program has been 
successfully implemented in Australia whereby horse vaccination has interrupted the 
transmission chain between Hendra virus from fruit bats, to hoses, to humans (Middleton 2014). 
Potential camel vaccines being researched are shown in Table 6, similar to candidate human 
MERS-CoV vaccines most of these focus on neutralization of the spike protein. Young camels have 
been reported as at a higher risk for MER-CoV infection and therefore may be a priority group 
when it comes to vaccination (Hemida, Chu et al. 2014, Khalafalla, Lu et al. 2015). Studies also 
show that camels can be re-infected meaning that a vaccination strategy may require multiple 
dosing and booster vaccinations to increase effectiveness overtime (Farag, Reusken et al. 2015, 
Timothy M. Uyeki 2016). A study was conducted using a modified vaccinia virus (Ankara vaccine) 
that expressed the MERS-CoV spike protein. The vaccine was administered intranasally and 
intramuscularly to dromedaries who subsequently had fewer signs of infection and lower MERS-
CoV titres in the upper respiratory tract than their unvaccinated counterparts when challenged 




Source Vaccine Status 
USG/Academic Institution Consortium 
Recombinant and 
inactivated whole virus 
Camel vaccination 
NIAID Rocky Mountain Laboratories, 
Hamilton, MT, USA/Colorado State 
University, Fort Collins, CO, USA 
Spike protein subunit 
vaccine/Advax adjuvant 
(baculovirus expressed) 




Erasmus University Rotterdam, 
Rotterdamn, The Netherlands; 
University of Marburg, Marburg, 
Germany; Ludwig-Maximilians 




challenge studies (Kim, 
Okada et al. 2014, 
Kupferschmidt 2015) 
Novavax AB, Uppsala, Sweden 
Spike nanoparticles 
with adjuvant likely 
In preclinical 
development 





development (Kim, Okada 
et al. 2014) 
Table 6: Camel vaccine candidates for MERS-CoV targeting spike protein (USG= US government, 
NIAID= National Institute of Allergy and Infectious Diseases, National Institutes of Health and 
MVA= modified vaccinia Ankara). Table sourced from CDC: Emerging Infectious Diseases 




1.2.9 Summary   
Although there are a number in preclinical and clinical trials, there are currently no approved 
vaccines against, or specific treatments for, any human coronaviruses, with the recent exception 
of SARS-CoV-2 (Prompetchara, Ketloy et al. 2020). The rate of reported MERS-CoV cases has 
decreased in time, and public interest has reduced, however the virus remains an important area 
of research due to its high mortality rate and the potential for a mutation to arise causing an 
increase in human to human transmission. Competition for funding, laboratory space and clinical 
expertise has arisen with other, more recent, emerging or re-emerging infectious diseases, such 
as the outbreaks of Ebola and Zika virus disease. The overall goal for clinical research in reference 
to MERS-CoV is the identification of effective therapies, the development of preventative vaccines, 
the optimization of diagnostics and the improvement of clinical management in order to improve 
survival rates and potentially eradicate the disease.   
Research into potential medical countermeasures for MERS-CoV remains preliminary. The 
repurposing of FDA approved drugs remains a potential route to treat infection, however would 
be able to be implemented quicker if the mechanism of action for antiviral activity can be defined 
and understood, if there is no change to the route and drug form already approved, if the dosing 
does not exceed current approved dosing and suitable pharmacokinetic data supports the dose 
and finally if the risk-benefit profile is deemed acceptable. 
To continue to make progress towards clinical developments animal models need to become 
standardised. Optimal challenge dose and route needs to be agreed on and greater access to NHP 
is required. Currently common marmosets are deemed the most suitable NHP as their onset and 
severity of disease requires a lower dose of therapeutic drug, however their small size makes 
repeat sampling difficult and models remain variable between laboratories (Timothy M. Uyeki 
2016). Large animal models, including camels and camelids, such as alpacas, are being developed 
(Adney, Bielefeldt-Ohmann et al. 2016). These models could give greater insight as to the 
pathology and subsequent immunology caused by the disease in its natural host dromedaries.  
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There is currently a limited availability of current or recently circulating MERS-CoV strains. There 
is a need for more epidemiological, clinical, virologic and immunologic data to be shared to 
improve understanding of MERS-CoV pathogenesis. Only one study has investigated MERS-CoV 
infection in autopsy tissues of a patient who died from the disease (Ng, Al Hosani et al. 2016). 
Collaborations are needed to pool and systematically collect clinical specimens from MERS-CoV 
patients to allow for analysis on biomarkers, immunology and clinical illness, as well as long-term 
follow-up studies of survivors of severe disease. Studies into the differences between 
asymptomatic and fatal cases are needed. Effort should be made to partner with clinical trial 
networks in affected countries to evaluate safety and efficacy of investigational therapeutics, 
WHO and the International Severe Acute Respiratory and Emerging Infection Consortium 
(ISAREIC) are collaborating in adapting standardized protocols for controlled clinical trials for 
MERS-CoV (Consortium 2017). 
This study hopes to assist research developments by focusing on the need for improved diagnostic 
testing, both for current human coronaviruses and for the use during potential novel outbreaks in 
the future.  
1.2.10 The SARS-CoV-2 pandemic 
 Introduction 
As stated in the prologue, this thesis was initially written in 2017, the more recent global SARS-
CoV-2 pandemic has required rapid development of vaccines and diagnostic testing kits to try and 
reduce the disease spread and burden. Whilst SARS-CoV-2 will appear omitted from the practical 
research element of this study, it is important to outline current diagnostic kits and vaccines for 
wider context. SARS-CoV-2 was first identified in Wuhan, China in December 2019 and declared a 
pandemic by the World Health Organization (WHO) in March 2020 (Triggle, Bansal et al. 2021). 
SARS-CoV-2 is a single-stranded, positive-sense, non-segmented enveloped RNA virus, 
approximately 29.9 kB in size with a diameter of 50–200 nm (Chen, Zhou et al. 2020). At the time 
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of writing, August 2021, there have been 207,784,507 cases reported to WHO resulting in 
4,370,424 deaths (WHO 2021) 
 Diagnostic tests 
The majority of diagnostic tests for SARS-CoV-2 are based on reverse transcription polymerase 
chain reaction (RT PCR) assays from nasopharyngeal samples which can be used to detect both 
symptomatic and asymptomatic cases and provide figures which can be used to calculate the R0 
number (basic reproduction number). The R0 value is a number relating the average number of 
people an infected individual is likely to infect. Whilst RT PCR screening can be conducted on 
asymptomatic carriers of the virus, it is unlikely such individual would feel the need to have the 
test and therefore it is thought that such cases are not routinely captured in common testing 
strategies (Nikolai, Meyer et al. 2020). In addition to this, a number of studies now suggest that 
persistent positive RT-PCRs do not necessarily indicate the presence of replication-competent 
viruses(Alexandersen, Chamings et al. 2020, Rhee, Kanjilal et al. 2021). 
Another commonly used option for SARS-CoV-2 detection are rapid antigen tests, commonly 
referred to as lateral flow tests. These show a lower sensitivity compared to the standard RT-PCR 
test however their specificity is generally reported to be high. Antigen tests offer a few advantages 
over RT-PCR in that they are quick, relatively low cost and can be done by the general public as 
point of care tests. Different organisations recommend different parameters of standards for the 
rapid antigen tests, WHO recommends a minimum performance requirement of ≥80% sensitivity 
and ≥97% specificity, while European Center for Disease Prevention (ECDC) advocates the use of 
tests with a performance closer to RT-PCR, ≥90% sensitivity and ≥97% specificity ((ECDC) 2020). 
The Department of Health and Social Care (DHSC) has agreed contracts with Omega Diagnostics 
and Global Access Diagnostics for the production of the LFT kits within the UK (Gov.UK 2021). 
 Track and trace and other control measures 
As with any communicable disease understanding transmission route is vital so that measures 
can be put in place to minimise the spread of the disease. SARS-CoV-2 is pneumotropic and 
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spreads through respiratory secretions, droplets generated through coughing, sneezing and 
talking. Contaminated surfaces can also facilitate the spread of the virus, some studies estimate 
the SARS-CoV-2 viral particles can remain infectious for up to six days (van Doremalen, 
Bushmaker et al. 2020, Zhang, Zhang et al. 2020, Zhang, Li et al. 2020). Due to the nature of 
transmission, non-pharmaceutical interventions (NPIs) such as hand hygiene, face masks, 
sufficient indoor ventilation, social distancing, contact tracing, quarantining, community lock 
downs and social restrictions have played a vital role during the pandemic (Triggle, Bansal et al. 
2021). 
 Therapeutics 
In a similar manner to the two previous novel HCoV outbreaks of SARS-CoV and MERS-CoV, no 
established therapeutic measure was available to effectively treat SARS-CoV-2 and as such, 
attention was focused on repurposing currently available drugs including, but not limited to, 
Chloroquine and Hydroxychloroquine, remedesivir, dexamethasone, ivermectin, 3CLpro and 
PLpro inhibitors, famotidine, TMPRSS2 and furin inhibitors and convalescent plasma and targeted 
antibody therapy (Kaddoura, AlIbrahim et al. 2020). The mechanism of actions for some of these 
SARS-CoV-2 potential treatments can be seen in 
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Figure 4, a more comprehensive list of potential and approved SARS-CoV-2 countermeasures can 
be seen in appendices three and four. 
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Figure 4: The mechanism of action of different therapeutics against COVID-19. (A) illustrates the 
mode of action of drugs targeting COVID-19 including chloroquine (CQ) and hydroxychloroquine 
(HCQ) and their multiple putative sites of action: (i). ACE2 receptor for SARS-CoV-2; (ii). 
increasing the pH of the endolysosome; and (iii). suppression of the immune response. Sites of 
action of TMPRSS2 inhibitors such as camostat, famotidine, and furin inhibitors are shown; 
famotidine is also a putative inhibitor of the 3CL/PLpro proteases; ivermectin is a putative 
TMPRSS2 inhibitor that also inhibits the importin (IMP) α-β complex and viral replication; while 
remdesivir inhibits viral RNA polymerase. (B) Dexamethasone suppresses expression of pro-
inflammatory cytokines. (C) Summary of role of convalescent plasma and monoclonal antibody 
therapy. (D) Ivermectin inhibits the heterodimeric importin (IMP) α/β complex via binding 
directly to IMPα preventing nuclear import of key viral proteins. Figure taken from (Triggle, 





 SARS-CoV-2 Vaccines 
Since the start of the pandemic a high importance was placed globally upon discovering a vaccine 
against SARS-CoV-2 to prevent the spread of the virus and reduce the burden of disease. An up to 
date status can be found through accessing vaccine tracker sites (Corum, Grady et al. 2020). There 
are a number of reports comparing the leading potential and approved vaccine platforms 
(Krammer 2020, Sharma, Sultan et al. 2020), summarised in Table 7. The two vaccines most 
commonly used in the UK are the mRNA BioNTech/Fosun/Pfizer (BNT162) vaccine and the 
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Table 7: Details of prime potential or approved COVID-19 vaccines and their latest stages of 
development. IM= Intramuscular. Table taken from (Triggle, Bansal et al. 2021) 
 
Ongoing genome sequencing of SARS-CoV-2 has shown multiple variants to be circulating globally 
(Koyama, Platt et al. 2020) some of which have proven to affect the infectivity of the virus and 
may have negative implications to vaccine effectiveness due to mutations in spike protein and 
subsequent neutralising antibodies. Alpha, beta, gamma and delta variants have been noted as 
variants of concern by WHO, with a further four (eta, iota, kappa and lambda) mentioned as 




 Research objectives 
1.3.1 Creating purified soluble N proteins for MERS-CoV, SARS-CoV, OC43-CoV, 
NL63-CoV, 229E-CoV and IBV 
A previous study has investigated the use of N proteins of HCoV as a basis for serodiagnosis 
(McCrory 2009) however in the case of some of the viral strains, the proteins made remained 
insoluble and proved impossible to purify. Although they could be used in the form of crude 
lysates, the lack of equivalence among the antigens used meant that comparisons between sera 
banks had a degree of uncertainty. This research aims to overcome that issue by re-investigating 
the use of coronavirus N proteins as soluble antigens and increasing the range of proteins used to 
include MERS-CoV. This was achieved by investigating the effect of re-locating the His-tag used 
for purification from the C to the N terminus of the protein. One study found that on average, N-
terminal fusion partners are preferable for optimal protein expression (Dyson, Shadbolt et al. 
2004). Having all N proteins in equivalent soluble form would allow more accurate sero-
prevalence tests to be conducted. The accession number and strains used in this study are as 
follows; IBV (FJ589731.1) isolate=IS/1045/03, NL63-CoV (NC_005831.2) strain= Amsterdam I, 
229E-CoV (DQ243962.1) strain= HCoV-229E-20/1/04, OC43-CoV (KF530063.1) 
strain=OC43/human/USA/9612-48/1996, MERS-CoV (KF600623.1) isolate=Al-Hasa_7b_2013 
and SARS-CoV (NC_004718.3) isolate=Tor2. 
1.3.2 Using purified N protein in sera testing  
Once generated, the N proteins will be used to conduct serosurveillance analysis. N proteins are 
used as they remain more conserved within CoV groups than S proteins (Meyer, Drosten et al. 
2014). Enzyme linked immunosorbent assays (ELISAs) will be used to ascertain if there has been 
any prior infection with, or related to, the identity of N protein used in the test. Human sera can 
be obtained from a human serum bank provided by Public Health England (PHE) among others. 
This study aims to confirm the previously obtained data (McCrory 2009) and expand it to include 
a wider range of viruses.  
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 General materials and methods 
This chapter covers the general materials and methods used in multiple experiments; more 
specific details are referred to in their relevant chapters. 
 Materials 
2.1.1 Chemicals 
All Chemicals used were of an analytical grade or higher and unless stated were purchased from 
Sigma or Fisher. 
2.1.2 Antibodies: 
 Primary antibodies 
• Anti-6X His tag antibody horseradish peroxidase (HRP) ab1187 (Abcam) developed in 
mouse, used at a 1:2,000 ratio, within manufacture’s advisory range of 1:1,000 - 1:5,000. 
• Anti-GFP antibody (HRP) ab184207 (Abcam) was used at a ratio of 1:5,000 which is 
within manufacturer’s recommendation of 1:5,000 - 1:20,000 
 
 Secondary antibodies 
• Anti-Chicken IgY (IgG) (HRP) (Sigma) was used 1:2,000 as advised by the manufacture. 
• Anti-Mouse (HRP) (Dako) was used 1:1,000 as advised by the manufacture.  
• Anti-Rabbit (HRP) (Dako) was used 1:3,000 as advised by the manufacture. 
• Anti-Human polyvalent immunoglobulins (whole molecules) peroxidase was used 
1:20,000 as advised by the manufacturer  
 
 Sera 
Chicken, mouse and rabbit sera were supplied by the Pirbright institute. 




2.1.3 Reagents used 
The buffers and solutions used throughout this study are shown in Table 8. 
Solution Composition Application 
 
Phosphate buffered saline (PBS) 
8% (w/v) NaCl 
0.2% (w/v) KCl 
1.15% (w/v) Na2HPO4 
0.2% (w/v) KH2PO4 
pH 7.4 
Miscellaneous 
Luria Agar (LA) with ampicillin 
 
1% w/v) tryptone 
0.5% (w/v) yeast extract 
0.5% (w/v) NaCl 





Lysogeny Broth-Luria (LB) with ampicillin 
 
1% (w/v) tryptone 
0.5% (w/v) yeast extract 
0.5% (w/v) NaCl 





Super optimised broth with catabolite 
repression (S.O.C.) medium (Invitrogen) 
 
2% (w/v) tryptone (Oxoid) 









Cell culture medium 
Biowhittaker® Insect-XPRESSTM 
medium (Lonza)   
supplemented with 
2% (v/v) foetal calf serum 
(Biosera) 
Insect cell culture 
and infection 
Tris-acetate, ethylenediaminetetraacetic acid 
(EDTA) buffer (TAE): 
7mM Tris-HCl 
2.5mM EDTA 




SDS lysis buffer 









25mM tris base 
192mM glycine 





25mM Tris base 
19.2mM glycine 

















0.2% (v/v) tween 
Western blotting 
Comassie staining solution 
0.25% (w/v) coomassie brilliant 
blue R250 
25% (v/v) methanol 
8 % (v/v) glacial acetic acid 
SDS-PAGE staining 
Destaining solution 
10 % (v/v) methanol 
10% (v/v) glacial acetic acid 
SDS-PAGE 
destaining 























Table 8: all of the solutions used in this study 
2.1.4 DNA modification and restriction enzymes 
The enzymes used were FastDigest enzymes (ThermoScientific). NcoI restriction enzyme 
recognizes C^CATGG sites, XhoI restriction enzyme recognizes C^TCGAG sites; both enzymes cut 
best at 37°C in 5-15 minutes using universal FastDigest Buffer.  
2.1.5 DNA and protein markers 
    
Figure 5: Four molecular gel ladders used. A) HyperladderTMI by Bioline used for DNA sizing in 
gel electrophoresis B) SeeBlue® Plus2 pre-stained protein ladder by ThermoFisher and C) 
BLUEeye protein ladder by Geneflow D) EXtended protein ladder by GeneOn Images taken from 
Bioline, Thermofisher, Geneflow and GeneOn’s websites respectively. 
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Hyperladder™ I, purchased from Bioline Reagents Ltd (London, UK), is a ready-to-use molecular 
weight ladder consisting of 14 bands spanning from ~200 base pairs (bp) to 10,000bp used to 
establish size and concentration of DNA when run using gel electrophoresis, as shown in Figure 
5. 
Also shown in Figure 5 is SeeBlue® Plus2, purchased from Thermofisher (Hemel Hempstead, UK), 
a tricoloured protein ladder consisting of eight blue polypeptides, a purple myoglobin red band 
and an orange phosphorylase band. The markers span between ~ 5-200 kilodaltons (kDa) and are 
used to size proteins analysed using sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) during western blots and/or coomassie staining. Whilst using this marker in some 
blots the eighth band, the bovine serum albumin BSA marker, used to signal ~98kDa was found 
to cross react with the anti his antibody and therefore an alternative marker was looked into in 
order to produce clearer blots. 
The final two ladders displayed shown in Figure 5 are BLUeye pre-stained protein ladder 
(Geneflow), a tricoloured protein standard displaying 12 proteins, these range from ~10 to 
245kDa and Extended protein ladder (GeneOn)with 13 proteins ranging from 5 to 245kDa. These 
ladders produced no cross reactivity with the anti his antibody and were therefore used for the 
majority of the blots, depending on availability within the laboratory.  
2.1.6 Antibiotics 
Ampicillin sodium salt (Melford) was dissolved in nanopure water and underwent 0.22µm syringe 
filtration for sterilization purposes. 1,000 × stock solutions were made up to a concentration of 
100mg/mL and kept as 1mL aliquots at -20oC to prevent unnecessary thaw/freeze cycles. 
Chloramphenicol (Boehringer Ingelheim) was used to make 1,000 × stocks (34mg/mL). This was 
done by dissolving 0.34g in 10mLs 100% ethanol before being 0.22µm filtered and kept at -20oC 





2.2.1 Prokaryotic generation methods 
 Baculovirus infection of Sf9 cells 
DNA for cloning into prokaryotic expression vectors was generated by amplification of N genes 
already cloned into recombinant baculoviruses. Baculovirus stocks expressing OC43-CoV, NL63-
CoV, 229E-CoV and IBV were used to infect a six well dish of Sf9 cells at 70% confluence and left 
for five days when cytopathic effects (CPE) of the cells were noticeable when viewed at ×40 
magnification. 
 DNA extraction 
The cells were carefully dislodged from the dish using a cell scrapper and centrifuged in 15mL 
falcons at 4,500 rpm at 4oC for 10 minutes. The DNA was then eluted to a final volume of 200µL 
using a DNeasy kit (Qiagen), used as per the manufacturer’s instructions.  
 PCR amplification of viral DNA plasmid 
In order to amplify the N encoding DNA, as opposed to any cellular DNA, specific primers were 
designed and ordered from Integrated DNA Technologies, these are shown in Table 9 
. The designed primers allowed for the insertion of a polyhistidine tag at the N terminal sequence 
as well as the addition of a stop codon at the C terminal sequence in order to prevent replication 
of a polyhistidine tag at the C terminal domain of the protein that would occur as a result of the 





number Product Description Section of sequence (5’-3’) 
Melting 
temperature 
(Tm) in oC 




65979000 25nmole DNA oligo IBV_NR GCGCTCGAGTTACAACTATTTTCACC 68.3 












65979004 100nmole DNA oligo IBV_NF CGCCCATGGGCAGCAGCCATCATCAT 73.9 








Table 9: The 8 primers used alongside their corresponding melting temperature and sequences. 
Oligo= Oligonucleotides, F=forward primer and R=reverse primer. 
 
Phusion® high-fidelity PCR master mix with high-fidelity (HF) buffer was purchased from New 
England Biolabs® Inc (Hitchin, Hertfordshire, UK). This was used in order to reduce error rates, 
as it has a “>50-fold lower error rate than that of Taq DNA Polymerase” (McInerney, 2014). All PCR 
reactions were performed using a SensoQuest labcycler (Geneflow) or Bio-Rad T100™ Thermal 
cycler from Bio-Rad Laboratories Inc (Hemel Hempstead, Hertfordshire, UK).  
Reactions were set up as follows: 
10µL X2 Phusion® Master Mix 
2µL forward primer (see table 3) 
2µL reverse primer (see table 3) 
1µL template  













Table 10:  PCR run conditions used. *initially a higher annealing temperature of 58oC was used 
however this proved to be unsuccessful for all amplicons and so subsequently was lowered to 
50oC. 
 
 Plasmid Miniprep 
The pTriEx1.1 vector was gained using a pre-existing construct within the laboratory containing 
a MERS-CoV N protein insert. The glycerol stock was grown up overnight in LB containing 
ampicillin and the plasmid was extracted using a QIAprep spin miniprep kit (QIAGEN) used as per 
manufacturer’s instructions; the bacterial cells were harvested by centrifugation at 10,000rpm 
for 15 minutes. The supernatant was discarded, and the cell pellet resuspended in 250µL of buffer 
P1 containing 0.1mg/mL RNase A. Lysis occurred with the addition of 250µL of Buffer P2, the 
mixture was left to incubate at room temperature (RT) for 5 minutes. 350µL of buffer N3 was 
added to neutralize the lysate and adjust to high-salt binding conditions required for binding of 
plasmid DNA to silica, all contents were mixed thoroughly by inverting the tube 4-6 times. Cell 
debris was pelleted by centrifugation at 13,000rpm for 10 minutes and the supernatant was 
applied to a QIAprep spin column containing a silica membrane. The QIAprep spin column was 
centrifuged at 10,000rpm for 1 minute. 500µL of buffer PB was added and centrifuged at 
10,000rpm for 1 minute to remove any impurities within the column before 750µL of buffer PE 
was added and centrifuged at 10,000rpm for 1 minute. To remove all wash buffers an additional 
centrifugation at 10,000rpm for 1 minute was done. The plasmid DNA was eluted from the column 
Number of cycles Temperature (oC) Time (seconds) Step 
1 98 30 Initial denature 
30 
98 10 Denaturing 
50 30 Annealing * 
72 45 Extension 
1 72 300 Final extension 
 4 ∞ hold 
80 
 
by the addition of 25µL of sterile water, incubation at RT for 2 minutes, and centrifugation at 
10,000rpm for 2 minutes. The resulting plasmid DNA solution was then aliquot into 2 
microcentrifuge tubes; one kept at -20⁰C as a master stock while the other was kept at 4⁰C as a 
working stock.   
 Double enzyme digest 
Fast digest enzymes were used to remove the MERS-CoV N protein sequence and make the 
pTriEx1.1 plasmid available for the N protein sequences of OC43-CoV, NL63-CoV, 229E-CoV and 
IBV to be inserted. The fast digest enzymes were used both on the pTriEx1.1 MERS-CoV N protein 
vector as well as the OC43-CoV, NL63-CoV, 229E-CoV and IBV PCR fragments, to generate “vector” 
and “inserts” accordingly. The enzymes used were NcoI and XhoI as the sites flanked the N protein 
sequence. The reaction was set up as detailed in Table 11 and incubated for 30 minutes at 37oC in 
order to separate the desired insert from the original vector. The double digest reaction was 
analysed by electrophoresis on a 1% agarose gel. 
Reagent Concentration/volume 
NcoI 10 units 
XhoI 10 units 
10X fast enzyme digest buffer 2µL 
DNA 10µL 
Nuclease-free water 6µL 
Total volume= 20µL 




 Gel electrophoresis 
Gel electrophoresis was used for resolution of DNA fragments.  Agarose powder (Bioline, UK) was 
weighed and mixed with TAE buffer to a concentration of 1.0% (w/v) and then completely melted 
in a microwave oven.  After the solution had cooled to about 60⁰C, 0.1µL/mL of gel red (Biotium 
Inc, USA) was added. The solution was poured into a casting tray containing a sample comb and 
left to solidify at RT. The sample comb was removed from the casting tray and the gel placed into 
the electrophoresis chamber with sufficient TAE buffer to cover. Samples were loaded with 1/6th 
the volume of 6×loading buffer (Bioline). Gels were run at 100V until the tracking dye had 
migrated until the end of the gel and DNA was visualised and photographed using a G:BOX Chemi 
(Syngene) with GeneSys software. 
 Gel extraction 
The pTriEx1.1 vector larger band (~5,300bp) produced by the double enzyme digest of the MERS-
CoV plasmid was extracted, as were the ~1,500-1,600bp bands produced by the PCR reactions 
conducted on various constructs. Gel extraction was carried out using a Zymoclean gel DNA 
recovery kit (Cambridge BioScience); the target DNA band was identified using the blue light 
transilluminator and (as such no images were taken) excised from the gel. The gel slice was then 
placed in a 1.5mL microcentrifuge tube (Sarstedt, Germany) and weighed. 3 times the volumes of 
agarose dissolving buffer (ADB) was added to 1 volume of gel and the tube was incubated at 55⁰C 
for 10 minutes in water bath to allow the gel to dissolve (CP instrument Co Ltd, UK). Next the 
solution was added to a Zymo-spin column and placed into a 2mL collection tube prior to 
centrifugation in a bench top microcentrifuge (MSE Micro Centaur, UK) at 10,000rpm for 1 minute. 
The flow-through was discarded before the column was washed twice by adding 200μl of wash 
buffer into the column, and centrifuging at 10,000rpm for 1 minute. 10µL of elution buffer was 
added into the column, incubated at RT for 2 minutes, before being centrifuged at 10,000rpm for 




T4 DNA ligase (Thermo Scientific) was used to ligate the insert into the newly extracted pTriEx1.1 
vector. The manufacture’s protocol for DNA insert ligation into vector DNA using sticky-end 
ligation was followed. In this case 1µL of vector was used with a 5:1 ratio insert to vector. 
Reagent Concentration/volume 
Linear vector DNA 20-100ng 
Insert DNA 1:1 to 5:1 molar ratio over vector 
10X T4 DNA ligase buffer 2µL 
T4 DNA ligase 1µL 
Nuclease-free water Up to 20µL 
Total volume= 20µL 
Table 12: The reagents, volumes and concentrations used in the ligation reactions 
 
A vector only sample was also made to check the occurrence of self-ligation. Once the reaction was 
prepared, it was incubated for 10 minutes at 22oC, before being ready for the initial 
transformation into Novablue singles (Millipore) E. coli cells.  
 Transformation 
The transformation occurred using the heat shock method as laid out in Novagen competent cells 
protocol; cells were thawed on ice before being mixed gently with 2µL of the ligation reaction and 
incubated on ice for 30 minutes. Heat shock occurred at 42⁰C for 30 seconds using a HAAKE B3 
water bath (CP instrument, UK) before being cooled on ice for 2 minutes. 800µL of SOC medium 
was added and the mixture was incubated at 37⁰C for 1 hour in a 250rpm-shaking incubator 
(Gallenkamp, UK) before being plated onto LB agar plates containing 100µg/mL of ampicillin.  




 DNA sequencing  
In order to ascertain that the ligation had been successful, and that the constructs’ DNA were 
correct, the post-ligation transformed colonies were grown overnight and had their plasmids 
extracted using miniprep method.  
Once the constructs had been confirmed correct subsequent transformation could take place in 
order to place the vectors into an inducible cell line to facilitate protein production. Reactions 
were conducted using purchased One shot® BL21(DE3) cells (Thermo Scientific) or 10µL of cells 
made competent in the laboratory (see section 2.2.1.13). Transformation for all cells, excluding 
the Novablue singles, followed the Invitrogen One shot BL21 manual. The Novablue singles 
transformation protocol followed that detailed in Novogen competent cells instead. The cells, once 
mixed SOC, were spread at two volumes of 50µL and 25µL onto plates containing chloramphenicol 
(34µg/mL) and ampicillin. Providing the ‘vector only’ control plate had few or no colonies present 
and the sample plates had grown, overnights were made as previously described. 
 Glycerol stocks 
Glycerol stocks were made using fresh overnight cultures. This was done by adding 800µL of the 
overnight cultures to 200µL 50% (v/v) glycerol in a cryogenic tube, before being stored at -80oC.  
The rest of the overnight sample underwent a miniprep in order to isolate the constructs now 
containing a His-tag. The plasmid was transformed into BL21 cells for future protein production. 
 Isopropyl β-D-1-thiogalactopyranoside (IPTG) induction 
IPTG triggers the transcription of the lac operon by binding to the lac repressor and can therefore 
be used to induce protein expression whereby the gene is under the control of the lac operator. 
IPTG (Melford) stocks were made up to 100mM by dissolving 0.23g in 10mLs of nanopure water 
and 1mL aliquots were then stored at -20oC until needed. Induction was carried out following the 
expression guidelines set out in Invitrogen One Shot BL21(DE3) user manual. The optical cell 
density (λ600nm = ~0.4) was reached after a 1:20 dilution of the overnight culture was grown for 
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approximately 2 hours at 37oC 225rpm and IPTG was added to a final concentration of 0.5mM and 
protein expression took place for 2-3 hours. 
 Competent cells 
Expression of NL63-CoV, 229E-CoV and IBV were all low in Bl21 (see Figure 12) therefore other 
strains of E. coli were looked in to. 10mLs of LB was inoculated with 0.5mLs of an overnight 
culture. The four strains used were BL21-star(DE3)pLysS, C41(DE3), C43(DE3) (Thermo 
Scientific) and Rosetta™(DE3)pLysS. These were then grown to mid log phase (OD600 ~0.6) after 
being incubated at 37oC in a shaking incubator at 250rpm for approximately 90 minutes. Cells 
were then spun at 4,500 rpm for 10 minutes at 4oC and the pellets resuspended in 0.5mLs ice cold 
100mM CaCl2. Importantly cells were kept cold at all times. The cells were then incubated on ice 
for 30 minutes and pelleted in a microfuge run at 4oC, 13,000 rpm, for two minutes. The 
supernatant was discarded, and the cells resuspended in 0.1mLs ice-cold 100mM CaCl2. Cells were 
kept on ice and used within 48 hours ready to be transformed. Plasmids were re-transformed into 
the four new cell types and the IPTG induction was conducted again.  
2.2.2 Protein extraction, purification, concentration and storage  
 Cell lysis 
Once the IPTG induced cells were pelleted the samples then needed to be lysed. Pellets were 
resuspended in 20-50 × initial volume in PBS. EDTA was also added in order to chelate ions. This 
was done because lysozyme is inhibited by any calcium ions that the cells may contain. However, 
the presence of EDTA in the sample proved to strip the column and so was not used thereafter. 
The lysis technique was done with the addition of Triton X100 to a final concentration of 0.1% 
(v/v) followed by using the cell disrupter at 50% amplification for 10 minutes; alternating 30 
seconds on with 30 seconds of rest. The sample was always kept on ice to prevent heat 
denaturation of the proteins. Further to this, lysozyme (Sigma) was added to a final concentration 
of 1 mg/mL and the sample was left on ice for half an hour in order to hydrolyse the peptidoglycan 
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present in bacterial cell walls.  Once the lysis had occurred a clarifying spin was done at 10,000rpm 
for twenty minutes at 4oC in the centrifuge. 
During the protein production process, other cell lysis techniques were tried and used including 
the use of the cell disruptor manufactured by Stansted Fluid Power Limited (Essex, England), cell 
lytic B and the sonicator was instead used for 1 minute at 60% amplification alternating 5 seconds 
on and 5 seconds off. 
 His-trap columns 
The His-trap column works using immobilized metal affinity chromatography (IMAC). The column 
is prepacked with Ni Sepharose Fast Flow; a medium containing highly cross-linked agarose beads 
with an immobilizing chelating group, pre-charged with nickel ions (Ni2+). The soluble histidine 
tags form complexes with the nickel ions, causing the tagged protein to become bound. This is a 
reversible process; the addition of imidazole out-competes the histidine for the nickel ions and 
the attached proteins become eluted.   
2.2.2.2.1 Buffers 
The 8 × phosphate buffer was initially made up to 90mL, then pH was adjusted to 7.4 using either 
1 M NaOH or 5 M HCl. The buffer was then 0.45µm filtered. The imidazole (MW=68.08) was made 
up to a 1M solution by dissolving 13.6g in 200mL H2O. 
2.2.2.2.2 Run protocol: 
The column was run in accordance with the manufacture’s protocol. BioLogic LP system was used 
supplied by Bio-Rad. The program was set to run 0-100 % elution buffer over 60 minutes with a 
flow rate of 2.5mL/min. To account for tubing length a secondary step of 100% elution buffer was 




The column doesn’t have to be stripped and recharged in between each individual use, however 
upon occasion the column may become hindered by contaminants and nickel ions can become 
depleted therefore it can become useful to regenerate the column using the following method. 
5 – 10 × column volume of stripping buffer (binding buffer+ 0.05M EDTA) 
5 – 10 × column volume H2O 
5 – 10 × column volume binding buffer 
5 – 10 × column volume 1M NaOH leave at 4oC for 2 hours 
5 – 10 × column volume H2O 
5 – 10 × column volume 1X binding buffer 
Recharge with 5mLs NiSO4 
Wash column with H2O 
 
2.2.2.2.4 Storage:  
For sterility, the column was stored in 20% ethanol at 4oC in between uses. 
 Protein concentration and storage: 
All column fractions shown to be positive by western blot were pooled and concentrated using a 
vivaspin column (Satorius) with a molecular cut off weight (MCOW) of 30,000. The sample was 
spun until the concentration was ~1mg/mL (OD280=1.0) and then stored at -20oC. 
2.2.3 Protein detection methods 
 SDS-PAGE 
Proteins were resolved by SDS-PAGE to determine their size and purity. 10% precast 
polyacrylamide gels (Bio-Rad) were used. Samples were mixed with an equal volume of 2×SDS-
loading buffer and heated to 100oC for 10 minutes. The denatured protein samples were vortexed 
and centrifuged (MS Microcentaur, Sanyo) for five minutes at 1,300rpm. Gels were run in 1×SDS 
running buffer at 200V until the bromophenol blue dye reached the bottom of the gel.   
 Western Blot Analysis  
Proteins separated by SDS-PAGE were transferred to a polyvinyl difluoride membrane (PVDF) 
(Millipore). This was conducted using 6 sheets of filter paper (Whatman, USA) and 1 sheet of PVDF 
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membrane which was cut to fit the size of the gel. The PVDF membrane was initially submerged 
in methanol before being covered in the transfer buffer together with the filter paper. The 
apparatus was set up so with 3 sheets of filter paper on the anode plate of semi-dry blotting 
apparatus (ATTO cooperation, Japan) followed by the membrane, the gel, and the last 3 sheets of 
filter paper. The semi-dry blotting apparatus was then connected to the power station electrodes 
and electrophoresed for 1 hour and 20 minutes 35V/ 150mA to allow proteins from the gel to be 
transferred onto the membrane.  
Membranes were then blocked in blocking solution overnight at 4oC. The membrane was 
subsequently washed three times for 5 minutes with TBST before being probed with the primary 
antibody diluted in the blocking solution for one hour. Following another three 5-minute washes, 
membranes were incubated for one hour with the secondary antibody conjugated to horseradish 
peroxide (HRP) again diluted in the blocking buffer. Finally, membranes were washed for three 
times of 5 minutes and signal was detected using ChemiFast Chemiluminescence Substrate 
(Syngene) according to the manufacturer’s instructions. Images were visualised and 
photographed using a G:BOX Chemi (Syngene) with GeneSys software. 
 Coomassie staining 
Coomassie staining could be conducted alongside or instead of western blot analysis after SDS-
PAGE has been conducted. The gel is extracted from the plastic container and left in the coomassie 
staining solution for >30 minutes at RT, the stain is then removed and replaced with the destaining 
solution which can be replaced as often as needs be for the bands to visualise and the remaining 
gel to destain.  Images were visualised and photographed using a G:BOX Chemi (Syngene) with 
GeneSys software. 
 Mass spectrometry  
To verify protein purification, matrix-assisted laser desorption-ionisation (MALDI) spectrometry 
was used. MALDI is an ionisation  technique  which  uses  a  laser  energy-absorbing  matrix to 
create ions with little fragmentation and  is  commonly  used  in  microbiology for the identification 
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of bacterial and fungal isolates (Israr, Bernieh et al. 2020). The process was outsourced to Protein 
and Nucleic Acid Chemistry (PNAC) Facility at the Biochemistry Department of the University of 
Cambridge and offers ease of use, high throughput, robustness, cost-effectiveness, rapid analysis 
and sensitivity (Israr, Bernieh et al. 2020).  
2.2.4 Baculovirus expression materials and methods 
 Sf9 cell culture and cell counting 
Sf9 cells (Invitrogen) were maintained in suspension at a concentration of between 3×105 to 
2×106 cells/mL in Biowhittaker® Insect-XPRESSTM medium (Lonza). For small scale production, 
cells were cultured in 100mL spinner flasks with 25mL working volume and incubated at 28oC in 
a rotary shaker at 30rpm. Aseptic technique was used consistently when working with Sf9 cells 
and all culturing was carried out in a laminar flow (Peteric Ltd, UK). Sf9 cell confluence and 
viability was determined by using trypan blue stain followed by cell counting using a Countess 
automatic cell counter (Invitrogen, USA). 
 Transfection and production of recombinant baculovirus 
Sf9 cells were transfected in order to generate new recombinant baculovirus. Cells at a 50% 
confluence level were used to produce a monolayer in a 6 well dish (~1x106 cells/well). Lipofectin 
reagent (Invitrogen) was used to transport the mixture of flashBACGOLD (Oxford Expression 
Technologies) and transfer vector into the cells. Reactions were made up to a total volume of 24µL 
using purified water. Each reaction used 1-2µL of flashBACGOLD, 8µL of Lipofectin and 100-500ng 
of the transfer vector. Positive control reactions were prepared in parallel to test transfections; 
these contained a Green Fluorescence Protein (GFP) plasmid (Laboratory strain; 1µL). The lipid-
DNA complex was incubated at RT for 30 minutes. Cells were left to attach to the plastic during 
this time, before being washed with serum-free media prior to the addition of the 24µL reaction 
mix. The cells were incubated for ~3/5 days, or until visible signs of infection. After ~3/5 days, 
the supernatant of the each well was added to a fresh monolayer of Sf9 cells (~1×106 cells/ mL) 
to increase the viral titre. Passaged cells were incubated at 2oC for a further three to five days. 
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Passaged cells were harvested by centrifugation (Jouan GR422) at 1500rpm for 10 minutes at 4oC.  
The resultant supernatant containing the baculovirus was stored at 4oC. 
2.2.5 Baculovirus amplification  
Baculovirus was amplified in T175 stacker flasks. Flasks were seeded with a monolayer of 
17.5×106 Sf9 cells and incubated with ~100-200µL of the relevant virus passage’s supernatant 
(typically passage 2 or 3) and left at 28oC for three to five days. The cells were harvested by 
centrifugation at 4,500rpm for 30 minutes and the resultant supernatant was stored at 4oC. 
2.2.6 Virus infection 
Once a significant baculovirus titre was reached virus infections were carried out by infecting Sf9 
cells (~1×106 cells/mL) cultured in media with 10% (v/v) recombinant baculovirus. Cells were 
cultured in T75 flasks with 10 mL working volume and incubated at 28oC for three to five days 
then harvested by low speed centrifugation. Pellets were stored at -20oC and supernatants were 
stored at 4oC following a clarifying spin. 
2.2.7 ELISA 
Protein samples were left to coat a flat 96 well plate (NUNC) overnight having been diluted to the 
required concentration in 0.1M NaHCO3. Wells were washed three times for five minutes in TBST 
and nonspecific binding was reduced by incubation in the blocking buffer for one hour at RT. Wells 
were washed again for 3 times 5 minutes using TBST and incubated in 50µL of primary antibody 
or sera following the required dilution series, diluted in blocking buffer solution for one hour at 
RT. The wells were washed as before 3 times 5 minute and incubated with 50µL secondary 
peroxidase conjugate antibody diluted in blocking buffer solution for one hour at RT. The wells 
were washed a further three times five minutes in TBST. 50µL 3,3′,5,5′-tetramethylbenzidine 
(TMB) ELISA Stable Stop (Europa Bioproducts) was added to each well until a blue colour 
appeared. The reaction was stopped by addition of 50µL 0.5M H2SO4 to each well. The absorbance 
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 Prokaryotic expression system introduction 
Prokaryotic expression systems are the most common expression systems used for protein 
production for a variety of reasons. Firstly, prokaryotic systems are simple and relatively 
inexpensive to conduct. They also allow large quantities of recombinant protein to be produced 
with a short generation time. The processes utilise well-known known mechanisms of 
transcription and translation. Finally, the simplicity of genetic modifications and the availability 
of many commercially adapted bacterial strains are additional advantages (Porowinska, Wujak et 
al. 2013).  
The principle prokaryotic system is based upon the bacteria E. coli. In optimised media E. coli has 
a doubling time of approximately 20 minutes (Sezonov, Joseleau-Petit et al. 2007). The system is 
not without disadvantages. Proteins can be produced misfolded and remain biologically inactive 
in insoluble forms called inclusion bodies (Rosano and Ceccarelli 2014). Some synthesized 
proteins are also toxic to the bacterial host preventing cell cultures from reaching a high density 
(although this can be overcome by incorporating an inducible promotor which can be activated, 
only allowing the inserted gene to be transcribed once the culture has reached an optimum 
density). Prokaryotic cells lack the ability to carry out some eukaryotic post-translational 
modifications, such as glycosylation and phosphorylation, therefore if these are necessary for the 
target protein then a mammalian cell expression system may be preferred (Francis and Page 
2010). Finally, the system requires aseptic techniques to be adhered to at all times to prevent 




 T7 polymerase-based pET System  
3.2.1 Overview  
The pET system is the principal system developed for the cloning and expression of recombinant 
proteins in E. coli (Studier, Rosenberg et al. 1990). The gene of interest is cloned into a pET plasmid 
under the control of a bacteriophage T7 promoter. Gene expression is induced when a source of 
T7 RNA polymerase becomes available within the host cell. T7 RNA polymerase is highly selective 
and powerful; the host cell’s resources are quickly switched to target gene expression. This system 
prevents gene expression until induction occurs. This is important if the desired protein were to 
have toxic effects towards the host cell. Initially target genes are cloned using hosts that do not 
contain the T7 RNA polymerase gene; in this study’s case Novablue cells, a K-12 strain derivative 
produced by Novagen, were used. After which, plasmids are transferred into an expression E. coli 
strain containing a chromosomal copy of the T7 RNA polymerase gene under the control of the lac 
promoter. The addition of IPTG induces gene expression as detailed below.  
3.2.2 Vectors 
The vector is a circular plasmid that is taken up by E. coli. When an E. coli cell divides, it makes 
new copies of its own large host chromosome, encoding all the proteins required for cell function. 
During the bacterial binary fission, new copies of the smaller cloning vector are also replicated. 
Each progeny cell also contains one, or more often multiple, copies of the vector along with the 
host chromosome. The pET vectors were originally constructed by Studier and colleagues (Studier 
and Moffatt 1986, Studier, Rosenberg et al. 1990). Commercial vectors use a T7 promoter that is 
only transcribed by the RNA polymerase from T7 bacteriophage. The E. coli RNA polymerase 
cannot recognize the T7 promoter upstream of the target gene and so leaky gene expression is 




Figure 6: A plasmid map of the pTriEx1.1 vector used, showing the positioning of the Xho1 and 
Nco1 sites as well as highlighting the plasmid’s polyhistidine site in blue. Image generated using 
SnapGene Viewer (from GSL Biotech; available at snapgene.com) 
 
pTriEx1.1 (Figure 1) was used as the T7 vector in this study. NcoI and XhoI were used for enzyme 
digestion within the multiple cloning site (MSC) for the insertion of target DNA. As Figure 6 shows, 
the XhoI site is situated just before the polyhistidine tag, highlighted in blue, and is generally used 
to fuse the His coding sequence to the incoming fragments to make a C-terminally His-tagged open 
reading frame. However, previous work in the host laboratory had suggested that an N-terminal 
His tag was beneficial for SARS-CoV N protein expression so in the cases described here, when the 
site was chosen the naturally occurring stop codon at the end of the N ORF was retained to prevent 
the addition of a polyhistidine tag to the C-terminal domain of the protein. Instead forward 
primers were used to insert the desired polyhistidine tag into the N-terminus of the N proteins to 
achieve an N terminal His tag.  
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3.2.3 Lac operon 
As mentioned T7 DNA polymerase synthesis within the E. Coli is under the control of the lac 
promoter. Two enzymes are required for lactose metabolism to occur within E. coli; permease and 
β-galactosidase. Permease is the lacY gene product which allows lactose to be transported into 
the cell. β-galactosidase is the lacZ gene product and cleaves the disaccharide molecule lactose 
into glucose and galactose, shown in Figure 7. The genes required for this metabolism process are 
negatively regulated via its repressor system, encoded by lac I (Jacob and Monod 1961). The lac 
operator site is the location of DNA where the lac repressor binds, normally located between the 
promoter and the lacZ gene. The lac promoter system can therefore be exploited as a molecular 
switch if a gene of interest is positioned after the promoter region, such that inactivating the 
repressor, would allow for its transcription. 
3.2.4 The lac Repressor  
In 1961 Jacob and Monod conducted research on gene regulation and looked into repressors 
acting as molecular switches  (Jacob and Monod 1961). The lac repressor was first isolated by 
Gilbert and Müller-Hill five years later (Gilbert and Muller-Hill 1966). It is now known that 
residues 1-49 code for the N-terminal “headpiece” domain of the repressor which contains helix-
turn-helix motifs essential for it to recognise the operator units (Friedman, Fischmann et al. 1995, 
Lewis, Chang et al. 1996). Residues 50-58 code a hinge-helix which connects the headpiece onto 
the main body of the repressor. If DNA is not present this region moves freely (Wade-Jardetzky, 
Bray et al. 1979) however when the operator is present it becomes ordered and binds to the 
central portion of the operator in the minor groove (Lewis, Chang et al. 1996). Residues 62-331 
encode the core of the repressor which is divided into two subdomains. Crystal structures have 
shown that when lactose is absent the tetrameric LacI binds the operator sequence on DNA 
bending it 40 degrees, blocking the access of RNA polymerase to the promoter site and preventing 
transcription (Bell and Lewis 2000). When lactose binds to LacI it induces a conformational 
change in the protein structure leaving it unable to bind to the operator DNA sequence causing it 
to detach and make way for RNA polymerase and translation.  
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3.2.5 Effector molecules 
Effector molecules alter the affinity of the repressor for the operator. Effector molecules are 
defined as inducers if their binding lowers the LacI’s affinity for the operator and anti-inducers 
their binding stabilizes the repressor-operator complex. Allolactose is an analogue of lactose and 
is the natural inducer of the repressor molecule (Jobe and Bourgeois 1972). IPTG is known to be 
an effective inducer as it lowers the affinity that LacI binds to its operator 1000-fold (Barkley, 
Riggs et al. 1975).  
3.2.6 IPTG 
As shown in Figure 7 IPTG is structural mimic of lactose/allolactose that can also bind to the lac 
repressor and induce a similar conformational change that greatly reduces its affinity for DNA.  
Unlike lactose, IPTG is not part of any cellular metabolic pathway and the sulphur atom creates a 
chemical bond which is non-hydrolysable by the cell, as a result the cell neither metabolises nor 
degrades it, meaning the concentration of IPTG added remains constant, making it a more useful 
inducer of the lac operon than lactose itself (Daber, Stayrook et al. 2007). 
 
Figure 7: Structural similarities between IPTG and lactose. Figures modified from (Berg, 




3.2.7 Gene expression 
The gene coding for T7 RNA polymerase has been engineered into many commercial E. coli strains 
under a modified lac promoter and repressor system. Cells denoted by “DE3” contain a λDE3 
lysogen that carries the gene for T7 RNA polymerase under control of the lacUV5 promoter.  With 
the addition of IPTG the lacI detaches from the operator DNA sequence, native E. coli RNA 
polymerase can attach and transcription and translation of T7 RNA polymerase can occur. The 
newly synthesised T7 RNA polymerase allows the gene of interest within the vector to be also 
transcribed. Some strains of E. coli add an additional gene coding for bacteriophage T7 lysozyme 
which inhibit T7 RNA polymerase and suppress basal expression of T7 RNA polymerase prior to 
induction (Stano and Patel 2004). All the steps are summarised in Figure 8. 
 
Figure 8: A schematic summarising the roles of IPTG, the pET expression vector, T7 RNA 
polymerase, the lac repressor and the lack operon functioning within the DE3 E. coli strain 




 Prokaryotic expression materials  
3.3.1 Materials/cell lines 
The prokaryotic cells used were all variants of E. coli. They were sourced commercially, ready to 
be transformed as; 
• Novablue singles™ competent cells (Millipore) were used in the initial cloning stage. One shot® 
BL21(DE3) cells from Thermo were then used for the initial screening of protein synthesis. The 
BL21 cells, and any strains containing the term “DE3”, carry the lysogen λDE3, meaning that the 
strain carries a chromosomal copy of the T7 RNA polymerase gene under the control of the lacUV5 
promoter, making them suitable for IPTG induction. Strains containing “pLysS” mean that the 
strain expresses T7 lysozyme, which is a T7 RNA polymerase inhibitor, used to suppress basal 
expression of T7 RNA polymerase prior to induction. Alternatively, the cells were made competent 
from strains available in the laboratory.  
• One shot® BL21(DE3) Star pLys: The BL21-star cells are advantageous as they have been 
optimised to have high mRNA stability with the aim of increasing protein yield. They have a 
transformation efficiency of greater than 1x108 cfu/µg plasmid DNA and also have low 
background expression in uninduced cells. The strain also reduces the degradation of 
heterologous proteins as it lacks both the Lon and OmpT proteases (Jiang, Oohira et al. 2002). 
• OverExpress C41(DE3) and C43(DE3) (Thermo Scientific) C43 was derived from C41. Both 
strains are beneficial when expressing toxic and membrane proteins. They also carry a 
chloramphenicol-resistant plasmid that encodes T7 lysozyme and are also deficient in the Lon and 
OmpT proteases (Miroux and Walker 1996).  
• Rosetta™(DE3)pLysS (Millipore): this strain contains a chloramphenicol resistance gene and is 
beneficial when trying to express proteins that contain codons rarely used in E .coli by supplying 
tRNAs for AGG, AGA, AUA, CUA, CCC, GGA (Doron 2015).  
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• LOBSTR (low background strain) (Kerafast) are a BL21(DE3) derivative designed specifically 
with His-tag affinity purification in mind. The strain eliminates the most abundant histidine-rich 
E. coli contaminant proteins amM and slyD, by containing modified copies of them. SlyD peptidyl-
prolyl cis/trans isomerase has a 48 amino acid unstructured C-terminal tail containing 15 
histidines (Andersen, Leksa et al. 2013). 
• ArcticExpress(DE3) and ArcticExpress(DE3)-Ril (Agilent Technologies). Aggregates of insoluble, 
misfolded proteins are known as inclusion bodies and can be produced when E. coli undergoes a 
forced high-level expression of a heterologous protein. It is possible to purify aggregated protein 
using denaturation and re-folding steps however this takes additional time and can often lead to 
biologically inactive proteins being purified (Singh, Upadhyay et al. 2015). ArcticExpress cells are 
derived from Agilent’s BL21-Gold competent cell line and aim to increase the yield of soluble 
proteins produced using low-temperature cultivation. The strain co-expresses the chaperonins 
Cpn10 and Cpn60 from the bacterium, Oleispira Antarctica, which have 74% and 54% amino acid 
identity to the E. coli GroEL and GroES chaperonins respectively. They are cold-adapted and used 
to aid protein refolding at temperatures of 4–12°C (Ferrer, Chernikova et al. 2003). ArticExpress-
ril cells contain extra copies argU, ileY, and leuW used to encode tRNA that recognise specific 
codons AGA, AGG, AUA and CUA. This is done in order to prevent the limiting effect and stall to 




 Prokaryotic Methods 
3.4.1 Summary of prokaryotic system methods 
Details of methods used during the expression of N proteins using the prokaryotic system are laid 
out in the methods section 2.2.1. To summarise; DNA for the OC43-CoV, NL63-CoV, 229E-CoV and 
IBV samples were obtained using previously constructed baculovirus stocks already available in 
the laboratory. PCR was conducted to amplify the N-protein sequences, adding a polyhistidine tag 
at the N terminal domain and a stop codon at the C terminal domain. Double digests using Xho1 
and Nco1 were conducted to create an “insert” for each construct ready to be ligated into a 
similarly digested pTriEx1.1 vector. Agarose gels were run to verify molecular sizes and the 
appropriate bands extracted and ligated. The plasmids were transformed into Novablue singles, 
colonies were selected and grown overnight with ampicillin and the plasmids were obtained using 
Miniprep ready to be sequenced. Once sequencing was conducted and proved successful the 
plasmids were transformed into a variety of expression cell lines suitable for IPTG induction and 
protein expression. Once the proteins had been produced and the cells lysed, the protein required 
purification. This was done using a 5mL HisTrap FF Crude column (GE Healthcare). The presence 
of the N-proteins was confirmed using western blots and/or coomassie staining and the proteins 
were concentrated using Vivaspin columns and stored at -80oC until needed. 
 Prokaryotic results 
3.5.1 Initial cloning 
The primers shown in Table 9 were used to conduct a PCR on extracted DNA templates obtained 
from previous baculovirus stocks already available in the laboratory encoding OC43-CoV, NL63-
CoV, 229E-CoV and IBV N protein, under the conditions as described in Table 10. The PCR samples 
were then analysed by gel electrophoresis in order to visualise the expected band size of ~1,500 
– 1,600kDa, construct dependant.  
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Previous work in the laboratory had meant that a MERS-CoV construct was already in the 
pTriEx1.1 vector with the polyhistidine tag correctly positioned at the N terminus and a stop 
codon preventing a polyhistidine tag addition at the C-terminal domain. The aim of the PCR was 
to amplify the other strains’ DNA in order to be able to perform a double enzyme digest and 
subsequent ligation, so that all constructs could be positioned within the pTriEx1.1 vector with 
the polyhistidine tag located at the N terminal domain and not at the C terminal domain.  
Bands denoted by the arrows in Figure 9 show clear success for the OC42, NL63-CoV and 229E-
CoV samples. The slight smear at the bottom of the gel shown in Figure 9 is the result of a primer 
overload. The 1:10 dilution of the original primers referred to as “stock concentration” needed 
further diluting.  
Although there was a slight band generated in the IBV sample when using 1:102 DNA dilution, 
shown in lane 16, the concentration was low, and the preparation did not produce successful 
results in further use. Therefore, the PCR was repeated but with the stock concentration of primer 
undergoing a further 1:10 dilution first, with the hope to increase the yield of PCR product, results 





Figure 9: Gel electrophoresis showing PCR products using OC43-CoV, NL63-CoV, 229E-CoV and 
IBV templates, using a 1 in 100 dilution of stock primers. Lanes 1 and 18 contain Hyperladder I 
as the molecular weight marker, lane 2-5 OC43-CoV, 6-9 NL63-CoV, 10-13 229E-CoV and 14-17 
IBV. Letters as marked on the bottom of the gel relate to the amount of template the PCR was 
conducted on, a= 1 µL of DNA template, b= 1:10 dilution, c= 1:102 dilution, d= 1:103 dilution. 
Arrows around the 1,500 bp mark indicate the size of predicted band.  
The 1µL of crude DNA template proved to be too concentrated for all samples as denoted by lanes 
marked with the letter “a”, however subsequent dilutions 1:10, 1:102 and 1:103 (marked “b” “c” 
and “d” respectively on the gel) produced a successful PCR product for all amplicons, except the 
IBV.  The bands for OC43-CoV, NL63-CoV and 229E-CoV were successful and went on to be gel 
extracted for double enzyme digestion and plasmid ligation. Further work was conducted on the 
IBV template shown in Figure 10. 
 
Figure 10: Gel electrophoresis showing results from second PCR conducted using IBV templates 
in order to try and produce a clear band. Hyperladder I was used in lane 1 and lane 6. 1 in 10 
dilution of 1uM primers used in lanes 2-5 and 1:102 dilution used lanes 7-10. Amount of DNA 
template used indicated by letters at the bottom of the gel, a= 1µL neat, b= 1:10 dilution, c=1:102 
dilution and d=1:103 dilution.  
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The samples generated when conducting the PCR using a 1:10 dilution of primer were run in lanes 
2-5 of Figure 10, however these proved unsuccessful as no bands were seen. The only clear two 
bands were seen in lane 8 and 9 produced by using a 1:102 dilution of the primers with a 1:10 and 
1:102 dilution of the DNA template. Although the band is faint this was a successful amplification 
of a band approximating the target size expected and therefore the bands were gel extracted. Once 
gel extracted, all positive bands for IBV, OC43-CoV, NL63-CoV and 229E-CoV, were double digest 
with XhoI and NcoI (as described in section 2.2.1.5). The enzymes were heat inactivated by heating 
at 80oC for 10 minutes. The pTriEx1.1 vector double digested with the same enzymes, removing 
the resident MERS-CoV N gene insert and the larger band ~5.3Kbp representing linearized vector 
was gel extracted. The DNA concentration was measured by a nanodrop spectrophotometer. 
The results of the nanodrop were as follows: 
OC43-CoV N-gene insert 23.9 ng/µL 
NL63-CoV N-gene insert 21.4 ng/µL 
229E-CoV N-gene nsert 21.8 ng/µL 
IBV N-gene insert 25.8 ng/µL 
 
pTriEx1.1 vector 5.8 ng/µL 
 
Subsequently each of the viruses N encoding DNA sequences were ligated into the pTriEx1.1 
vector as described in section 2.2.1.8. Once ligated the samples were transformed into Novablue 
singles™ competent cells (EMD Millipore) and the plasmids obtained from the resulting colonies 
were extracted and sent for DNA sequencing. Once the sequence was deemed correct the plasmids 
were transformed into a variety of E. coli expression hosts to allow for protein production.  
3.5.2 DNA sequences 
See appendix two for sequencing data and basic local alignment search tool (BLAST) results. Two 
colonies/samples were sequenced per isolate. In all cases sequence A was selected for 
transformation of BL21 type strains, except in the case of IBV whereby B was used as the sequence 
obtained better results.  
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3.5.3 IPTG induction  
As mentioned, the MERS-CoV construct already had the polyhistidine tag correctly situated at the 
N terminal domain and was situated within the pTriEx1.1 vector, therefore this was used as a 
control to test IPTG induction. This was done as described in section 2.2.1.12  in BL21(DE3) cells, 
the western blot results are shown in Figure 11. 
 
Figure 11: Western blot of a MERS-CoV N protein 3 hour 0.5mM IPTG induction using BL21 DE3 
cells. The blot was conducted using an anti his antigen. BLUEeye pre-stained protein ladder was 
run and the corresponding molecular weights are marked alongside of the blot. Uninduced 
samples are marked with a cross under the blot in lane 1 and induced samples a tick in lane 2. 
The arrow indicates the band matching the expected molecular weight. 
 
The band seen in lane 2 in the induced sample, which is not present in the uninduced sample in 
lane 1, shows the induction of a band of ~48kDa indicated by the arrow, which is near the 
predicted 45kDa size of the MERS-CoV N product. The smaller band also seen is likely to be minor 
breakdown of the protein which retains the His tag. 
The other four constructed coronavirus N expressing strains underwent the same process of 




Figure 12: Western blot results using a his tag antibody on E. coli lysates expressing OC43-CoV, 
NL63-CoV, 229E-CoV and IBV N proteins. The samples were generated following 3 hour 0.5mM 
IPTG inductions conducted using Bl21 DE3 cells. BLUEeye pre-stained protein ladder was run in 
lane 1 and the corresponding molecular weights are marked alongside of the blot. Uninduced 
samples are marked with a cross under the blot and induced samples a tick. 0C43 samples were 
run in lanes 2 and 3, NL63-CoV in lanes 4 and 5, 229E-CoV in lanes 6 and 7 and IBV in lanes 8 
and 9. The arrow indicates the band matching the expected molecular weight. 
 
 There is a polyhistidine signal even in the uninduced OC43-CoV sample shown in lane 2 but this 
is amplified post induction in lane 3 and is an indication of leaky expression. Faint bands can also 
be seen in lanes 5 and 7 for induced NL63-CoV and 229E-CoV respectively. These bands are 
around the expected weights of 42-50kDa. Although the OC43-CoV band appears higher as it 
approaches 63kDa rather than the 49kDa expected. However, this may be due to overloading of 
sample and/or poor gel running. IBV in lane 9 failed to produce a signal. As only the OC43-CoV 
sample was able to produce a strong polyhistidine signal when induced, other E. coli strains were 
tested to try and increase yields. 
Firstly C41, C43, BL21-star and Rosetta strains were all screened with each construct as they were 




Figure 13: Western blot results using a his tag antibody on E. coli lysates expressing NL63-CoV N 
protein, using a variety of E. coli strains. The samples were generated following 3 hours 0.5mM 
IPTG inductions at 36oC. BLUEeye pre-stained protein ladder was run in lane 1 and the 
corresponding molecular weights are marked alongside of the blot. Inductions using C41 and 
C43 were run in lanes 2 and 3, BL21 cells were used for the induction shown in lane 4 and the 
Rosetta strain was displayed in lane 5. The arrow indicates the band matching the expected 
molecular weight. 
 
Figure 13 shows the western blot produced when screening the NL63-CoV construct with C41, 
C43, BL21-star and Rosetta cell lines. The only cell line not to produce some level of his-expression 
in the case of NL63-CoV is C43; although C41 shown in lane 2 only appears to show breakdown 
product as opposed to the full-length protein. The most successful combination was with BL21-
Star displayed in lane 4. Rosetta provided a slight signal seen in lane 5. The bands appear around 
the 48kDa mark which is slightly higher than the 43kDa expected but this may be due to the 




Figure 14: Western blot results using a his tag antibody on E. coli lysates expressing 229E-CoV N 
protein, using a variety of E. coli strains. The samples were generated following 3 hours 0.5mM 
IPTG inductions at 36oC.  BLUEeye pre-stained protein ladder was run in lane 1 and the 
corresponding molecular weights are marked alongside of the blot. Inductions using C41 and 
C43 were run in lanes 2 and 3, BL21 cells were used for the induction shown in lane 4 and the 
Rosetta strain was displayed in lane 5. The arrow indicates the band matching the expected 
molecular weight. 
 
Figure 14 shows the western blot produced when screening the 229E-CoV construct with C41, 
C43, BL21-star and Rosetta cell lines. As seen in lanes 2 and 3 of Figure 14, in the case of 229E-
CoV neither C41 nor C43 produced a noticeable signal. . BL21-star produced the strongest signal 
in lane 4 and Rosetta had a good signal in lane 5. The bands appear around the 48kDa mark which 





Figure 15: Western blot results using a his tag antibody on E. coli lysates expressing IBV N 
protein, using a variety of E. coli strains. The samples were generated following 3 hours 0.5mM 
IPTG inductions at 36oC. BLUEeye pre-stained protein ladder was run in lane 1 and the 
corresponding molecular weights are marked alongside of the blot. Inductions using C41 and 
C43 were run in lanes 2 and 3, BL21 cells were used for the induction shown in lane 4 and the 
Rosetta strain was displayed in lane 5. The arrow indicates the band matching the expected 
molecular weight. 
 
Figure 15 shows the western blot produced when screening the IBV construct with C41, C43, 
BL21-star and Rosetta cell lines. The IBV construct showed a successful induction using C41 
shown in lane two of Figure 15. The band appears around the 48kDa marker which is near the 
45kDa expected. Lane 3 and 5, C43 and Rosetta respectively, show no signal. And only breakdown 
bands can be seen in lane 4 in the case of BL21-star. 
It is worth noting that the sucessful production of IBV N protein using the C41 strain prove 




As such, the combination of strain and cell lines were as follows; OC43-CoV-BL21, NL63-CoV-
BL21-Star, 229E-CoV-BL21-Star and IBV-C41. 
 
Figure 16: Western blot results using a his tag antibody on E. coli lysates expressing OC43-CoV, 
NL63-CoV, 229E-CoV and IBV N proteins, using a variety of E. coli strains, as written in the lanes 
at the bottom of the blot. The samples were generated following 3 hours 0.5mM IPTG inductions 
at 36oC. BLUEeye pre-stained protein ladder was run in lane 1 and the corresponding molecular 
weights are marked alongside of the blot. The arrow indicates the bands matching the expected 
molecular weight. 
 
Figure 16 shows all combinations to be successful and capable of producing a strong band in the 
expected range 42-50kDa. OC43-CoV with BL21 cells is displayed in lane 2, BL21-star cells were 
used with NL63-CoV and 229E-CoV in lanes 3 and 4 respectively and IBV in C41 cells is shown in 
lane 5. The IBV signal in lane five appears above the expected 45kDa but this may be due to the 
running of the gel or ladder. The slight variation in size is minimal and is potentially because of 
the viral strains used or simply the running of the gel. 
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3.5.4 Column chromatography 
After IPTG induction of the MERS-CoV-His tagged sample in BL21 DE3 cell line, lysis and IMAC 
was conducted as described in section 2.2.2.2, Figure 17 shows the western blot analyses of the 
results.  
 
Figure 17: Western blot using his antibody, showing the results of IMAC on an IPTG induced 
MERS-CoV sample. Run conditions were 0-100 % elution buffer over 60 minutes with a flow rate 
of 2.5mL/min. Samples were collected every 2 minutes. BLUEeye pre-stained protein ladder was 
run in lane 1 and the corresponding molecular weights are marked alongside of the blot. The 
initial lysis load is in lane 2, the flow through is shown in lane 3. Tubes 1-7 are displayed in lanes 
4-10 as marked at the bottom of the gel. The arrow indicates the bands matching the expected 
molecular weight. 
 
A polyhistidine signal can be seen in lanes 8-10, indicating tubes 5, 6 and 7 contain the his-tagged 
protein. The three positive samples in tubes 5-7 (lanes 8, 9 and 10) were then pooled. The 15mLs 
was concentrated down to 500µL using a vivaspin column with a MCOW of 30kDa. The OD280 




3.5.5 Large scale inductions 
In order to produce a high yield of N-protein five large scale infections were set up (OC43-CoV in 
BL21 cells, NL63-CoV in BL21star cells and 229E-CoV also in BL21star cells) albeit with varying 
degrees of breakdown product, as shown in Figure 18. The signal from MERS-CoV is present but 
at a low level. IBV, however, has failed to produce a signal even in the C41 cell line it had previously 
been successful in (see Figure 15). Therefore, the pellets from OC43-CoV, NL63-CoV and 229E-
CoV were lysed and purified and further investigation was conducted on IBV, see chapter 5. 
 
Figure 18: Western blot using his antibody on E. coli lysates of MERS-CoV, OC43-CoV, NL63-CoV, 
229E-CoV and IBV N protein production. 1 litre IPTG induction were conducted on all five 
strains using 0.5mM IPTG inductions for 3 hours in 3L flasks at 36oC. BLUEeye pre-stained 
protein ladder was run in lane 1 and 6; the corresponding molecular weights are marked 
alongside of the blot. Uninduced samples are marked with a cross under the blot and induced 
samples a tick. MERS-CoV samples were run in lanes 2 and 3, OC43-CoV in lanes 4 and 5, NL63-
CoV in lanes 7 and 8, 229E-CoV in lanes 9 and 10 and IBV in lanes 11 and 12. The arrow 
indicates the bands matching the expected molecular weight. 
 
Figure 18 shows the western blot results from large scale inductions of all constructs and their 
corresponding expression strain. All constructs were able to produce signal around the expected 
molecular weight when induced (42- 50kDa) except for IBV as there is no band visible in lane 12. 
IBV induction was repeated on multiple occasions but the ability to produce signal at the expected 
molecular weight was unreliable and inconsistent, as a result further work was conducted in order 
to see if IBV yield could be increased and stability increased, this included the possibility of 
eukaryotic expression systems detailed in chapter 4 as well as structural manipulations described 




After the majority of the proteins were successfully expressed the proteins went on to be purified 
and concentrated. Then pellets from the one litre preparations mentioned in section 3.5.5 were 
stored at -20oC until they were ready to be lysed and purified using the his trap column, protocol 
detailed in section 2.2.2.2. Once the sample was loaded onto the column a gradient of 0-100% 
elution buffer was run, samples were collected every 2minutes. Two peaks were seen on the 
graph. Western blot analysis was conducted on four samples from the first peak and two from the 
second in order to see which, if any, contained the polyhistidine tagged MERS-CoV N protein, the 
results of which are shown in Figure 19. 
 
Figure 19: Western blot using his antibody, showing the results of IMAC on a 1L IPTG induced 
MERS-CoV sample. Run conditions were 0-100 % elution buffer over 60 minutes with a flow rate 
of 2.5 mL/min. Samples were collected every 2 minutes. BLUEeye pre-stained protein ladder 
was run in lane 1 and the corresponding molecular weights are marked alongside of the blot. 
The initial lysis load is in lane 2, the flow through is shown in lane 3. Tubes 7-10 are displayed in 
lanes 4-7 samples from the second peak, tube 17 and 18, are shown in lanes 8 and 9. The arrow 
indicates the bands matching the expected molecular weight. 
 
Although the column run appears to be successful, in that the polyhistidine-tagged protein was 
able to successfully bind and be eluted in a defined peak, when comparing this signal’s molecular 
weight on the blot (~30kDa) to the expected weight of ~46kDa it is clear that something has not 
gone as anticipated. The load sample shares this problem, but the original induction seen in  Figure 
18 did not. This implies that the cleavage occurred either during the freezing of the sample, or 
whilst it was being lysed.  
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3.5.7 Molecular weight 
To see if the cleavage of the protein occurred before or after the pellet lysis, the remaining pellets 
from the 1litre infections were gently thawed and run on a gel to examine their molecular weight. 
 
Figure 20: Western blot using his antibody, showing the molecular weight comparison pre and 
post -20oC storage of 4 types of N proteins. A “-“symbol at the bottom of the blot shows the 
sample is un-lysed whilst a “+” symbol indicates that lysis has occurred. BLUEeye pre-stained 
protein ladder was run in lane 1 and the corresponding molecular weights are marked alongside 
of the blot.  
Figure 20 is a western blot to show the molecular weights of the N proteins produced from the 
other 1L inductions that had not yet been lysed or purified. The signal has been all but lost in lane 
3 probably due to the fact the lysed sample is far more dilute than the original frozen pellets and 
this was not adjusted for when the blot was run. More importantly it is clear to see all four samples 
maintained a higher molecular weight (~60kDa) even post -20oC storage. This would imply that 
the thawing process and/or the lysing process is either too harsh or allows for proteolytic cleaving 
of the protein. Subsequent lysis used protease inhibitor tablets (complete protease inhibitor 




3.5.8 All five proteins post IPTV induction, lysis, HisTrap™ column 
With the new addition of protease inhibitors to the method to try and maintain the correct 
molecular weight of the proteins 200mLs of all samples in their optimized E. Coli strain were 
induced and lysed without being stored at -20oC. They were purified through the IMAC HisTrap 
column and concentrated using the Vivaspin columns (Epsom) before being run on a western blot 
as shown in Figure 21. Care was taken to keep all proteins chilled and the new methods and care 
proved beneficial in keeping the proteins intact.  
 
Figure 21: Western blot using his antibody conducted on all 5 N-proteins post purification and 
concentration. BLUEeye pre-stained protein ladder was run in lane 1 and the corresponding 
molecular weights are marked alongside of the blot. 
 
Although the IBV band is hardly visible in lane 6 it is still present. The concentrations of the 
proteins were all measured using the nanodrop in order to be standardised for future ELISA tests. 
MERS-CoV in lane 2 had a concentration of 1.55 mg/mL, OC43-CoV shown in lane 3 had a 
concentration of 1.19mg/mL, NL63-CoV shown in lane 4 had a concentration of 5.60mg/mL, 
229E-CoV in lane 5 had a concentration of 4.49mg/mL and although a band remains faint and 
overshadowed by the 229E-CoV band next to it, IBV had a band in lane 6 with a concentration of 
0.26mg/mL. Molecule weight was hard to assess due to the strength of signal however they all 




This chapter shows the successful expression and purification of most constructs using the 
prokaryotic expression system. The exception being that of the IBV construct, which was hoped 
to be used as a negative control when it came to sera testing using ELISAs. Due to the fact that 
protein expression of the IBV construct at a consistent yield and the correct molecular sized 
proved inconsistent using prokaryotic expression, eukaryotic expression was also investigated 
shown in chapter 4. The prokaryotic system proved beneficial in terms of effectiveness for the 







 Eukaryotic N protein expression and purification 
 Baculovirus expression system introduction 
4.1.1 Introduction to the baculovirus expression vector system (BEVS) 
Having struggled to consistently produce a stable IBV N protein using the prokaryotic methods 
described in chapter 3 this chapter focuses instead on recombinant protein production in 
eukaryotic cells. Baculoviruses are viruses that infect insects and other athropods, particularly 
insects of the order Lepidoptera. Baculoviruses have double-stranded, circular, supercoiled DNA 
contained within a rod-shaped capsid. Two of the most common isolates used in gene expression 
are Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) and Bombyx mori 
nuclear polyhedrosis virus (BmNPV) (LifeTechnologies 2011). AcMNPV was first used as an 
expression vector for human beta interferon in 1983 (Smith, Summers et al. 1983). Baculoviruses 
can be modified so that a redundant highly expressed, very late gene is replaced by a gene of 
interest to produce a recombinant virus that goes on to express the recombinant protein as part 
of its life cycle. The polyhedrin and p10 genes are both very late and have been successfully used 
for this purpose, shown in Figure 22. Because insect cells are eukaryotic they are able to carry out 
most of the post-translational modifications found in mammalian cell lines (Jones and Morikawa 
1996) giving the system an advantage over prokaryotic cell lines in that respect. Linearised viral 
DNA is used in the system as it cannot initiate a viral infection unless rescued by the 
recombination event, as the virus DNA transfected into cells with a constructed transfer vector. 
This limits the production of background wild type virus alongside the recombinant and further 
enhances the efficiency of baculovirus expression (Kitts and Possee 1993, Zhao, Chapman et al. 
2003). The DNA used today ensures essentially 100% recombination and a plaque assay to isolate 




Figure 22: A pictorial overview of the BEV system (Yamaji 2011) 
 
Advancements to the system came in 1993 whereby an alternative method for producing 
recombinant baculoviruses was developed using site-specific transposition in E. coli (Luckow, Lee 
et al. 1993). A baculovirus genome was constructed to contain a mini F replicon to allow 
replication in E. coli as a bacterial artificial chromosome (bacmid), an attTn7 target site for 
transposition and a kanamycin resistance gene. Transformation of these bacmid-containing cells 
with a transfer plasmid containing regions of the Tn7 transposon that flank a baculovirus 
promoter and gene of interest, in addition to a helper plasmid that provides the transposon 
functions, results in transposition of the gene and promoter into the attTn7 locus sited in the 
baculovirus genome. The addition of a kanamycin resistance gene meant this event can be isolated 
using antibiotic selection. Recombinant Bacmid DNA, with the gene of interest, can then prepared 
and transfected into insect cells where it initiates virus replication and growth. The technology 
has gained widespread usage through commercialisation as the Bac-to-Bac system (Invitrogen), 
however it is worth noting that instability has been noted in the final virus stocks with deletions 
mapped to the mini F replicon region still contained in the final recombinant baculovirus genome  
(Pijlman, van Schijndel et al. 2003). 
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4.1.2 Advantages of baculovirus expression  
Using BEVS has many advantages as a eukaryotic expression system over prokaryotic systems or 
other eukaryotic methods such as mammalian cell lines. Safety is a major advantage as 
baculoviruses have a restrictive host range and are non-pathogenic to mammals and plants. As 
previously mentioned the fact that the baculovirus propagates in eukaryotic insect cells means 
that post-translational modifications can be made to the required proteins in a manner similar to 
that achieved using mammalian cells, with the exception of glycosylation which is restricted to 
high mannose types in insect cells (Shi and Jarvis 2007). AcNPV is used in cell lines derived from 
the fall armyworm Spodoptera frugiperda (Sf9) or from the cabbage looper Trichoplusia ni (TiNi). 
Both cell lines grow well in suspension cultures and so the system is easy to scale-up to produce 
high levels of recombinant gene expression. Sf9 cells were used for this study. 
4.1.3 Disadvantages of baculovirus expression  
Although eukaryotic cells are used, not all insect cell lines used in BEVS are able to produce 
glycoproteins with complex‐type N‐glycosylation patterns  although Sf9 cells still can (Steele, 
Stone et al. 2017). Also, when infected with baculovirus cells lyse and die which limits protein 
production. To combat this expression plasmids have been transformed into cell lines coding for 
anti-apoptotic proteins to try and delay the cell death and lysis that baculovirus infection causes.  
4.1.4 AcMNPV  
AcMNPV is the most intensively studied and commonly used protein expression vector 
baculovirus (Chen, Zhong et al. 2013). AcMNPV has a double-stranded DNA genome that is 
133.9kbp and contains at least 156 open reading frames (ORFs) (Chen, Zhong et al. 2013).  
4.1.5 The flashBAC™ System 
The flashBAC™ System (Oxford expression technologies) used within this study, uses the partial-
deletion of an essential gene encoding ORF1629 from the AcMNPV genome in order to prevent 
non-recombinant virus from replicating within insect cells (Chen, Zhong et al. 2013). The 
complementing section of the gene is also present on the transfer vectors allowing reconstruction 
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of a viable copy by the recombination event. This eliminates the need to plaque-purify 
recombinant virus from parental virus. The chitinase gene (chiA) is also deleted which results in 
the production of a higher yield of secreted or membrane targeted recombinant proteins (Lu, 
Chapple et al. 2002). Additional non-essential genes are also deleted in flashBAC™ GOLD to 
enhance both the quality and the yield of proteins expressed. Insect cells are transfected with 
lipofectin, flashBAC™ DNA, and the transfer plasmid containing the gene of interest. Homologous 
recombination takes place within the insect cells and inserts the gene of interest under the control 
of the polyhedrin promoter. It also restores the function of ORF1629 allowing viral DNA to 
replicate and produce virus particles. The baculovirus produced by the replication of the 
recombinant virus genome can be harvested directly from the culture medium of transfected 
insect cells, forming a seed stock of recombinant virus. The recombinant virus is then passaged to 
a high enough titre whereby it can be used to produce a synchronous infection of a large culture 




4.1.6 Similar studies 
 Baculovirus-expressed N protein in human sera studies 
Similar to the proposed screening described in this thesis, a 2008 U.S. study has used ELISAs to 
screen human sera to ascertain a metropolitan population’s exposure rates to several HCoVs 
(Severance, Bossis et al. 2008). The study used BEVS to produce the recombinant nucleocapsid 
proteins. The study looked at 229E-CoV, KHU1-CoV, NL63-CoV, and OC43-CoV and used feline 
coronavirus as a control. Instead of using a poly-histidine tag for purification, the study added a 
bovine polyomavirus (BVP) large T antigen peptide tag to the C terminus and fused the 
recombinant N proteins with glutathione S-transferase (GST) at the N terminus. This allowed 
verification that the full-length proteins, GST positive and BVP peptide positive by western blot, 
were being expressed. The recombinant CoV N proteins were expressed in Trichoplusia ni (High 
Five) insect cells and released by cell lysis. Interestingly the fusion proteins were not purified but 
used as crude lysates with a layer of casein-glutathione providing a capture layer for each antigen 
before being exposed to human sera (Sehr, Zumbach et al. 2001). Whether the capture of 
processed GST only or the fixed orientation of the fusion protein lessened sensitivity or sterically 
restricted antibody binding was not investigated. Using this format, sera were screened from 10 
children aged between 2 and 4, and 196 adults between the ages of 18 and 65. The proportion of 
seropositive adults for each coronavirus were as follows: 229E-CoV, 91.3%; KHU1-CoV, 59.2%; 
NL63-CoV, 91.8%; and OC43-CoV, 90.8%. There was no evidence of a significant serological 
response to the feline coronavirus control. Significant associations of coronavirus seropositivity 
and antibody levels were tested with chi-square and regression analyses. The betacoronaviruses 
OC43-CoV and KHU1-CoV were significantly associated with race (P ≤ 0.009 and P ≤ 0.03, 
respectively). OC43-CoV levels were further elevated with an association to smoking status (P ≤ 
0.03). High NL63-CoV titres were seen to be associated with socioeconomic status (P ≤ 0.04). In 
all four of the coronaviruses high-level immunoreactivity was significantly associated with the 
summer season (P ≤ 0.01 to 0.0001). The study showed a generally high level of seroprevalence 
(90.8 to 91.8%) in 196 adults for three of the four human coronaviruses (229E-CoV, NL63-CoV, 
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and OC43-CoV) and a moderate exposure rate for the fourth (59.2% for KHU1-CoV). The results 
indicate that these viruses have an established presence within the population studied with race, 
socioeconomic and smoking status as risk factors for coronavirus exposure. Higher rates of 
seropositivity were observed in African Americans, smokers, and individuals of low 
socioeconomic status. All three of these risk factors have been previously shown to make 
individuals more prone to a variety of other respiratory illnesses (Nuorti, Butler et al. 2000, 
Chatila, Hoffman et al. 2006, Hegewald and Crapo 2007).  
 Baculovirus-expressed N protein in animal sera studies 
BEVS expressed N proteins have also been used to screen animal sera. A 2001 study looked at 
turkey sera to check for prevalence of turkey coronavirus (TCV) using ELISAs  (Breslin, Smith et 
al. 2001). The ELISAs detected antibodies specific for TCV and IBV, a closely related avian 
coronavirus, but did not detect antibodies specific for other avian viruses (such as avian influenza, 
avian reovirus, avian paramyxovirus 3, avian adenovirus 1, or Newcastle disease virus). The study 
deemed that baculovirus-expressed TCV N protein was a suitable source of antigen for ELISA-
based detection of TCV-specific antibodies in turkeys. In a different study, the sensitivity and 
specificity of a competitive ELISA for the detection of TCV antibodies were determined by 
comparison with the indirect fluorescent antibody test (IFAT) (Guy, Smith et al. 2002). Again, the 
ELISA detected antibodies specific for TCV and the closely related IBV. Sensitivity and specificity 
of the ELISA relative to IFAT were 92.9% and 96.2%, respectively, which was deemed high. The 
study also concluded that the ELISA was a rapid, sensitive, and specific serologic test for detection 
of TCV antibodies in turkeys.  
 Other uses of baculovirus-expressed CoV proteins 
4.1.6.3.1 SARS-CoV S protein vaccine 
Other CoV proteins have also been expressed using BEVS, namely the spike protein. Recombinant 
proteins are useful not only for diagnostics in terms of sera screening and ELISAs, but also for 
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potential vaccines. One such BEVS S protein has been engineered as a potential vaccine against 
SARS-CoV when administered with an adjuvant (McPherson, Chubet et al. 2016). 
4.1.6.3.2 MERS-CoV virus-like particles (VLP) 
MERS-CoV VPLs made following co-expression of MERS-CoV M, E and S proteins have been 
expressed in insect cells and shown to induce specific humoral and cellular immunity in rhesus 
macaques (Wang, Zheng et al. 2017). Electron microscopy and immunoelectron microscopy 
showed that the MERS-CoV VLPs were structurally similar to the native virus. When Rhesus 
macaques were inoculated with MERS-CoV VLP and alum adjuvant, they produced virus-
neutralizing antibodies titres, specific IgG antibodies against the receptor binding domain (RBD) 
and a T-helper 1 cell (Th1)-mediated immunity. The data showed that MERS-CoV VLP have 
excellent immunogenicity in rhesus macaques and could be a promising vaccine candidate. The 
structural equivalence of the recombinant VLPs and virus particles as well as their performance 
as candidate vaccines suggested the insect cell background allowed authentic protein folding of 
all components and that any individual protein expressed similarly should be an excellent 
diagnostics antigen.    
4.1.6.3.3 IBV VLP 
VLP have also been studied in regard to their use with animal CoVs. Baculovirus-derived IBV VLPs 
have been produced with a membrane, envelope and the recombinant spike proteins and had 
their humoral immune responses measured in chickens (Xu, Wu et al. 2016). The IBV VLP were 
generated through the co-infection with three recombinant baculoviruses separately encoding the 
recombinant M, E or S genes. After subcutaneous injections into chickens the results of 
immunogenicity tests demonstrated that the efficiency of the VLP was comparable to that of the 
inactivated M41 virus vaccine in eliciting IBV-specific antibodies and neutralizing antibodies.  
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 Baculovirus expression materials and methods 
4.2.1 Materials and growth conditions 
There are a variety of growth conditions to consider when using the BEVS: 
 Foetal bovine serum (FBS)  
FBS is a growth supplement used in insect cell culture medium, even in cases where serum free 
media is used. FBS provides cells with growth-promoting factors such as amino acids, peptides, 
and vitamins. It is used to promote growth, provides shear force protection, protect against 
proteolytic degradation and environmental toxicities, and it can contribute to cellular attachment. 
There are negatives to its use; it may cause excessive foaming in bioreactors, its addition it may 
introduce contamination, its use increases cost and complexity of downstream processing, there 
may be fluctuations in price, quality, and availability, and there is a chance that FBS may cause 
suboptimal cell growth, toxicity and result in a decreased product yield. In the case of baculovirus 
growth it has been found that the presence of serum increases the viability of virus on long term 
storage (Maranga, Coroadinha et al. 2002).   
 Serum free media (SFM) 
SFM may be favoured as opposed to FBS for the negative reasons listed previously. SFM contain 
optimized concentrations of amino acids, carbohydrates, vitamins, and lipids. The media can 
reduce or eliminate the effect of rate-limiting nutritional restrictions or deficiencies. Many 
commercially available medias have been optimized to support faster insect cell population 
doubling times and high saturation cell densities. Optimized SFM formulations offer numerous 
advantages over using FBS; they eliminate the cost of FBS, they can increase cell and product 
yields, using them can improve sterility by reducing the risk of contamination and they provide 
lot-to-lot consistency. For these reasons and the negative reason listed for the use of FBS, SFM 
Insect-XPRESS™ (Lonza) was used throughout the studies described here. However, to maintain 
long-term virus stocks FBS was added to 2% final volume. With this addition and the insect-
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XPRESS™ used Sf9 cell densities in excess of 4×106 cells/mL were achieved. It also contains L-
glutamine and supports superior production of recombinant proteins when using the BEVS. 
4.2.2  Environmental Factors  
As well as medium and serums, there are other environmental factors to be considered when 
cultivating insect cells including, temperature, pH, osmolarity, aeration and shear forces. 
 Temperature 
25oC to 30oC is the preferred range for growth and infection of most cultured insect cells, with the 
optimal range 27oC to 28oC. (Shao-Hua, Hong-Liang et al. 1998). 
 pH  
pH during insect cell cultivation affects both cellular proliferation and production of both viral 
and recombinant proteins. A slightly acidic pH range of 6.2 to 6.9 is advised for most lepidopteran 
cell lines and is controlled by the use of phosphate buffers in commercial media (Zitzmann, Sprick 
et al. 2017).  
 Osmolality 
360 to 375 milliosmoles per kilogram (mOsm/kg) is the optimal osmolality of medium for use 
with most insect cell lines (Manual 2011) and is provided by the use of commercial media. 
 Aeration 
When growing is suspension insect cells need adequate transfer of dissolved oxygen by either 
passive or active methods for optimal cell proliferation and recombinant protein expression. On 
a larger scale, not used herein, bioreactor systems that use active or controlled oxygenation 
systems require dissolved oxygen at 10% to 50% of air saturation (Manual 2011).  
 Shear Forces 
Suspension culture techniques generate mechanical shear forces. The total shear stress is 
contributed to by a variety of factors including the mechanism used to create motion, the size and 
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velocity of any bubbles and the turbulent action at the culture surface. For large suspension batch 
cultures of insect cells, shear force protection is advised. Serum concentrations between 5% and 
20% are recommended to be used as specialised shear force protectant products (Lynn 2007). 
 Summary of growth conditions 
For this study the insect cells were from the caterpillar Spodoptera frugiperda (SF9 cells) 
(Invitrogen). Sf9 cells are a clonal isolate of the Spodoptera frugiperda cell line IPLB-Sf21-AE, they 
were originally established from ovarian tissue of the fall armyworm (Vaughn, Goodwin et al. 
1977). They were grown in Insect-XPRESS™ media (Lonza) and incubated at 28oC without the 
addition of antibiotics. Cells were maintained in suspension until needed, at a density of 3×105 to 
3×106 cells/mL and incubated in small batch cultures in a rotary shaker at 99rpm. These were 
used to allow infection with, and amplification of, recombinant baculovirus stocks and were also 
used for protein expression. 
4.2.3 Transfection using BEVS 
Sf9 cells were transfected in order to generate new recombinant baculovirus. Cells at a 50% 
confluence level were used to produce a monolayer in a 6-well dish (~1x106 cells/well). Lipofectin 
reagent (Invitrogen) was used to transport the mixture of flashBACGOLD (Oxford Expression 
Technologies) and transfer vector into the cells. Reactions were made up to a total volume of 24 
µL using purified water. Each reaction used 1-2µL of flashBACGOLD, 8µL of Lipofectin and 100-
500ng of the transfer vector. The lipid-DNA complex was incubated at RT for 30 minutes. Cells 
were left to attach to the plastic during this time, before being washed with serum-free media 
prior to the addition of the 24µL reaction mix. The cells were incubated for ~5 days, or until visible 
signs of infection. The supernatant recovered from centrifuging harvested cells (13,000rpm for 
15 minutes at 4oC) was used to infect fresh cells for subsequent passages to increase the viral titre. 
4.2.4 Protease inhibitors 
One problem with the BEVS when expressing recombinant protein is sometimes the level of 
proteolytic degradation. Although a proteasome has not been noted within insect cells, 
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ubiquitination of proteins produced within them has been seen (Low, Doherty et al. 1995). The 
baculovirus AcMNPV encodes a protein that has 76% identity with the eukaryotic protein 
ubiquitin called v-ubi (Guarino 1990). A frame-shift mutational study showed that the 
viral ubiquitin was a nonessential protein but reported however that it may confer a slight growth 
advantage (Reilly and Guarino 1996). Protease inhibitors are often used within protein 
production to prevent degradation. The use of the proteases inhibitors was studied on the insect 
cell line BTI-TN-5B1-4 (High Five™) and Sf9 cells (Martensen and Justesen 2001). The study 
observed that recombinant proteins migrated in SDS-PAGE in agreement with poly-ubiquitinated 
forms of the protein, suggesting a ubiquitin/proteasome degradation pathway. The study looked 
at the effect of adding proteasome inhibitors to both the growth medium of recombinant 
baculovirus-infected High Five insect cells and to the lysis buffer, to establish the most efficient 
way to inhibit proteolytic activity. It was shown that the use of cocktail protease inhibitors such 
as Complete™ (Roche Molecular Biochemicals, Hvidovre, Denmark) was insufficient, as the yield 
of protein produced in High Five cells was still impaired with 20%–50% of the protein being 
degraded.  The study screened multiple protease inhibitors: LLL (Z-Leu-Leu-Leu-CHO) also 
known as MG132; ALL (N-Acetyl-Leu-Leu-Met-CHO); Lactocystin (clasto-Lactocystin β-lactone); 
Leupeptin; E-64 (N-[N-(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucyl]-agmatin); Chloroquine; 
TPCK (tosyl-phenylalanin chloromethyl keton); Pepstatin; Pefabloc SC (4-(2-Aminoethyl)-
benzenesulfonyl-fluoride, HCl (AEBSF)); Complete (cocktail of inhibitors); P8340 (inhibitors for 
mammalian cell extracts) and P8849 (inhibitors for poly-histidine tagged proteins). As well as 
testing both High Five and Sf9 cells, two different recombinant baculoviruses were used each 
producing a different non-secreted protein (p46 and human tryptophanyl-tRNA synthetase 
(hWRS)). 
The study concluded by recommending the addition of 20µg/mL E-64 to the growth medium 24 
hours after infection, together with 100µM Leupeptin in the lysis buffer when using High Five cells 
in order to avoid extensive degradation of non-secreted recombinant proteins. This differed to Sf9 
cells, whereby treatment with the proteasome inhibitor MG132 was recommended. It is a specific 
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inhibitor of proteasome activity in eukaryotic cells (Lee and Goldberg 1998). It was shown that 
although the addition of MG132 did lead to a reduction to protein degradation, higher 
concentrations lead to a considerable reduction to recombinant protein yield. Without the 
addition of MG132 52% of the total p46 expressed was degraded, with 25µM this marginally 
reduced to 42%, however expression of the full-length protein reduced to 93%. At 50µM there 
was a marked improvement to degradation as only 3% of the protein was degraded, however 
overall expression was limited to 60%. The final concentration looked at was 125µM in which no 
protein was expressed. For this reason, when screening with MG132 during this study the 
concentration used will be 50µM in order to have the lowest amount of degradation without 




4.2.5 Protein production 
A six well dish infection was conducted over five days to ascertain whether it was possible to 
produce an IBV-his signal using the BEVS in Sf9 cells. A recombinant baculovirus expressing GFP 
was used for a control infection. A “Cells only” sample was used as a negative control. A purified 
his-tagged human scavenger receptor class B protein (SCARB2) was used as a positive control for 
the western blot. All secondary antibodies were used 1:2,000. The WB was done in two stages, the 
first to ensure the infections were efficient and the second to probe for IBV N expression.      
 
Figure 23: Western blot of baculovirus expression trials. BLUEeye pre-stained protein ladder 
was run in lane 1 and the corresponding molecular weights are marked alongside of the blot. 
Lane 2 - cells only sample, lane 3- IBV N sample, lane 4 - GFP control, lane 5 – SCARB2 control.  
Blot A) used primary antibody against P39 1:250 with secondary anti-mouse, blot B) used 
human sera as a primary antibody source and a human antibody as secondary. 
 
Figure 23 blot A was probed with an antibody to the baculovirus major capsid protein P39 and 
shows that both the IBV N protein and GFP infected tracks have strong baculovirus expression in 
lanes 3 and 4 respectively. Blot B was probed with an anti-Human SCARB2 antibody identifying 
purified SCARB protein in tack 5. As infection was clearly achieved a second blot was probed for 




Figure 24: Western blot showing the polyhistidine signal produced by each sample generated 
from BEV expression using an anti-his antibody at 1:2000. BLUEeye pre-stained protein ladder 
was run in lane 1 and the corresponding molecular weights are marked alongside of the blot. 
Lane 2 contained a “cells only” sample, lane 3 the IBV samples, lane 4 a GFP control and lane 5 a 
SCARB control. 
 
The western blot, Figure 24, shows a poly-histidine signal produced by the SCARB2 protein at 
~135kDa and a strong signal from the GFP protein and a possible faint signal for the adjacent IBV 
sample in lane 3. A repeat of this WB with reduced levels of GFP control was done to ensure a 
better balance of signal by the chemiluminescence imager, lane order was changed to try to 
prevent an overriding signal from the GFP sample (Figure 25) to allow the his-tag signal from the 
IBV sample to be visualised in lane 2.  
 
Figure 25: Western blot showing the polyhistidine signal produced by each sample using an anti-
his antibody 1:2000 and secondary mouse antibody. BLUEeye pre-stained protein ladder was 
run in lane 1 and the corresponding molecular weights are marked alongside of the blot. Lane 2 
contained the IBV sample, lane 3 a cells only negative control and finally lane 4 a GFP control 
following an additional 1:100 dilution from the sample used in Figure 24. Lanes 2 and 4 both 
show the successful production of a polyhistidine signal in both the IBV and GFP samples, the 
control lane of cells only in lane 3 remains blank. 
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4.2.6 Protease inhibitor effects 
As discussed in section 4.2.4 protease inhibitors can be beneficial whilst using the BEVS. 50µM of 
MG132 was added to Sf9 cells one-hour post infection and the results were as shown in Figure 26. 
 
Figure 26: Western blot showing the polyhistidine signal produced by each sample using an anti-
his antibody 1:2000. BLUEeye pre-stained protein ladder was run in lane 1 and the 
corresponding molecular weights are marked alongside of the blot. Lanes 2 and 3 contained a 
cell only sample, lanes 4 and 5 the IBV expression and lanes 6 and 7 a GFP control. The ticks and 
crosses under each lane denote the addition of, or lack of, 50 µM of the protease inhibitor MG132 
respectively. The MG132 was added one-hour post infection. Lane 5 shows a cleaner banding 
pattern to that of lane 4 showing that the protease inhibitor worked for the IBV example. Lane 7 
was overloaded so no comparison to lane 6 with the GFP sample could be made. 
 
Figure 26 shows that MG132 works well as a protease inhibitor in terms of reducing the amount 
of degradation shown with the IBV sample in lanes 4 and 5; however, the signal is still not at the 
expected size to be an intact IBV N protein signal (45kDa). If the BEVS was to be used to produce 
the remainder of the CoV N proteins the addition of MG132 may prove beneficial in reducing 




 Baculoexpression summary 
The results in this chapter show that the BEVS is suitable for the producing of the CoV N proteins 
required for this study however the IBV N protein would have to be extracted and purified via 
IMAC and tested on ELISAs. Transfections would need to be carried out on the other viral strains 
too. The process takes a longer amount of time than that of the prokaryotic techniques described 
in chapter 3 and would also potentially incur additional costs as protease inhibitors may need to 
be used. As such work was conducted to see if there was a better way of utilising the prokaryotic 
system to consistently produce IBV N protein without high levels of break down, detailed in 




 IBV and the generation of a truncated IBV construct 
 IBV introduction 
First described in the 1930’s in the USA, and seen in 1948 in the UK, avian infectious bronchitis 
virus (IBV) is an important pathogen within the global commercial poultry industry (Jones 2010). 
IBV can be a cause of economic loss due to reduced egg and meat productivity, the need to 
slaughter sick birds and a high mortality rate (Najafi, Ghalyanchi Langeroudi et al. 2017) which 
can reach 70% when the virus infects a farm for the first time (Cavanagh 2007). The total adverse 
effects make IBV the biggest single cause of infectious disease-related economic loss in the UK 
(Jones 2010). IBV is a Gammacoronavirus and infects avian hosts, principally chickens (Gallus 
gallus), however other bird species are thought to be infected too (Cavanagh 2007). The virus 
primarily affects the respiratory tract, including the trachea and lungs, however strains differ in 
both virulence and tropism and other organs such as the alimentary tract, spleen, ovaries and 
kidneys can also be targeted (Najafi, Ghalyanchi Langeroudi et al. 2017). Chicks of all ages are 
susceptible to infection and symptoms include coughing, sneezing, gasping and nasal discharge 
(Liu, Zhang et al. 2009). In younger chicks, death may arise due to the primary infection or as a 
result of a secondary bacterial infection. Many vaccines are available however disease control 
remains problematic for a variety of reasons. The main issue is the virus’ ability to generate 
antigenic diversity. Among the large number of IBV serotypes the S1 amino acid sequence, the 
receptor binding domain of the spike protein, may differ by 20 to 25% although sometimes this 
figure can be as high as 50% (Jones 2010) (Lai and Cavanagh 1997). Studies have shown that as 
little as 2-3% difference (10 to 15 residues) within the S1 sequence can result in a change of 
serotype producing a lack of cross-neutralization using convalescent sera (Jones 2010). This 
diversity results in the continuous emergence of new serotypes or variants and complicates the 





Whilst this study is not focusing on the use of recombinant IBV nucleocapsid as a diagnostic 
antigen as avian sera are not being screened. The IBV N protein will be used as a negative control 
when looking for sero-reaction to other coronaviruses in human sera. Any sero-reactivity to the 
IBV N protein will be used as a cut-off, and anything at this level and below will be deemed a 
negative response. Dedicated work on the expression of IBV N for the purpose was necessary as 
at the time it was conducted both the prokaryotic methods and eukaryotic methods described in 
chapters 3 and 4 respectively, were unable to provide a consistent source of stable recombinant 
IBV N protein. Of all the coronavirus N proteins expressed, IBV N proved to be the most 
problematic with either poor yields or evident breakdown of the full-length protein to smaller 
fragments. The problem was eventually overcome by use of expression in commercially bought 
BL21-star E. coli strain. This chapter details the expression work conducted in the interim on IBV 
N protein and details the construction of a novel truncated construct, designed to remove a 
potential protease sensitive region in the middle of the protein was constructed and tested.     
 IBV results  
5.2.1 Additional bacterial strains tested 
Initially the E. coli strains screened in chapter three for robust expression of soluble coronavirus 
N protein included BL21, BL21-Star, C41, C42 and Rosetta. The strongest IBV signal was seen post 
induction using C41 cells, however the results remained inconsistent in terms of both yield and 
stability, and as such two additional E. coli strains compatible with the T7 based expression 
system were also tested.   
 ArcticExpress cells 
ArticExpress cells (Agilent Technologies) are designed to increase the yield of soluble protein 
produced in E. coli by using low temperature cultivation to reduce the problem caused by 
inclusion bodies. However as shown in Figure 27, although the strain was able to produce a signal 




Figure 27: Western blot conducted on E. coli lysates from an 0.5 mM IPTG inductions of 
ArticExpress cells for 24 hours at 10oC for both MERS-CoV N protein and IBV N protein 
expression. Primary antibody was anti-his and the secondary anti-mouse-HRP conjugate. 
BLUEeye pre-stained protein ladder was run in lane 1; the corresponding molecular weights are 
marked alongside of the blot. Uninduced samples are marked with a cross under the blot and 
induced samples a tick. IBV samples are in lanes 2 and 3 and repeated with a different initial 
overnight sample in 4 and 5; neither provided a positive result. MERS-CoV inductions were run 
in lanes 6 and 7 and repeated in 8 and 9. MERS-CoV showed strong signal even in the un-induced 
in 6 and 8. 
 Mass spectrometry 
Further analysis of the lower molecular weight band seen in Figure 15 was done to ascertain if the 
protein was undergoing a specific cleavage event and, if so, at which sites the breakdown was 
occurring. Following SDS-PAGE the IBV samples were stained with coomassie blue and the band 
was cut out and set to the Protein and Nucleic Acid Chemistry (PNAC) Facility at the Biochemistry 
Department of the University of Cambridge for mass spectrometry. All buffers were filtered, and 
the gel was only handled with gloves to avoid risk of contamination. The results, detailed in 
appendix five, showed the bands in question not to be related to IBV nucleocapsid protein but 
instead to be three E. coli contaminant proteins; peptidylprolyl cis-trans isomerase A (PPIA), 30S 
ribosomal protein S4 and GTP cyclohydrolyase 1 (GTPCH). Thus, low level IBV N expression may 
be masked by high background E. coli protein binding to the IMAC column.  
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 LOBSTR and LOBSTR-ril 
As a result of the contamination seen by the mass spectrometry, LOBSTR (low background strain) 
cells were tested as the induction hosts for the expression of IBV N. LOBSTR cells (Kerafast) are 
designed specifically for polyhistidine-tag affinity purification of proteins expressed in E. coli, as 
they reduce the presence of naturally histidine-rich contaminant proteins (Andersen, Leksa et al. 
2013). However, Figure 28 shows that protein induction at the molecular weight indicative of N 
protein expression was again only successful with the control MERS-CoV N-protein 
transformation and not the IBV construct. 
 
Figure 28: Western blot of E. coli lysates using primary anti-his antibody and anti-mouse HRP 
conjugate as a secondary antibody. 0.5 mM IPTG inductions were conducted using LOBSTR and 
LOBSTR-ril cells for 3 hours. BLUEeye pre-stained protein ladder was run in lane 1; the 
corresponding molecular weights are marked alongside of the blot. Uninduced samples are 
marked with a cross under the blot and induced samples a tick. Neither LOBSTR nor LOBSTR-ril 
provided a successful IBV induction as shown in lanes 6-9. MERS-CoV was able to be successfully 





5.2.2 IBV temperature  
Similar to the use of ArcticExpress cells, the optimized combination of IBV N expression in C41 
was assessed at two different temperatures, 37oC and 28oC. However as shown in Figure 29, the 
reduced temperature showed no real benefit. Even when induction was conducted at 37oC the 
yield was very low and a band was only visible on a high contrast negative of the image, again 
showing the inconsistency of results seen when using C41 to express IBV N protein.  
 
Figure 29: Western blot of E. coli lysate using primary anti-his antibody and anti-mouse HRP as a 
secondary antibody. 0.5mM IPTG inductions were conducted on IBV N protein C41 cells for 3 
hours. Induction at 37oC shown in lanes 2 and 3 and a lower temperature of 28oC in lanes 4 and 
5. A negative repeat of the image is shown to the right in order to help visualize bands. BLUEeye 
pre-stained protein ladder was run in lane 1; the corresponding molecular weights are marked 
alongside of the blot. All samples are post induction. The – at the bottom of the blot indicates 
that the sample is yet to be lysed whereas the + symbol indicates the lysis has taken place. The 





5.2.3 Autoinduction media 
As a way of making the process more efficient an autoinduction medium (Formedium) was trialled 
on all the N expressing strains constructed to date.  This media has been formulated to grow all 
strains until a density at which natural induction of the lac promoter takes place. This is achieved 
by having a limited glucose concentration which is preferentially metabolised by the E. coli during 
growth. Once this is depleted in mid- to late- log phase, the bacteria switches to metabolising 
lactose and the lac promoter is activated, which induces expression of the chromosomally 
encoded T7 RNA polymerase and any genes under T7 promoter control. 
 
Figure 30: Western blot on E.coli lysate using primary his antibody and anti-mouse as a 
secondary antibody, conducted using lysate from all 5 HCoV N constructs when grown using 
autoinduction media. Cultures were incubated for 3 hours. BLUEeye pre-stained protein ladder 
was run in lane 1; the corresponding molecular weights are marked alongside of the blot. All 
samples are post induction. The –ve at the bottom of the blot indicates that the sample is yet to 
be lysed whereas the +ve symbol indicates the lysis has taken place. MERS-CoV shown in lanes 2 
and 3 used BL21 cells, as did OC43-CoV seen in lanes 4 and 5. NL63-CoV seen in lanes 6 and 
seven used BL21-Star, as did 229E-CoV shown in lanes 8 and 9. Lane 10 was left blank. IBV at 
two different temperatures was done using C41. No signal remained for any samples post lysis. 
 
Figure 30 shows that although four of the proteins were expressed after autoinduction had 
occurred (MERS-CoV, OC43-CoV, NL63-CoV and 229E-CoV) IBV was not one of them. In all cases 
signal appears lost post-lysis either as a result of volumes not being accounted for in preparation 
for SDS-PAGE or possibly as a result of inclusion bodies.  These results show that neither varying 
the temperature of the induction nor the use of autoinduction media helped to make IBV N protein 
expression more efficient. As a result of these findings a dedicated new IBV construct was 
designed following an analysis of the N protein secondary structure.   
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 IBV expression and purification 
5.3.1 Comparative IBV expression 
To clarify which cell line provided optimal expression of N protein all five T7 compatible E. coli 
strains used to date were screened alongside each other. The ArcticExpress was induced as per 
manufacturer’s recommendation of 10oC for 24 hours, instead of the 37oC for 3 hours protocol 
used for all other strains. Figure 31 again shows C41 cells to produce the strongest band by 
western blot with an anti His antibody. However as mentioned in section 3.5.5 Large scale 
inductions this was unable to be replicated at a larger scale and the second band seen between 
the 20-25kDa marker in the majority of successful constructs shows breakdown of the protein is 
occurring even with the use of protease inhibitors. 
 
Figure 31: Western blot on E.coli lysate using primary his antibody and anti-mouse as a 
secondary antibody. Lysate gained from all strains of E.coli used to express IBV N protein. 
BLUEeye pre-stained protein ladder was run in lane 1; the corresponding molecular weights are 
marked alongside of the blot. All inductions were done using 0.5 mM IPTG and took place for 3 
hours at 37oC except the ArticExpress ones shown in lane 7 and 8 which were conducted at 10oC 
for 24 hours. The band shown appears around the expected 45 kDa mark. Bold inductions went 
on to be pooled, lysed and manually put through the his trap column (BL21, BL21-star, c41, 
Rosetta and ArcticExpress 2 shown in lanes 2,3,4,6 and 8 respectively. C42 and ArticExpress 1 in 




5.3.2 Immobilized Metal Affinity Chromatography (IMAC) 
Any single N proteins expressed post IPTG induction should be identical regardless of which E. 
coli strain was used to express it, therefore pooled IPTG induced IBV samples were lysed as 
described in the methods (2.2.2.1 Cell lysis), before being applied, washed and eluted by syringe 
through the IMAC column, each eluted fraction being 5mLs in volume.  
 
Figure 32: Western blot on E.coli lysate using primary his antibody and anti-mouse as a 
secondary antibody, showing the results of IMAC on an IPTG induced pooled IBV samples. 
BLUEeye pre-stained protein ladder was run in lane 1 and the corresponding molecular weights 
are marked alongside. The initial lysis load is in lane 2, the flow through is shown in lane 3. 
Fractions 1-6 are displayed in lanes 4-9 as marked at the bottom of the gel. Signal can be seen in 
lanes 4 and 5, indicating that tubes 1 and 2 contain the protein. Bands appear just under 48kDa, 
showed by a black arrow. Possible breakdown bands are indicated with a red arrow around the 
25kDa mark. 
 
Although there is signal present in the flow through (lane 3), fractions 1 and 2 contain signal of 
the correct MW too, albeit with other proteins. A main signal appears just under the 48kDa 
molecular weight marker, which is close to expected 45kDa, in the 10mL combined fractions of 




5.3.3 Testing part purified IBV N-protein with positive sera 
Positive animal sera was used to test bind to the IBV N-protein to show its utility as an ELISA 
antigen, the results are shown in Figure 33.  The ELISA was conducted in duplicates and the 
averages were plotted. The mouse monoclonal antibody gave the strongest signal, as expected of 
a purified MAb.  Weaker although still positive binding was seen in the chicken and rabbit sera. 
Unfortunately, no data on titre or strain was given with the gifted sera and the animals themselves 
may not have produced high titre antibodies to the virus used as immunogen.  
 
Figure 33: ELISA results of suspected positive animal sera against recombinant IBV protein. Sera 
used is colour coded; chicken in blue, mouse in red and rabbit in purple. The dilution series 
started with the stock sera being diluted 1:500 and followed a two-fold dilution series. As such 
1= 1:500, 2=1:1,000, 3=1:2,000, 4=1:4,000, 5=1:8,000, 6=1:16,000, 7=1:32,000 and 8=1:64,000. 
The results show that only the mouse sera produced a reaction. Error bars not shown due to lack 
of repeats. 
 
 As such, the ELISA was repeated with the mouse sera starting with an initial dilution of 1: 10,000. 
This was done in duplicate as indicated by test one and test two shown in Figure 34. The drop-off 
in absorbance as dilution of sera increases indicates a true reaction. The concentration of mouse 
sera may have been much higher than that of the chicken and rabbit or it may be that the mouse 
































Figure 34: ELISA result of further diluting the mouse sera against recombinant IBV protein. The 
test was done in duplicate, test one results are in blue and test two results are in red. The 
dilution series started with the stock sera being diluted 1:10,000 and followed a two-fold 
dilution series. As such dilution 1=1:10,000, 2=1:20,000, 3=1:40,000, 4=1:80,000, 5=1:160,000, 
6=1:320,000 and 7=1:640,000 and 8=1:1,280,000. The results shows the expected drop-off of 
absorbance with increased dilution indicating that the mouse sera has a true reaction to the 
recombinant IBV N protein. Error bars not shown due to lack of repeats. 
 
As the purpose of the recombinant IBV N protein is to be a negative control when screening human 
sera, an ELISA was also conducted using known positive human coronavirus sera with the 































Figure 35: ELISA result of human sera known to be positive for HCoVs against recombinant IBV 
N protein. Sera used is colour coded; MERS-CoV in blue, OC43-CoV in green, NL63-CoV in purple, 
229E-CoV in yellow, SARS-CoV in red. The dilution series started with the stock sera being 
diluted 1:50 and followed a two-fold dilution series. As such 1= 1:50, 2=1:100, 3=1:200, 4=1:400, 
5=1:800, 6=1:1,600, 7=1:3,200 and 8=1:6,400. Although no reaction should be seen OC43-CoV 
and 229E-CoV produce strong signals, it is worth noting that due to the volume of sera available 
10 times less was used during the animal sera screening. Error bars not shown due to lack of 
repeats. 
 
Ideally Figure 35 would show that the recombinant IBV N protein produced no reaction when 
screened with the known positive human sera. However, OC43-CoV and 229E-CoV sera appear to 
react with IBV N protein suggesting that the use of IBV N as a method to recognise nonspecific 
binding may not be valid. There is only one positive sera for each HCoV to test on and it may be 
that the concentration or stickiness of the sera is high enough to produce false positives. The sera 
would need to be screened with both recombinant IBV N protein and its corresponding HCoV 
protein to see if the IBV result would interfere with the overall interpretation of results. In any 
event, screening on IBV N was only envisaged in cases where there was apparent reaction with 
multiple sera. In order for IBV to play the role of a negative control first a more stable recombinant 































 Protein structure 
5.4.1 N protein structure introduction 
The N proteins of different coronaviruses share regions of homology and can be divided into five 
parts; the N terminal flexible arm, the N terminal domain (NTD), the middle-disordered region 
referred to as the linker region (LKR), the C terminal domain (CTD) and the C terminal flexible tail 
(Gui, Liu et al. 2017). Three domains (NTD, LKR and CTD) have been shown in different CoVs to 
bind with viral RNA (McBride, van Zyl et al. 2014). Most of the literature available focuses on the 
SARS-CoV N protein structure however the homology of the proteins allows for structural 
similarities to be inferred for IBV. 
 N Terminal Domain 
The NTD, also referred to as the RBD (RNA-binding domain), varies in sequence and length among 
CoVs. The NTD of IBV-CoV has been mapped to aa 19-162 as seen in part a of Figure 36 (Jayaram, 
Fan et al. 2006). Common characteristics of CoV N protein NTDs include predicted secondary 
structures including a central β-sheet platform bordered by α-helices (Jayaram, Fan et al. 2006), 
a basic RNA binding groove along the β-sheet platform and an extended β-hairpin (McBride, van 
Zyl et al. 2014). The NTD is rich in aromatic and basic residues and the 3-dimensional (3D) 
structure is said to resemble a right hand with a hydrophobic palm, basic figures extending 
beyond this and an acidic wrist (Fan, Ooi et al. 2005, Tan, Fang et al. 2006). The β-hairpin finger-
like projections are flexible and positively charged and are thought to bind RNA by neutralizing 
the DNA phosphate groups, whilst at the same time the RNA base moieties can come into contact 
with exposed aromatic residues located in the hydrophobic palm (Fan, Ooi et al. 2005). There are 
two prominent regions within loops corresponding to residues 22 to 23 and 74 to 86; they 
protrude from the globular core resulting in a “U” shaped monomer (Jayaram, Fan et al. 2006). 
Site-directed mutagenesis studies have identified Tyr-94 and Arg-76 as critical residues for RNA 
binding (Tan, Fang et al. 2006). Tyr-94 is located in strand β3 of the four-stranded anti-parallel β 
sheet and Arg-76 is located close by at the base of the extended flexible hairpin loop (Tan, Fang et 
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al. 2006). However as no single mutation is able to completely disrupt RNA binding it is thought 
that other aromatic/basic residues at the surface of the NTD also contribute to nucleic acid 
binding (Tan, Fang et al. 2006). A 2006 study by Jayaram, Fang et al was able to use limiting 
amounts of trypsin to identify two stable independent domains of IBV N protein (Jayaram, Fan et 
al. 2006). The treatment showed two major cleavage sites at residues 19 and 219 and two 
secondary sites at 27 and 226 as seen in Figure 36 (Jayaram, Fan et al. 2006). The study referred 
to the constructs produced from residues 19 to 162 aa as the NTD and from 219 to 349 aa the 
CTD; they found that the NTD was monomeric at moderate protein concentrations but even at low 
concentrations the CTD formed a dimer (Jayaram, Fan et al. 2006). The study went on to conduct 
x-ray crystallography of the Gray strain of IBV which diffracted to 1.3-Å resolution. The structure 
of the Gray strain of IBV has been found to be quite similar to the Beaudette strain previously 
reported, as used in this study, with the exception of five additional residues in the NTD (Jayaram, 
Fan et al. 2006). Biochemical studies have located the RNA binding site in the N-terminal domain 
with the minimal region being mapped to residues 177 to 231 in MHV (corresponding to residues 






Figure 36: The structural domains of the IBV N protein and the NTD RNA binding domain (A) 
Schematic diagram showing the major (arrow) and minor trypsinization sites (short vertical 
line) seen in the Jayaram, Fan et al study. The locations of the N- (residues 19 to 162) and C-
terminal domains (residues 219 to 349) are depicted as black rectangles. (B) Ribbon 
representation of the 1.3-Å structure of the NTD Gray strain asymmetric homodimer each 
monomer labelled A and B. The LKR is coloured orange. (C) The NTD of the Beaudette strain 
determined by Fan et al. (Jayaram, Fan et al. 2006). (D) Electrostatic potential surface of the 
linear array of NTD dimers molecules A and B that form the dimers are indicated. The N-
terminal arm is indicated by a black arrow and the region corresponding to the internal arm, 
rich in basic residues, a cyan arrow. The LKR in the B molecule is indicated by a dotted line. 
Image from (Jayaram, Fan et al. 2006) 
 
 Intrinsically disordered regions (IDRs) 
The NTD and the CTD are interspersed with areas termed intrinsically disordered regions (IDR), 
meaning they lack a tertiary structure and have no fixed 3D shape in the native form. The IDRs 
account for almost half of the molecule (Chang, Hsu et al. 2009). In SARS-CoV N protein there are 
three main IDRs, one before the NTD (aa 1-44), one after the CTD (aa 366-422) and a central one 
referred to as the LKR (aa 182-247). One study used electrophoretic mobility shift assays (EMSA), 
small-angle X-ray scattering (SAXS) and nuclear magnetic resonance (NMR) to examine the RNA 
binding behaviour of all three disordered regions of the SARS-CoV N protein. It was shown that all 
three regions are involved in RNA binding (Chang, Hsu et al. 2009). The study showed that the 
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presence of either the first SARS-CoV IDR (aa 1-44) or the LKR (aa 182-247) increased the 
apparent binding affinity to ssRNA three to fourfold over that of the NTD alone (aa 45-181) 
(Chang, Hsu et al. 2009). There was a six to eightfold increase in binding affinity seen with the 
inclusion of either the LKR or the C-terminal IDR (aa 366-422) in the construct of the CTD (aa 248-
365). This is likely to be due to the dimeric state of the CTD which has two disordered regions 
attached whereas the NTD only has one. The presence of IDR allows for extended conformation of 
the N protein which can increase the collision radius with RNA. In SARS-CoV, both the middle and 
C-terminal IDRs have been implicated in the oligomerization of the N protein (Chang, Sue et al. 
2006, Luo, Chen et al. 2006) and the middle IDR (the LKR) is also associated with N protein 
functionality and N-M interaction (McBride, van Zyl et al. 2014). 
 Linker region (LKR) 
The LKR, also referred to as the SR-domain due to the high frequency of serine and arginine 
residues, is intrinsically disordered (Chang, Sue et al. 2006, Hurst, Koetzner et al. 2009). The 
region is flexible, capable of direct RNA interaction in vitro and is known to be involved in cell 
signalling (You, Dove et al. 2005, Chang, Hsu et al. 2009, Chang, Chen et al. 2013). Unlike the 
structural CTD and the NTD, the disordered regions of the different coronaviruses share little 
sequence homology. However, they do have similar physiochemical properties; all Coronavirus N 
protein LKRs start with the SR-rich region, followed by a helix, and end with a region rich in basic 
residues (Jayaram, Fan et al. 2006, Chang, Hsu et al. 2009). One study showed the RNA binding 
affinity of the LKR was comparable with that of the CTD and NTD (Chang, Hsu et al. 2009). Studies 
have shown the LKR to be directly involved in N protein oligomerization; mutational deletions to 
the area has been shown to abolish N protein self-multimerization (He, Dobie et al. 2004). The 
LKR contains phosphorylation sites and it is proposed that hyperphosphorylation of the area 
reduces the total positive charge of the protein and leads to enhanced oligomerization of di-
domain constructs (Chang, Chen et al. 2013). However, some studies oppose this idea and report 
that the LKR interferes with oligomerization if it is phosphorylated (Peng, Lee et al. 2008) or when 
the CTD is also present (Luo, Ye et al. 2005). The LKR is prone to degradation and limited 
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structural information is available due to its flexible nature and high positive charge (Chang, Hsu 
et al. 2009). Inclusion of the LKR has been shown to increase ssRNA binding affinity and also has 
a noticeable effect on the apparent Hill coefficient, which is a measure used to quantify the degree 
of interaction between ligand binding sites (Weiss 1997, Chang, Hsu et al. 2009).  
 SR-rich region 
The beginning of the LKR contains a Serine and Arginine rich area (Chang, Chen et al. 2013). The 
SR-rich region has been shown to carry out a number of protein-protein interactions and play a 
part in self-association (He, Dobie et al. 2004, Chang, Hsu et al. 2009). The region has multiple 
phosphorylation sites and contains the highest density of positive charges within the LKR and 
making it important for RNA binding (Surjit, Kumar et al. 2005). 
 CTD disordered region 
The IDR located at the CTD has also been shown to participate in the oligomerization of the N 
protein (Luo, Chen et al. 2006) and to bind to nucleic acid (Chang, Hsu et al. 2009). The highly 
charged nature of both the LKR and the CTD IDR hinders N protein to N protein interaction due 
to charge repulsion between the domains. However this may be neutralized by the binding of 
nucleic acids, allowing two protein molecules to come into contact and oligomerise (Chang, Hsu 
et al. 2009).  
 Summary of IDR 
The presence of the IDRs is advantageous when it comes to the formation of the RNP. The LKR’s 
flexibility allows more freedom for different parts of the N protein to interact with each other, 
resulting in specific packaging of the helical RNP molecule. The ID regions could also play a role 
in optimizing the interaction of the RNA molecule with all the other segments of the N protein 




 C-terminal domain (CTD) 
The CTD, sometimes referred to as the dimerization domain (DD), is hydrophobic and helix rich. 
It has been mapped to aa 219-340 for IBV (Fan, Ooi et al. 2005). The CTD is a tightly intertwined 
dimer with twofold symmetry (Jayaram, Fan et al. 2006). It has two β strands and one α helix from 
one monomer making extensive contacts with the other monomer. The CTD dimer has a 
rectangular shape. There is a concave floor consisting of an antiparallel βsheet (β1A-β2A-β2B-
β1B) contributed by monomers A and B, surrounded by several α helices and one short 310 helix. 
Several biochemical studies map the dimerization domain of the full-length protein to its C-
terminal domain (Surjit, Liu et al. 2004, Yu, Gustafson et al. 2005). One study conducted in vitro 
oligomerization using cross-linking techniques showed that residues 218-329 within the CTD of 
IBV play a major role in the proteins multimerization (Fan, Ooi et al. 2005).  
In its monomeric form the CTD folds into a structure with a large cavity in the centre, rendering it 
unstable and making oligomerization necessary for a stable conformation (Yu, Oldham et al. 
2006).  
Reverse genetic-complementation assays have shown the CTD to be responsible for N protein 
interaction with M proteins within the viral membrane (Kuo and Masters 2002). It is thought that 
this interaction is principally electrostatic in nature; involving the basic C terminus of the M 
protein and an acidic β-sheet floor in the CTD dimer (Luo, Wu et al. 2006).  
A 2005 study by Tang, Wu et al., used monoclonal antibodies (mAb) directed to specific epitopes 
along the N protein structure of SARS-CoV and concluded that the C-terminal fragment (amino 
acids 214 – 422) is buried within the entire N protein (Tang, Wu et al. 2005) this could explain 
why locating the polyhistidine tag at the C terminus in previous work undertaken in the laboratory 
was less successful in producing detectable soluble protein, whereas relocating the polyhistidine 






Figure 37: Structure of the CTD dimerization domain. The left panel shows a ribbon 
representation of the “front” and “back” of the CTD dimer related by a rotation of 180° about the 
vertical axis, and the right panel shows the electrostatic potential surface of the dimer in the 
same orientations. Positively charged surfaces are represented in shades of blue and the 
negatively charged surfaces in shades of red. Left: The intertwined CTD dimer is formed by 
exchanging two β strands and one α helix between the two monomers. The two monomers, 
shown in yellow and grey, are related by a noncrystallographic twofold axis of symmetry. The β 
strands from both monomers form an extended antiparallel β-sheet floor flanked by several α 
helices. Secondary structural elements are labelled. Right: a large patch of positively charged 
residues (blue) that could be involved in RNA binding is visible on one of the faces of the CTD 




 Tertiary structure 
The N protein packages the viral genome into a helical ribonucleocapsid and is vital for viral self-
assembly (Chang, Chen et al. 2013). There are two main activities involved in packaging the viral 
genome with structural proteins to produce the RNase resistant ribonucleoprotein (RNP) 
complexes (Jayaram, Fan et al. 2006). One is the interaction between protein and nucleic acid, the 
other is the ability of the complex to oligomerise (Zlotnick 2005). Coronavirus N proteins preform 
both of these functions (McBride, van Zyl et al. 2014).  
As mentioned N proteins are dimeric, in vitro these dimers have shown a tendency to form 
tetramers and oligomers with higher molecular weights (Yu, Gustafson et al. 2005). X ray 
crystallography of the CTD has shown that two dimers create a butterfly-shaped tetramer which 
then come together to form an octamer (Chen, Chang et al. 2007). The SARS-CoV N protein dimer 
is formed principally by insertion of the β-hairpin of one subunit into the cavity of the opposite 
subunit, this causes four β-strands of two subunits to form an anti-parallel β-sheet that is covered 
by two long alpha helices (Yu, Oldham et al. 2006). The interaction is highly stable as a result of 
the extensive hydrogen bonds between the two hairpins alongside the hydrophobic interactions 
between the beta-sheet and the alpha helices (Chang, Sue et al. 2005). The octamer’s structure is 
maintained through hydrophobic interactions and hydrophilic contacts among the four dimers; 
inter-dimer hydrogen bonds help stabilize the octamer further (Chen, Chang et al. 2007). The CTD 
has also been shown to cause oligomerization in 229E-CoV via its C terminal IDR (Lo, Lin et al. 
2013). Disruption of N protein self-association via oligomerization could be a possible target area 




5.4.2 Structure of other positive-stranded ssRNA viral N proteins 
Other positive-stranded ssRNA viruses have had their nucleocapsid proteins studied. Crystal 
structures are available for porcine reproductive and respiratory syndrome virus (PRRSV) in 
the Arteriviridae family (Doan and Dokland 2003), West Nile virus in the Flaviviridae family 
(Dokland, Walsh et al. 2004), and Sindbis virus and SemLiki Forest virus in the Togaviridae family 
(Choi, Lu et al. 1997) (Choi, Tong et al. 1991). A systematic structural homology search (Holm and 
Sander 1998) showed the coronavirus N protein CTD closely resembles the N protein of PRRSV. 
The PRRSV CTD (aa 73-123) has a similar dimeric structure and displays self-association as seen 
in the IBV CTD (Doan and Dokland 2003). Although the CTD fold is shared with the arterivirus 
PRRSV, the NTD fold is seen only in the coronavirus N proteins (Fan, Ooi et al. 2005). The N protein 
of PRRSV is shorter and the NTD appears to be largely disordered (Doan and Dokland 2003). It is 
thought that members of the Coronaviridae and Arteriviridae families (order Nidovirales) share 
a common mechanism of filamentous nucleocapsid formation, as their structures appear similar. 
However, it is assumed that there are adaptations in order to interact specifically with their 
respective genomes. Structural differences occur with flaviviruses and togaviruses, which display 
icosahedrally symmetric exteriors and are not pleomorphic like coronaviruses (Zhang, Corver et 
al. 2003, Mukhopadhyay, Kuhn et al. 2005), probably reflect variations in their replication 
strategies and assembly pathways  (Jayaram, Fan et al. 2006). The two distinct domains whereby 
one dimerises and the other interacts with the viral gene, remains a common N protein feature 




5.4.3 Protein stability 
5.4.4 Predicted protein disorder plots 
Other studies have noted that recombinant coronavirus N protein expressed in E. coli can be 
highly susceptible to proteolysis (Fan, Ooi et al. 2005, Jayaram, Fan et al. 2006, Zuwała, Golda et 
al. 2015). As discussed in section 5.4.1.3 one of the main areas of disorder is the flexible LKR. This 
can be further seen when using protein predicted disorder software PrDOS (Protein disorder 
prediction system) (Ishida and Kinoshita 2007) to plot the disordered areas of the amino acid 
sequence of IBV N, shown in Figure 38. Similar patterns showing a disordered central region are 
seen for all of the CoV N protein sequences, results not shown. 
 
Figure 38: Predicted protein disorder plots for the full-length IBV construct, created using 
PrDOS (Ishida and Kinoshita 2007). Section A shows the amino acid sequence, disordered 
residues are shown in red, the block box indicates the main area of disorder being focused on 
from Isoleucine 167 to Arginine 235. Section B shows the disorder plot with the false positive 
rate threshold set to 5.0%, again the area of disorder being focused on corresponding to the 





 Delta IBV 
5.5.1 Introduction to delta IBV 
To improve IBV N expression levels and minimise degradation, it was decided to delete the 
disordered region to see if it would produce a more stable truncated protein construct, which 
would remain antigenic. Amino acids 167 to 235 were chosen to be removed creating a construct 
IBVΔ167-235 which will be simply referred to as ΔIBV. The original full length IBV sequence was 
418 amino acids and had an expected molecular weight of 46kDa, whereas ΔIBV is 349 amino 
acids long with an expected molecular weight of 39kDa. A truncated recombinant nucleocapsid 
protein has been successfully used for diagnostic purposes already in the case of OC43-CoV 
(Blanchard, Miao et al. 2011). The study created three sections of OC43-CoV N protein, (N1= aa1-
119, N2=120-332 and N3=333-448 of MWs 17kDa, 25kDa and 17.5kDa respectively) to be used 
as antigens in immunoassays (Blanchard, Miao et al. 2011). A total of 15 acute and 11 convalescent 
sera from OC43-CoV patients were screened against all three constructs. All three constructs 
showed reactivity against antibodies in the convalescent sera, however detection by acute-phase 
sera was limited. The predominant response (11 out of 11) was seen against N3, followed by a 
lesser response to N2 and N1 (4 and 3 out of 11 respectively). The study saw cross-reactivity of 
full-length recombinant OC43-CoV N protein with convalescent 229E-CoV and SARS-CoV sera. 
However, the absorbance seen was reduced by 88-90% when the sera was screened against the 
N3 construct as opposed to the full-length N protein (Blanchard, Miao et al. 2011). Although this 
study is not planning on separating N proteins into three fragments it does imply that the antigenic 
reactivity is not limited to the central domain of the protein but that is lies rather in the CTD and 
therefore ELISA results should not be substantially affected by the removal of the central region.  
After varying PCR conditions to try and produce the truncated IBV construct using the QuikChange 
II site-mutagenesis proved unsuccessful, the sequence was instead designed and ordered in from 
Life Technologies Limited. The ΔIBV sequence is 1047bp long, 207bp smaller than the full-length 




Figure 39: Gel electrophorisis showing the size difference between the full length IBV insert and 
the ΔIBV. Hyperlader I was used in lane 1, the lane labelled 2 contains the full length IBV and 
lane 3 ΔIBV. Although the lanes were overloaded and did not run at the ~1200bp and ~1000bp 
expected the difference seen between the two bands indicated the 200bp deletion was 
successful (~1000bp and ~800bp) the gel molecular sizes may be better assessed with a more 
dilute loading and/or longer running of the gel for a greater resolution. 
 
The ΔIBV synthetic DNA was digested by restriction enzyme NcoI and XhoI and ligated into the 
pTriEx1 vector, similar digested. Following transformation and isolation, the correct construct 
was characterised and digested by both enzymes next to all previously isolated N expression 
constructs digested similarly. Results for the double digest to show vector and inserts for NL63-





Figure 40: Gel electrophoresis showing five constructs after a double enzyme digest using Nco1 
and Xho1. HyperLadder I was loaded in lane 1, lane 2=blank, lane 3= NL63-CoV, lane 4=OC43-
CoV lane 5=229E-CoV lane 6= IBV and lane 7=ΔIBV. Bands denoted by the letter A show the 
larger his-tagged vector pTriEx1 (5301bp) and bands shown by the letter B are the viral-specific 
inserts, lane 6 and 7 show the ~200bp deletion lost by the mutation to IBV. 
 
Based on published sequences found on NCBI the size of each insert band, should be 1,131bp for 
NL63-CoV, 1,344bp for OC43-CoV, 1,344 for 229E-CoV and 1,167 for IBV. As shown in Figure 40 
the bands lie in between the 1,000bp and 1,500bp size markers with OC43-CoV being greater than 
the rest. Similar correct band sizes were observed for MERS-CoV and SARS-CoV (data not shown). 
Figure 40 shows the ΔIBV construct has been successfully inserted into the pTriEx1 plasmid and 
is therefore ready to be transformed into a suitable E. coli strain for IPTG induction. 
Whilst work was being undertaking to construct the ΔIBV construct, DNA encoding for SARS-CoV 
N protein was sourced and underwent the same processes detailed in section 3.4, results not 
shown, such that purified SARS-CoV N protein could be screened alongside the previous 5 H-CoV 




5.5.2 Delta IBV expression and purification 
Also whilst work was done on creating the truncated IBV protein, the laboratory purchased some 
SoluBL21 cells and found that to be the preferred T7 compatible expression host at consistently 
expressing all coronavirus N proteins, as shown Figure 42. Therefore, SoluBL21s were also used 
to express ΔIBV as shown in Figure 41. The corresponding band appears around the expected 
39kDa mark, smaller than the full length expected 46kDa, although appears slightly overloaded. 
The reduced protein size of the ΔIBV construct seen in lane 16 was accompanied by apparently 
less break protein down as fewer lower MW bands are visible.  
 
Figure 41: Western blot on E.coli lysate using primary his antibody and anti-mouse as a 
secondary antibody. Lysates generated from eight 0.5mM IPTG 50mL inductions using SoluBL21 
cells. Lanes 1 and 11 contain BLUEeye pre-stained protein ladder and the corresponding 
molecular weights are marked alongside of the blot. Crosses and ticks underneath the blot 
indicate whether the sample is uninduced or induced respectively. Lanes 2 and 3 contain the 
SARS-CoV recombinant N protein induction, lanes 4 and 5 MERS-CoV, lanes 6 and 7 NL63-CoV, 
lanes 12 and 13 229E-CoV, lanes 14 and 15 IBV, lanes 16 and 17 ΔIBV and lanes 18 and 19 a cell 





5.5.3 Delta IBV comparison to full length IBV ELISA 
ELISAs were conducted in order to see if the ΔIBV N protein retained the antigenicity of the full-
length protein. Methods for purifying IBV and ΔIBV N protein via IMAC were the same as detailed 
in section 2.2.2Protein extraction, purification, concentration and storage, results not shown. The 
same mouse, chicken and rabbit sera used for the original IBV N protein ELISAs, section 5.3.3, 
were used. The ELISA was conducted in duplicates and the average results plotted in Figure 42. 
 
Figure 42: ELISA results showing the average results of suspected positive animal sera against 
recombinant full-length IBV N protein and the mutant ΔIBV N protein. Sera used is colour coded; 
chicken in blue, mouse in red and rabbit in purple. The results for the full-length construct are 
marked with solid lines and markers and the ΔIBV with hollow markers and dotted lines. The 
dilution series started with the stock sera being diluted 1:500 and followed a two-fold dilution 
series. As such 1= 1:500, 2=1:1,000, 3=1:2,000, 4=1:4,000, 5=1:8,000, 6=1:16,000, 7=1:32,000 
and 8=1:64,000. The results show that only the mouse sera produced a reaction and also that the 
ΔIBV N protein is able to produce a similar pattern to the full-length construct with a slightly 
lower absorbance. Error bars not shown due to lack of repeats. 
 
The results in Figure 42 show that the ΔIBV is able to bind test sera to produce similar absorbance 
readings and titration patterns as the full length IBV N construct. Similar mutations could be 
undertaken in the other 5 viral strains to improve stability however due to time limitations this 



































 ΔIBV discussion   
This chapter looked to overcome the problem of protein break down and inconsistent expression 
of the IBV N protein that was seen prior to the purchase and use of SoluBL21 cells. Two additional 
prokaryotic cell lines (Artic Express and LOBSTR) were investigated but were unable to produce 
a band on westerns blot, as seen in sections 5.2.1.1and 5.2.1.3 respectively. Autoinduction media 
was also not deemed beneficial.  
Removing the disordered flexible LKR region, amino acids 167 to 235, produced an IBV N protein 
construct that was 349 amino acids long with an expected molecular weight of 39 kDa. Post 
protein expression and purification the protein was shown to be able to elicit comparable ELISA 
results to the full-length protein, see figure Figure 42, and deemed a success.  
The concept of using truncated recombination nucleocapsid proteins for diagnostic purposes is 
not new, as already mentioned Blanchard et al in 2011 looked at doing this for OC43-CoV N protein 
(Blanchard, Miao et al. 2011).  
Yu, Lee et al used truncated SARS-CoV N protein to conduct ELISAs; the team found the 
(N)Delta(121) truncated protein was able to provide them with better levels of sensitivity and 
specificity when screening health care workers in Vietnam compared with the full length N 
protein based ELISA; making it useful for large scale epidemiological studies (Yu, Le et al. 2005) 
 In 2008 Mu, Niu et al worked not on a truncated N protein but a fusion of a truncated N and 
truncated S protein for SARS-CoV (Mu, Niu et al. 2008). The study showed that the truncated S-
N SARS-CoV fusion protein was a suitable immunodiagnostic antigen as well as a potential vaccine 
candidate when animal trials were conducted. 
Similar studied using truncated proteins have been done looking at animal CoVs also, such as one 
carried out by Chang, Peng et al who used a truncated S protein when conducting ELISAS detecting 
antibodies against porcine epidemic diarrhoea virus (Chang, Peng et al. 2019). The full-length 
ELISA had a sensitivity of 97.8% and a specificity of 94% however this was improved on when the 
157 
 
truncated version (S1-501) of the protein was used gaining a sensitivity of 98.9% and a specificity 
of 99.1% (Chang, Peng et al. 2019). 
Further work could be done to see if specificity and sensitivity values could be generated for the 
IBV and ΔIBV used in this study. It would be interesting also to produce truncated versions of the 
five HCoVs used in this study too to see if they produced the benefits aforementioned in previous 
studies. However due to time constraints and the successful production of IBV N using SoluBL21 




 ELISAs results  
 ELISA introduction 
6.1.1 Previous ELISA studies on HCoV 
Recombinant N-proteins expressed in E. coli have previously been used as antigens for ELISA 
screening in respect to both SARS-CoV (Shi, Yi et al. 2003, Lau, Woo et al. 2004) and MERS-CoV 
(Chen, Chan et al. 2015). The studies commend ELISA as a technique, noting that it is cost-effective, 
sensitive and user-friendly as well as highlighting the fact that the use of recombinant N protein 
as opposed to virus lysates makes the screening technique safer. One study even found that the 
ELISA they conducted on positive nasopharyngeal aspirate and faecal specimens picked up 
positives that the RT-PCR had missed (Lau, Woo et al. 2004).   
6.1.2 Previous ELISA studies on animal CoV 
Similar studies have used recombinant CoV N protein in animal sera studies looking at IBV in 
turkeys (Gomaa, Yoo et al. 2008), Bovine Coronavirus (BCV) in cows (Cho, Hoet et al. 2001), 
Porcine epidemic diarrhoea virus (PEDV) in swine (Wang, Jiyuan et al. 2015), porcine 
deltacoronavirus (PDCoV) in swine (Su, Li et al. 2016) and BatCoV HKU9 in bats (Lau, Poon et al. 
2010). Screening of animal sera with the recombinant HCoV N proteins generated within this 
study could be conducted to see if there are any circulating coronavirus strains that show cross-




 ELISA results on known positive sera 
6.2.1 Screening of recombinant HCoV N protein with positive sera 
Known positive sera was gifted by Public Health England and used as positive controls to test that 
the recombinant N proteins created were structurally able to bind to their respective antibodies. 
The purified proteins were coated onto ELISA plates at 5µgs/mL and the ELISAs were conducted 
as described in section 2.2.7. The data obtained shows clear sero-conversion to produce 
antibodies to the cognate viral antigen, suggesting that purified N protein can be used for 
serosurveillance. It should be noted that most people have been serially infected with the common 
coronaviruses so reactivity may be more complex when general population sera are tested, as 
indicated by the minor reaction to NL63-CoV N protein by more than one sera shown in Figure 
43.   
 
Figure 43: ELISA results showing known positive human sera against recombinant NL63-CoV 
protein. Sera used is colour coded; MERS-CoV in blue, OC43-CoV in green, NL63-CoV in purple, 
229E-CoV in yellow and SARS-CoV in red. The dilution series started with the stock sera being 
diluted 1:50 and followed a two-fold dilution series. As such 1= 1:50, 2=1:100, 3=1:200, 4=1:400, 
5=1:800, 6=1:1,600, 7=1:3,200 and 8=1:6,400. Error bars not shown due to lack of repeats. 
Reactivity can be seen with 229E-CoV which is a HCoV known to cause the common cold. It is 
possible that the person from whom the 229E-CoV positive sera was collected had also had a 
prior infection or exposure to NL63-CoV. The highest absorbance was seen with the NL63-CoV 






































Figure 44: ELISA results showing known positive human sera against recombinant 229E-CoV 
protein. Sera used is colour coded; MERS-CoV in blue, OC43-CoV in green, NL63-CoV in purple, 
229E-CoV in yellow and SARS-CoV in red. The dilution series started with the stock sera being 
diluted 1:50 and followed a two-fold dilution series. As such 1= 1:50, 2=1:100, 3=1:200, 4=1:400, 
5=1:800, 6=1:1,600, 7=1:3,200 and 8=1:6,400. Error bars not shown due to lack of repeats. The 
ELISA shows a strong positive reaction to the 229E-CoV sera with minimal cross-reaction.  
 
Figure 45: ELISA results showing known positive human sera against recombinant MERS-CoV N 
protein. Sera used is colour coded; MERS-CoV in blue, OC43-CoV in green, NL63-CoV in purple, 
229E-CoV in yellow and SARS-CoV in red. The dilution series started with the stock sera being 
diluted 1:50 and followed a two-fold dilution series. As such 1= 1:50, 2=1:100, 3=1:200, 4=1:400, 
5=1:800, 6=1:1,600, 7=1:3,200 and 8=1:6,400. Error bars not shown due to lack of repeats. This 































































Figure 46: ELISA results showing known positive human sera against recombinant OC43-CoV N 
protein. Sera used is colour coded; MERS-CoV in blue, OC43-CoV in green, NL63-CoV in purple, 
229E-CoV in yellow and SARS-CoV in red. The dilution series started with the stock sera being 
diluted 1:50 and followed a two-fold dilution series. As such 1= 1:50, 2=1:100, 3=1:200, 4=1:400, 
5=1:800, 6=1:1,600, 7=1:3,200 and 8=1:6,400. Error bars not shown due to lack of repeats. The 
ELISA shows strong positivity to the OC43-CoV sera and minimal reactivity to the other sera.  
 
The MERS-CoV and SARS-CoV sera used were both UK index cases and the 229E-CoV, OC43-CoV 
and NL63-CoV were convalescent serum. The data obtained show clear sero-conversion in the 
known status sera to the cognate viral antigen. Figure 43 shows that the recombinant NL63-CoV 
N protein produces the highest OD450 readings when screened with the NL63-CoV-positive sera. 
Similarly Figure 44 shows a clear high reading between the 229E-CoV-positive sera and the 229E-
CoV recombinant N protein, Figure 45 and Figure 46 show similar positive results to the 
corresponding N proteins with both the MERS-CoV and OC43-CoV sera respectively. These results 
suggest that purified N protein can be used for serosurveillance.  
In the case of the NL63-CoV ELISA in Figure 43 some minor reactivity with a 229E-CoV positive 
serum was also apparent. Both NL63-CoV and 229E-CoV are Alphacoronavirus so there is a 
possibility that this is a cross-reaction, although the reaction seen is more likely due to the fact 
that members of the general population will have been serially infected with the common 
coronaviruses. This means that reactivity may be more complex when general population sera are 
































In order to generate a cut-off value, more known-positive sera could generate a mean OD450, -
whereby standard deviation values could be obtained. Often the cut-off OD450 readings of the 
ELISAs are defined as the mean and two standard deviations; these values may vary between 
Coronavirus strains (Lau, Woo et al. 2004). Any values that were known to be negative but shown 
to give positive results above said cut-off value, could be used to ascertain the specificity of the 
test. Similarly, any sera known to be positive that were unable cross the cut-off thresh-hold would 
help to calculate the sensitivity of the ELISA. Ideally there would be more than one serum example 
for positive cases to screen with, in order that the ELISAs cut-off values could be calculated and 
sensitivity and specificity calculated. However unfortunately in this study none are available. 
6.2.2 Nickle coated plates 
One negative element in the current ELISA process is the need for the recombinant N proteins to 
be purified using IMAC using a 5mL HisTrap FF Crude column and subsequently concentrated 
using vivaspin column with an appropriate MCOW. The use of nickel-coated 96-well plates could 
eliminant the need to purify and concentrate the protein before using it to coat the plate; making 
the overall ELISA procedure more time-effective and potentially reducing any loss to the yield that 
the various processes each risk. Pierce™ Nickel Coated Plates (Fisher Scientific) were purchased. 
The nickel surface of the plates enables metal-chelate binding of polyhistidine-tagged proteins. 
Detergents used in the lysis of the cells do not inhibit binding as they do with plain polystyrene. 
The crude bacterial lysate containing the polyhistidine-tagged fusion proteins can be added 
directly to the plates with no need for prior purification or concentration. OC43-CoV was selected 
at random for the nickel coated plate to be used upon to see if it proved beneficial, results shown 




Figure 47: ELISA results showing known positive OC43-CoV, know positive MERS-CoV and an 
unknown human sera being screened on both purified OC43-CoV recombinant N proteins and 
crude induced cell lysate coated on the 96-well plate. Sera used is colour coded; OC43-CoV in 
green, MERS-CoV in blue and the human sera in pink. The results seen when the sera were 
screened with the crude lysate coating the plate are shown by hollow markers and dashed lines. 
The results seen when the sera were screened with purified N protein are shown with full 
markers and straight lines. The dilution series started with the stock sera being diluted 1:50 and 
followed a two-fold dilution series. As such 1= 1:50, 2=1:100, 3=1:200, 4=1:400, 5=1:800, 
6=1:1,600, 7=1:3,200 and 8=1:6,400. Error bars not shown due to lack of repeats. The results 
show reactivity to the OC43-CoV sera as expected and the human sera shows some reactivity. 
The crude lysate was shown to produce a similar pattern to that of the purified lysate.  
 
The results shown in Figure 47 show that the crude lysate is able to produce similar patterns to 
the purified N proteins. The true positive readings shown in green by the OC43-CoV remain the 
closest in values, and in the case of the human and MERS-CoV-positive sera the crude lysate 
produces slightly higher OD450 readings. This may be due to higher concentration of any potential 
contaminants that would cause a false positive result. However, the point remains that the crude 
lysate produces similar readings to that of the purified sample with a much quicker and easier 
production process. The cost of the nickel-coated plates would need to be off-set against the cost 
of the his-tag columns, buffers, viva spin columns and process time taken and as such would most 
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6.2.3 Pre-exclusion incubation 
Another potential change to the pre-existing ELISA method used in this report would be pre-
exclusion of the sera being screened against all antigens/ recombinant N proteins aside from the 
one being investigated to minimise any non-specific results. Any antibodies that carry out non-
specific binding in the sera would bind to the recombinant N protein mixture added to the sera, 
preventing them from binding to the specific N protein coated on to the plate being screened. This 
should reduce non-specific background levels. However, this was unable to be successfully 
conducted in the laboratory, possibly due to the age of the sera tested as a positive result was 
unable to be achieved with or without the pre-exclusion step, data not shown. Future work could 
look into this as a principle with a fresh positive set of sera to screen with. 
6.2.4 Summary 
The results shown in this chapter demonstrate that the recombinant N proteins generated are 
sufficiently antigenic to be able to proceed with the screening unknown sera samples. Although 
the nickel-coated plate has been shown to be effective both in terms of cost and time saving, the 
previously generated and purified N protein are of sufficient quantity to use and therefore there 





 ELISAs conducted on unknown sera: diabetic and non-diabetic sera 
6.3.1 Introduction 
Having generated soluble versions of all six CoV recombinant N-proteins to a reasonable level of 
purification, the next step essential to their sue as a diagnostic reagent was to test their 
effectiveness as coating antigens by conducting a small-scale serum screening by ELISA. Sera 
samples were taken from eight colleagues working in the laboratory. As this was a limited 
experiment with few test subjects, no records were made of the age or gender of each person. 
However, it is worth noting that subject 1 is an immunocompromised individual and that subject 
5 is unusual in that the individual has had a multi-national upbringing. The simple hypothesis 
under test here was that the recombinant N proteins would be a suitable protein set to distinguish 
recent CoV infection. That is, that different reactivity would be found per individual, consistent 
with random exposure to a number of viruses in the general population.  
6.3.2 Materials and methods 
 Serum preparation 
Whole blood samples were collected using single-use finger lancing devices on washed hands. The 
blood was left at RT for thirty minutes to allow it to clot. The clot was removed by centrifugation 
at 13,000 rpm for 10 minutes at 4oC.  The resulting supernatant is designated the serum and was 
immediately pipetted into a clean polypropylene tube and kept at 4oC until needed. 
 Plate set up 
The ELISAs were run as detailed in section 2.2.7. The sera underwent a 2-fold dilution series, 
recorded on the x axis of the data graph as 1/[log2] and was started at a dilution of 1:50 with eight 
subsequent dilutions - a range of 1:50 to 1: 6,400.  
6.3.3 Results 
The ELISAs were run in duplicate and the graphs plotted use the mean of the two, to reduce the 
impact of any anomalous results. Discriminating between non-infected and infected individuals 
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(D=0 and D=1 respectively) requires a discrimination or cut-off value (c) to be ascertained to 
define positive and negative test results. Assuming that a higher marker value would be associated 
with infection, individuals with a diagnostic test value (T) equal to, or higher than, c would be 
classified as infected (positive test T+) whereas individuals with a test value lower than c would 
be classified as non-infected (negative test T-). Ideally the test would correctly identify an 
infection individual (true positive, TP) and a person disease-free (true negative, TN), however 
classifying results in this manner is not free from error as the test may classify a healthy person 
incorrectly (false positive, FP) or it may fail to detect a diseased individual (false negative, FN). 
Errors of classification would need to be quantified before a diagnostic test could be routinely 
applied (López-Ratón, Rodríguez-Álvarez et al. 2014). This quantification of accuracy is usually 
expressed by the terms sensitivity (Se) and specificity (Sp) previously discussed in section 1.2.5.1.  
 
There are several methods that can be used to help determine optimal cut-off values however 
most require known positive and negative individuals in order to ascertain the cut-off value that 
will best discriminate between the two (López-Ratón, Rodríguez-Álvarez et al. 2014). This is 
particularly challenging where the infection is common as finding a true negative is difficult. 
Moreover, it cannot be ruled out in closely related infections, such as is the case with the human 
coronaviruses, that a level of cross reactivity would occur, further complicating the choice of a cut-
off value.     
A general formula for a cut off value is: 
𝐶𝑢𝑡 𝑜𝑓𝑓 = 𝑎. ?̅? + 𝑓. 𝑆𝐷 
Whereby ?̅? is the mean and SD is the standard deviation of the independent negative control 
readings and a and f are two multipliers which can be set arbitrarily depending on the test design 
(Lardeux, Torrico et al. 2016). If a=2 and f=0 then the role of the standard deviation is not included 
in the cut-off value, as such it would be calculated as twice the mean absorbance obtained from 
the negative control/s. 
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Other methods for determining cut-off values are more complex with some using the (1-
α)th percentile of the one-tailed Student t-distribution with (j-1) degrees of freedom (Frey, Di 
Canzio et al. 1998) or the additional use of positive controls alongside negative ones (Pan, 
Rosenberg et al. 1992). Alternatively, there are a variety of software packages that can be used; 
DiagnosisMed (Luo and Xiong 2012), pROC (Robin, Turck et al. 2011) and Epi (Carstensen and 
Hills 2013) and OptimalCutpoints (López-Ratón, Rodríguez-Álvarez et al. 2014). 
In the case of human coronavirus infections, it is reasonable to suppose that no reactivity would 
be expected for IBV as this virus does not circulate in humans. Hence any reactivity to IBV N could 
be considered a bottom threshold for human serum reactivity with proteins of this type, that is, 
RNA binding proteins with shared properties of charge and molecular mass. Accordingly, the cut-
off values were worked out to 3 significant figures for each serum using IBV as a negative value at 
1:50 dilution and setting a=2 and f=0. Any CoV with OD450 readings equal to, or greater than, c is 







C calculated at 
2nd dilution 
T+ C calculated 














5 0.32 None 0.25 SARS-CoV 
6 0.40 NL63-CoV N/A N/A 
7 0.27 None N/A N/A 
8 0.20 None N/A N/A 
Table 13: Cut-off values based on the 8 ELISAs conducted and subsequent positive results for 8 
sera screened 
 
In two examples (serum 3 and serum 5) human judgement deemed it necessary to observe results 
seen at subsequent dilutions and so the cut-off values were calculated using the second dilution 
1: 102. Using twice the IBV negative control values seen at this dilution, showed serum 5 to in fact 
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have a positive result with SARS-CoV and discounted the OC43-CoV and NL63-CoV positive results 
that serum 3 first appeared to have.  
However, although SARS-CoV circulated in the population following its emergence on 2003, that 
circulation was restricted, and the virus has since become extinct, so the apparent positivity was 
observed in one individual (serum 5) is suspect. MERS-CoV positivity was not seen in any of the 
sera, but NL63-CoV and 229E-CoV positivity were both observed in two individuals (sera 1 and 4, 
Figure 48 and Figure 51 respectively). OC43-CoV positivity was not observed in any individuals. 
The graphs shown from Figure 48 through to Figure 55 show the ELISA results per each individual 
serum along with the cut-off value. 
 
Figure 48: ELISA results of sample 1, human serum reactivity on recombinant CoV proteins. The 
recombinant N protein used is colour coded; SARS-CoV in red, MERS-CoV in blue, OC43-CoV in 
green, NL63-CoV in purple, 229E-CoV in yellow and IBV in grey. The dilution series started at 
1:50 and followed a two-fold dilution series. The line y=0.30 indicates the suggested cut-off 
value. Error bars not shown due to lack of repeats. 
 
The ELISA results shown in Figure 48 suggest low level of reactivity on all proteins with possible 
prior infection with 229E-CoV and NL63-CoV consent with the highest reactivity to these proteins. 

































Figure 49: ELISA results of sample 2, human serum reactivity on recombinant CoV proteins. The 
recombinant N protein used is colour coded; SARS-CoV in red, MERS-CoV in blue, OC43-CoV in 
green, NL63-CoV in purple, 229E-CoV in yellow and IBV in grey. The dilution series started with 
the stock sera being diluted 1:50 and followed a two-fold dilution series. The line y=0.40 
indicates the suggested cut-off value outside of the graph’s plot area. Error bars not shown due 
to lack of repeats. 
 
A low level of absorbance (OD450 <0.25) was also shown by the ELISA results for serum two, 
Figure 49. Reactivity on SARS-CoV N protein was the highest, but the bunching of the data does 
give confidence that this is anything more than a high background reaction. The pattern of antigen 


































Figure 50: ELISA results of sample 3, human sera against recombinant CoV proteins. The 
recombinant N protein used is colour coded; SARS-CoV in red, MERS-CoV in blue, OC43-CoV in 
green, NL63-CoV in purple, 229E-CoV in yellow and IBV in grey. The dilution series started with 
the stock sera being diluted 1:50 and followed a two-fold dilution series. The solid line y=0.18 
indicates the suggested cut-off value based on the first dilution series’ values, the dashed line 
y=0.13 shows the cut-off value based on the values in the second dilution. Error bars not shown 
due to lack of repeats. 
 
Serum 3 also showed poor overall reactivity with the set of N proteins, Figure 50, with the highest 
reactivity with the N protein of NL63-CoV. However, the titration fails to follow the dilution curve 



































Figure 51: ELISA results of sample 4, human sera against recombinant CoV proteins. The 
recombinant N protein used is colour coded; SARS-CoV in red, MERS-CoV in blue, OC43-CoV in 
green, NL63-CoV in purple, 229E-CoV in yellow and IBV in grey. The dilution series started with 
the stock sera being diluted 1:50 and followed a two-fold dilution series. The solid line y=0.35 
indicates the suggested cut-off value. Error bars not shown due to lack of repeats.  
 
In contrast to serum samples 1-3, the ELISA result for serum sample 4, Figure 51, appear more 
convincing. The maximum OD is significantly higher for reactivity with the N proteins of both 4 
229E-CoV and NL63-CoV and the sera titres follow the dilution series, clearly remaining above 


































Figure 52: ELISA results of sample 5, human sera against recombinant CoV proteins. The 
recombinant N protein used is colour coded; SARS-CoV in red, MERS-CoV in blue, OC43-CoV in 
green, NL63-CoV in purple, 229E-CoV in yellow and IBV in grey. The dilution series started with 
the stock sera being diluted 1:50 and followed a two-fold dilution series. The solid line y=0.32 
indicates the suggested cut-off value based on the first dilution series’ values, the dashed line 
y=0.25 shows the cut-off value based on the values in the second dilution. Error bars not shown 
due to lack of repeats. 
 
Serum 5 was unusual in that the predominant reactivity was to SARS-CoV N protein, Figure 52. 
However, the titration does not follow the dilution series and overall reactivity was low.  
Individual 5 is a foreign national who had visited a town which had known SARS cases. However, 
the individual is also asthmatic and prone to respiratory infections. Overall, the reactivity to SARS-




































Figure 53: ELISA results showing sample 6 human sera against recombinant CoV proteins. The 
recombinant N protein used is colour coded; SARS-CoV in red, MERS-CoV in blue, OC43-CoV in 
green, NL63-CoV in purple, 229E-CoV in yellow and IBV in grey. The dilution series started with 
the stock sera being diluted 1:50 and followed a two-fold dilution series. The solid line y=0.40 
indicates the suggested cut-off value. Error bars not shown due to lack of repeats. 
 
Serum sample 6, the ELISA data presented n Figure 53 show convincing evidence for recent prior 
infection with NL63-CoV. The maximum OD values are reassuringly high and follow the titration 


































Figure 54: ELISA results showing sample 4 human sera against recombinant CoV proteins. The 
recombinant N protein used is colour coded; SARS-CoV in red, MERS-CoV in blue, OC43-CoV in 
green, NL63-CoV in purple, 229E-CoV in yellow and IBV in grey. The dilution series started with 
the stock sera being diluted 1:50 and followed a two-fold dilution series. The solid line y=0.27 
indicates the suggested cut-off value outside of the graph’s plot area. Error bars not shown due 
to lack of repeats. 
Serum 7 had very low OD readings throughout (OD450 <0.2) the ELISA, Figure 54. There was no 


































Figure 55: ELISA results showing sample 8 human sera against recombinant CoV proteins. The 
recombinant N protein used is colour coded; SARS-CoV in red, MERS-CoV in blue, OC43-CoV in 
green, NL63-CoV in purple, 229E-CoV in yellow and IBV in grey. The dilution series started with 
the stock sera being diluted 1:50 and followed a two-fold dilution series. The solid line y=0.20 
indicates the suggested cut-off value. Error bars not shown due to lack of repeats. 
Serum 8 was also generally poorly reactive with any N protein by ELISA, Figure 55. There was no 


































The preliminary ELISAs results, using 8 serum samples of unknown status with regard to previous 
CoV infection indicate that the use of recombinant CoV N proteins as diagnostic antigens for serum 
survey is justified. The general level of background binding was low (OD=~0.2) and the shape of 
the binding curves by such sera generally did not follow the dilution series.  
A true more statistical analysis of the data was not justified as the sample size tested would need 
to be far greater in order to improve significance.  
Other comparisons between the data sets would also need to be made e.g. if incidence rates in 
males compared to females, or above the age of “x” verses under.  Of the 8 samples, serum 4 is 
suggested to have had prior infection with 229E-CoV and NL63-CoV. Interestingly these viruses 
are more closely related to each other than to any other human coronavirus suggesting serum 
cross-reactivity could be possible. However, serum 6 showed clear reactivity to only NL63-CoV 
indicating that seroconversion to only this virus is possible. It has since been shown that more 
complex “double sandwich” ELISA assays may be required to distinguish between these activities 
(Sastre, Dijkman et al. 2011).   
Nevertheless, recombinant CoV N proteins were able to differentiate between prior CoVs infection 
or not and so a slightly larger sera set and variables were examined as shown in Section 6.3.5.9.1, 
which details the differences in N protein coronavirus reactivity observed between sera of type 
one diabetics compared to non-type one diabetics and chapter eight details the differences in N 




6.3.5 Comparing type one diabetic sera to non- type one diabetic sera  
 Introduction 
Type 1 diabetes mellitus (DM) (T1DM) is a lifelong autoimmune condition that arises from a lack 
of insulin production due to autoimmunity damage and the loss of pancreatic islet β- cells; 
resulting in increased blood glucose levels (hyperglycaemia) (Katsarou, Gudbjornsdottir et al. 
2017).  It is estimated that 5-10% of all people living with diabetes are classified as having T1DM 
(Maahs, West et al. 2010) whereas the more common type of diabetes, due to a combination of 
resistance to insulin action and inadequate compensatory insulin secretory response, is type 2 
diabetes mellitus (T2DM). It is estimated that T1DM is diagnosed in almost 90,000 children a year 
world-wide; the incidence rate is increasing globally although it varies greatly between countries 
(Diaz-Valencia, Bougneres et al. 2015). The highest incidence rates are reported in Scandinavian 
countries, followed by other European countries (such as the UK), then North America and 
Australia. T1DM diagnosis is rare in some Asian countries such as China, Korea and Japan (Diaz-
Valencia, Bougneres et al. 2015). Differences in incidence rates may be linked to genetic 
susceptibility and environmental and lifestyle factors, including hygiene and childhood infections. 
The high incidence recorded in developed countries has led to a “hygiene hypothesis” that 
suggests lack of exposure to infectious agents increases risk and prevalence of autoimmune 
conditions (Borchers, Uibo et al. 2010). However, incidence rates may appear low in less 
economically developed counties in part due to a lack of diagnostic resources as opposed to a true 
reduced incidence rate. 
 Diabetes and virology 
Onset of T1DM within populations often follows a seasonal pattern which has suggested a viral 
aetiology (Adams 1926). A variety of viruses have been examined as potential inducers of T1DM; 
cytomegalovirus (CMV) (Pak, Eun et al. 1988), parvovirus (Guberski, Thomas et al. 1991, Kasuga, 
Harada et al. 1996), encephalomyocarditis virus (Craighead and McLane 1968), retroviruses 
(Conrad, Weissmahr et al. 1997), rotaviruses (Honeyman, Coulson et al. 2000), rubella (Gale 
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2008) and mumps (Goto, Takahashi et al. 2008). However, none of the associations have been 
proven but the differing ages of diagnosis in monozygotic twins do suggest that nongenetic 
variables must also play a role in T1DM pathogenesis (Redondo, Jeffrey et al. 2008).  
 Enteroviruses 
The most robust association with viruses and T1DM involves enterovirus species; single-stranded 
positive sense RNA (ssRNA) viruses belonging to the picornavirus family (Katsarou, 
Gudbjornsdottir et al. 2017) (Yeung, Rawlinson et al. 2011) (Oikarinen, Martiskainen et al. 2011). 
Some strains of enterovirus have been shown to induce or accelerate T1DM in animal models 
(Coppieters, Boettler et al. 2012). Epidemiological and clinical studies have supported the role of 
enterovirus, especially Coxsackie B4 and B3 virus, in the development of T1DM in genetically 
predisposed individuals (Flyvbjerg 2010) (Clements, Galbraith et al. 1995) (Banatvala, Bryant et 
al. 1985) (Gamble, Kinsley et al. 1969). The rate of progression from islet autoimmunity to T1DM 
has been shown to be significantly increased following detection of enteroviral RNA in serum 
(Stene, Oikarinen et al. 2010). There is thought to be an association between the occurrence of 
T1DM and peaks of enterovirus infection and other evidence linking the two include; the detection 
of anti-enterovirus antibodies, enterovirus RNA, and the capsid protein VP1 in blood, small 
intestine biopsies, and autopsy pancreas specimens of individuals with T1DM (Hober and Sane 
2010). Such samples are difficult to obtain however as the target organ in T1DM, the pancreas, 
has a fairly inaccessible anatomical location (Coppieters and von Herrath 2009) and pancreas 
samples from recently diagnosed T1DM individuals are limited due to improved clinical 
management of the condition.   
Various mechanisms can explain the role of enterovirus in the pathogenesis of T1DM as 
summerised by  (Stene, Oikarinen et al. 2010): “(1) persistent infection of pancreatic beta cells 
provoking cell damage and release of sequestered antigens inducing an autoimmune response; (2) 
molecular mimicry (partial sequence homology) between the 2C viral protease and the epitope 
GAD65 (Glutamic Acid Decarboxylase) which is a major target antigen in T1DM (Kaufman, Erlander 
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et al. 1992) and between the VP1 viral capsid protein and the IA2 protein; (3) bystander activation 
of autoreactive T cells; (4) thymus infection; and (5) loss of regulatory T cells.” However, a direct 
causative correlation has not been shown for any of these possibilities and an active mechanism 
still needs to be established. In contrast, some studies report no such correlations suggesting that 
the notion that any potential association with virus infection is not absolute but depends on 
genetic susceptibility or other environmental factors (Fuchtenbusch, Irnstetter et al. 2001, Graves, 
Rotbart et al. 2003).  
 Immunity in T1DM 
Most researchers conclude that there is clinical evidence pointing to the higher prevalence of 
infectious diseases among individuals with DM (Geerlings and Hoepelman 1999, Muller, Gorter et 
al. 2005, Vardakas, Siempos et al. 2007). The main pathogenic mechanisms involved in DM 
infections are: the hyperglycaemic environment which may increase the virulence of some 
pathogens; lower production of interleukins in response to infection; reduced chemotaxis and 
phagocytic activity, immobilization of polymorphonuclear leukocytes; glycosuria, gastrointestinal 
and urinary dysmotility (Joshi, Caputo et al. 1999).   
 Respiratory infections and T1DM 
Respiratory tract infections are responsible for a significant number of medical appointments by 
persons with DM compared to those without DM (Barros, Cartagena et al. 2005, Peleg, 
Weerarathna et al. 2007, Cano, Iglesias et al. 2010). The most frequent respiratory infections 
associated with DM are caused by Streptococcus pneumoniae and influenza virus (Joshi, Caputo et 
al. 1999, Barros, Cartagena et al. 2005). It is estimated that individuals with DM are six times more 
likely to need hospitalization during influenza epidemics than non-diabetic patients (Peleg, 
Weerarathna et al. 2007). Individuals with diabetes are also at a higher risk of contracting 
tuberculosis than individuals without DM (Harries, Lin et al. 2011, Restrepo, Camerlin et al. 2011).  
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 Coronavirus and T1DM 
Studies examining risk factors associated with MERS-CoV infection often include DM, although no 
reference is made to distinguish between type1 and type2 (Alraddadi, Watson et al. 2016). 
Similarly DM has been noted as being a risk factor during SARS-CoV infection (Booth, Matukas et 
al. 2003) (Chan, Ng et al. 2003). Plasma glucose levels and diabetes have been reported as 
independent predictors for mortality and morbidity in SARS patients (Yang, Feng et al. 2006). 
 Experimental aim and hypothesis 
Although the causative virological agent for the initiation of T1DM is more likely to be one of those 
described, for example an enterovirus, as opposed to a coronavirus, the immunocompromising 
effects that hyperglycaemia and T1DM brings could mean a correlation between T1DM and CoV 
infection still exists. As a small serum set from six confirmed T1DM was available, it was screened 
for CoV N reactivity as before and the results compared with those of six non-T1DM individuals 
working in the laboratory. The hypotheses under test were:  
H0: There is no association between diabetic and non-diabetic status and coronavirus 
recombinant N-protein reactivity (the proportion is the same for T1DM individuals vs non-
diabetic individuals) 
H1: There is an association between diabetic/ non-diabetic status and coronavirus recombinant 
N-protein reactivity (the proportion is different for T1DM individuals vs non-diabetics 
individuals) 
 Materials and methods 






Cut-off values (c) were determined per sera using the formula: 
𝐶𝑢𝑡 𝑜𝑓𝑓 = 𝑎. ?̅? + 𝑓. 𝑆𝐷 
Whereby ?̅? is the mean and SD is the standard deviation of the independent negative control 
readings and a and f are two multipliers which can be set arbitrarily. For this study, the cut-off 
values were set to 3 significant figures for each serum using IBV as a negative value at 1:50 dilution 
and setting a=2 and f=0. A line has been drawn on each graph showing Y=c. 
6.3.5.9.1 Diabetic vs non-diabetic sera screened on all six purified N proteins 
displayed per individual 
6.3.5.9.2 Non-diabetic sera screening displayed per individual 
Figure 56 shows the serum from non-diabetic individual 1 to show sign of infection against SARS-
CoV. This is the same individual whose results were displayed in Figure 52 previously. The results 
from non-diabetic individual number 2 show no sign of prior CoV infection as all values remain 
below the cut-off value shown. Prior infection with OC43-CoV may be likely in the non-diabetic 
individual 3 sample. Non-diabetic individual number 4 shows no sign of prior CoV infection as all 
values remain below the cut-off value. The results for non-diabetic individual number 5 also all 
remain below the cut-off level, suggesting that prior CoV infection is unlikely. Finally, the results 
of non-diabetic individual number 6 suggest prior infection with both 229E-CoV and NL63-CoV at 






Figure 56: ELISA results of all non-diabetic sera against recombinant N proteins. The 
recombinant N protein used is colour coded; SARS-CoV in red, MERS-CoV in blue, OC43-CoV in 
green, NL63-CoV in purple, 229E-CoV in yellow and IBV in grey. The dilution series started with 
the stock sera being diluted 1:50 and followed a two-fold dilution series. The line seen on each 
graph denotes the cut-off value; for serum 1 y=0.38, for serum 2 y=0.60, serum 3 y=0.47, serum 
4 y=0.42, serum 5 y=0.79 and for serum 6 the solid line seen on the graph denotes the cut-off 
value using data from the first dilution y=0.37, the dashed line y=0.25 is the cut-off value gained 






6.3.5.9.3 Diabetic sera screening displayed per individual 
 
Figure 57: ELISA results of all diabetic sera against recombinant N proteins. The recombinant N 
protein used is colour coded; SARS-CoV in red, MERS-CoV in blue, OC43-CoV in green, NL63-CoV 
in purple, 229E-CoV in yellow and IBV in grey. The dilution series started with the stock sera 
being diluted 1:50 and followed a two-fold dilution series. The line seen on each graph denotes 
the cut-off value; for serum 1 y=0.55, for serum 2 the solid line seen on the graph denotes the 
cut-off value using data from the first dilution y=0.44, the dashed line y=0.27 is the cut-off value 
gained using data from the second dilution, serum 3 y=0.89, serum 4 y=0.55, serum 5 y=0.64 and 






The results from diabetic individual number one shown in Figure 57 indicate a prior 229E-CoV 
infection. The results of diabetic individual number 2 suggest prior infection with both NL63-CoV 
at the first dilution however the gradient steeply drops and using the data from the second 
dilution (1:102) shown on the graph with a dashed line, shows no CoV reactivity. The results from 
diabetic individual number three indicate a prior OC43-CoV infection. The results for diabetic 
individual number 4 all remain below the cut-off level, suggesting that prior CoV infection is 
unlikely. The results for diabetic individual number 5 also all remain below the cut-off level, 
suggesting that prior CoV infection is unlikely. Finally, the results from diabetic individual number 
six indicate a prior 229E-CoV infection. 
Next the results are displayed based on recombinant-N protein with and without individual sera 
cut-off levels imposed and with diabetic status colour coded. 
 The only individual showing SARS-CoV reactivity shown in Figure 57 is a non-diabetic individual, 







6.3.5.9.4 Diabetic vs non-diabetic sera screened on all six purified N proteins displayed with colour coding for diabetic status 
 
Figure 58: ELISA results comparing diabetic vs non-diabetic sera screened against recombinant SARS-CoV N protein with results seen when 
individual sera’s cut off values were implemented. Sera obtained from non-diabetics are coloured blue, sera obtained from a diabetic are coloured 
red. The dilution series started with the stock sera being diluted 1:50 and followed a two-fold dilution series. Error bars not shown due to lack of 
repeats. 









Figure 59: ELISA results comparing diabetic vs non-diabetic sera screened against recombinant OC43-CoV N protein with results seen when 
individual sera’s cut off values were implemented. Sera obtained from non-diabetics are coloured blue, sera obtained from a diabetic are coloured 
red. The dilution series started with the stock sera being diluted 1:50 and followed a two-fold dilution series. Error bars not shown due to lack of 
repeats. 








Figure 60: ELISA results comparing diabetic vs non-diabetic sera screened against recombinant 229E-CoV N protein with results seen when 
individual sera’s cut off values were implemented. Sera obtained from non-diabetics are coloured blue, sera obtained from a diabetic are coloured 
red. The dilution series started with the stock sera being diluted 1:50 and followed a two-fold dilution series. Error bars not shown due to lack of 
repeats. 





Figure 61: ELISA results comparing diabetic vs non-diabetic sera screened against recombinant 
NL63-CoV N protein. Sera obtained from non-diabetics are coloured blue, sera obtained from a 
diabetic are coloured red. The dilution series started with the stock sera being diluted 1:50 and 
followed a two-fold dilution series. Error bars not shown due to lack of repeats. 
 
In the case of NL63-CoV shown in Figure 61, once cut-off limits were imposed no sera showed 




























Diabetic vs non-diabetic sera ELISA results 




Figure 62: ELISA results comparing diabetic vs non-diabetic sera screened against recombinant 
MERS-CoV N protein. Sera obtained from non-diabetics are coloured blue, sera obtained from a 
diabetic are coloured red. The dilution series started with the stock sera being diluted 1:50 and 
followed a two-fold dilution series. Error bars not shown due to lack of repeats. 
 
As expected in the case of MERS-CoV shown in Figure 62, once cut-off limits were imposed no sera 
showed indication of prior infection. Potentially the low OD readings seen in Figure 62 imply that 
using recombinant MERS-CoV N protein may have proven useful in determining cut-off limits, 





























Diabetic vs non-diabetic sera ELISA results 







Figure 63: ELISA results comparing diabetic vs non-diabetic sera screened against recombinant 
IBV N protein. Sera obtained from non-diabetics are coloured blue, sera obtained from a diabetic 
are coloured red. The dilution series started with the stock sera being diluted 1:50 and followed 
a two-fold dilution series. Error bars not shown due to lack of repeats. 
 
Figure 63 shows the data obtained when screening sera from T1DM positive and negative 
individuals against recombinant IBV N protein, used as a negative control in order to ascertain 
cut-off values for the HCoV recombinant N proteins being screened. Interestingly values seen in 
dilutions 1 and 2 of IBV appear much higher than those seen in MERS-CoV, Figure 62, suggesting 
that a different cut-off value would have been calculated using data from the MERS-CoV 
recombinant N proteins as a negative control either instead of, or averaged with, IBV. Without 
being able to test known positive and negative sera though it is unable to see if this would be 
beneficial or not. 
There were no technical problems encountered whilst conducting the trial. It does not appear that 
being a type one diabetic has any effect on likelihood to have a coronavirus infection as overall 



























Diabetic vs non-diabetic sera ELISA results 








reactivity to SARS-CoV, OC43-CoV and 229E-CoV respectively, and diabetic individuals number 1 
and 6 showed 229E-CoV reactivity whilst diabetic number 3 showed OC43-CoV reactivity. 
Although there were twice as many diabetics as non-diabetics showing 229E-CoV reactivity in 
such a small data set it is unlike to prove statistically significant. In order to truly accept the null 
hypothesis statistical analysis needs to take place. 
 Statistical analysis of data 
In order to know if the null hypothesis can be accepted or rejected the level of statistical 
confidence needs to be measured. 
6.3.5.10.1 Selecting which statistical test to use 
Binomial testing can be conducted on the data obtained as all results are either diabetic positive 
or negative and recombinant Coronavirus N protein reactivity positive or negative. Chi-square or 
G-tests could be used to test for statistical significance however these work best on a larger sample 
size (Kim 2017). Fisher’s exact test of independence will be used instead.  
6.3.5.10.2 Fisher’s exact test  
Fisher’s exact test is used when there are two nominal variables and is easily conducted on 2x2 
contingency tables whereby rows (R) contain data sets and columns (C) contain outcomes 
(McDonald 2014). The null hypothesis states that the relative proportions seen in one variable are 
independent of the second variable, so that the probability of getting the observed data are the 
same for both groups. In the two screenings done in this report the null hypotheses would be that 
being T1DM has no correlation to the likelihood of a coronavirus infection, and in the second case 
it would be that prior influenza infection has no effect on the likelihood of a coronavirus infection. 
In contrast, the hypothesis would be that there is a correlation and T1DM status does impact the 
coronavirus reactivity results seen, either in a causative suggestion or a preventative suggestion, 




The test calculates the probabilities of all possible combinations of numbers in an R×C 
contingency table, then adds the probabilities of those combinations that are as extreme or more 
extreme than the observed data. The test better suits smaller data sets as when R and C get larger, 
and as the total sample size increases, the number of possible combinations dramatically 
increases, and the time taken for a computer to calculate the results may be unreasonable. 
 Data set 1 Data set 2 Row total 
Outcome 1 a b a + b 
Outcome 2 c d c + d 
Column total a + c b + d a + b + c + d (=n) 
Table 14: Example of a 2x2 contingency table 
Fisher showed that the probability of obtaining any such set of values was given by the 
hypergeometric distribution, this is a discrete probability distribution used to describe the 
probability of successes in a fixed number of draws, without replacement, from a finite population 
of size, whereby each draw is either a success or a failure (Fisher 1922, Rivals, Personnaz et al. 
2007). 










The above equation is used to calculate the p value, (𝑛
𝑘
) is the binomial coefficient and the symbol 
“!” indicates the factorial operator, the letters correspond to the numbers that would be observed 
in Table 14. Often the result is calculated using a spreadsheet or a website, in this study GraphPad 
Software was used (GraphPad 2017). Two-tailed testing was carried out, which is where the 





6.3.5.10.3 2x2 contingency tables for each coronavirus recombinant N protein 
SARS-CoV  
Reactivity No Reactivity       Total 
Diabetic 0 6 6 
Non-Diabetic 1 5 6 
Total 1 11 12 
MERS-CoV  
Reactivity No Reactivity       Total 
Diabetic 0 6 6 
Non-Diabetic 0 6 6 
Total 0 12 12 
NL63-CoV  
Reactivity No Reactivity       Total 
Diabetic 0 6 6 
Non-Diabetic 0 6 6 
Total 0 12 12 
OC43-CoV  
Reactivity No Reactivity       Total 
Diabetic 1 5 6 
Non-Diabetic 1 5 6 
Total 2 10 12 
229E-CoV  
Reactivity No Reactivity       Total 
Diabetic 2 4 6 
Non-Diabetic 1 5 6 
Total 3 9 12 
Table 15: The six 2x2 contingency tables for each recombinant coronavirus N protein using 
T1DM positive and negative sera 
 
 Discussion 
For all of the tables listed in Table 15, the following outcome was observed “The two-tailed P value 
equals 1.0000, so the association between rows (groups) and columns (outcomes) is considered 
to be not statistically significant”. This allows the null hypothesis to be accepted and states that 
there is no association between diabetic and non-diabetic status and coronavirus recombinant N 
protein reactivity seen in this study of a limited number of individual sera. Further work will be 
needed on a larger data set to test the null hypothesis and see if diabetics are at a higher risk of 
coronavirus infections.  
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 ELISAs conducted on unknown sera: influenza sera set gifted from 
Germany 
6.4.1 Influenza sera introduction 
The use of a limited set off sera (12 in all) used in chapter 7 had shown that the use of purified N 
proteins was generally acceptable as a coating antigen for diagnosis of recent coronavirus 
infection with readings well about background for cases of 229E-CoV and OC43-CoV. No cases of 
NL63-CoV were found in this limited analysis. A single individual had an apparently strong 
reaction to the SARS-CoV N protein which, while not impossible to discount based on the history 
of the SARS epidemic, is unlikely to be real. Accordingly, the same format was used to interrogate 
a larger sera set (n=24) supplied by a collaborator group in Hannover, Germany. While the 
previous study sought a relationship between T1DM and coronavirus infection the novel aspect 
of this set of sera was that they had been screened for influenza infection, albeit only by the use of 
bedside diagnostics. Sera 1-11 were deemed influenza virus infection negative and sera 12-24 
influenza virus infection positive. However it is worth noting that a study conducted a meta-
analysis and found the pooled sensitivity and specificity of such tests were 62.3% and 98.2% 
respectively (Chartrand, Leeflang et al. 2012). As such the reliability of said bedside diagnostic is 
questionable.  
It was of interest to know if influenza infection was more or less likely in those recently infected 
with coronaviruses. A coronavirus infection would stimulate a number of antiviral responses 
which might provide partial protection form influenza infection.  
On the other hand, individuals who are prone to reparatory infections, such as asthmatics, might 
be more susceptible to both viruses. In addition, the laboratory was able to provide reagents to 
confirm influenza serum reactivity and to discriminate between H1 and H3, the circulating strains 
at the time. Thus, confirmation of recent influenza status to accurately differentiate between 
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positive and negative influenza infection was done, followed by a screen on recombinant 
coronavirus N proteins as before.  
6.4.2 Influenza virus introduction 
Influenza viruses are segmented negative-sense single stranded RNA enveloped viruses of the 
family Orthomyxoviridae (Arbeitskreis Blut 2009). There are three genera of influenza, A and B 
consisting of eight genome segments and C with seven. Table 16 shows a list of the proteins 
corresponding to the RNA segments along with their functions. Seroconversion in this study 
focused on the use of the virus surface haemagglutinin glycoprotein (HA), used to anchor the virus 
to the cellular surface. The second glycoprotein, the neuraminidase (NA), used to digest host sialic 
acid for the release of viral particles from the host cell (Fields, Knipe et al. 2007, Labella and Merel 
2013) was not used. Influenza B is only known to infect humans and seals (harbour seals (Phoca 
vitulina) and grey seals (Halichoerus grypus) (Osterhaus, Rimmelzwaan et al. 2000)). Influenza A 
has been shown to infect a variety of warm-blooded animals, including birds, swine, horses and 
humans (Webster 2002). Whereas coronaviruses are thought to have their natural reservoir in 
bats, aquatic birds serve as the natural reservoir for all known subtypes of influenza A virus 
(Webster, Bean et al. 1992). Influenza A viruses are subdivided by antigenic characterization of 
the haemagglutinin (HA) and neuraminidase (NA). Eighteen HA and eleven NA subtypes are 
known (Tong, Zhu et al. 2013). The nomenclature system follows the pattern H(x)N(y) including 
the host of origin, geographical location, strain number, and year of isolation (Fouchier, Munster 
et al. 2005). Influenza B viruses are not divided into subtypes.  




PB2 Cap binding 
PA Protease activity 
HA Haemagglutinin Anchoring the cell 
NP Nuclear protein RNA binding and transport 
NA Neuraminidase Virus release 
M1/M2 Matrix proteins 
M1= major component of virion 
M2= ion channel 
NS1/NS2 Non-structural proteins 
NS1=RNA transport and translation 
NS2=nuclear export of virion RNAs 
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Table 16: The RNA segments of influenza along with the protein they encode and the protein 
function. 
 Mutation 
Influenza viruses can undergo two types of genetic changes allowing the HA and NA to evade 
previously acquired immunity; antigen drift and antigenic shift (also known as re-assortment). 
The accumulation of point mutations during replication occurs in influenza viruses because, like 
coronaviruses, their RNA polymerase complex has limited proofreading activity (Taubenberger 
and Morens 2008). Antigenic drift occurs when the accumulation of point mutations in the 
antigenic portions of surface glycoproteins limit or prevent antibody binding, allowing the virus 
to evade any pre-existing immunity the host may have. Influenza virus’ genes have high mutation 
rates (~ 1×10−3 to 8×10−3 substitutions per site per year) (Chen and Holmes 2006). Antigen shift 
is a term used to define re-assortment that occurs whereby there is an exchange of whole genome 
segments, which might result in influenza viruses which have a selective advantage compared 
with their parent viruses (Fields, Knipe et al. 2007).  Re-assortment can only occur when a cell is 
simultaneous infected with different influenza A viruses resulting in hybrid viruses.  
 Influenza infection 
Influenza virus infection is associated with high morbidity and mortality (Taubenberger and 
Morens 2008), especially in the elderly, infants and people with certain chronic diseases. Influenza 
virus is amongst the most common cause of human respiratory infection (Fields, Knipe et al. 
2007). Annual influenza epidemics are estimated to result in about 3 to 5 million cases of severe 
illness, and about 250,000 to 500,000 deaths worldwide (Clem and Galwankar 2009).  Influenza 
infection symptoms include; fever, coughs, headache, inflammation of the upper respiratory tract, 
inflamed glands, malaise, weakness and catarrh production.  
 Pandemics 
Alongside seasonal influenza mortalities numerous pandemics have been reported within the past 
century with varying degrees of severity; all as a result of an influenza A virus. Spanish influenza 
occurred in 1918 due to H1N1 resulting in an estimated 40 million deaths worldwide (Patterson 
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and Pyle 1991, Mills, Robins et al. 2004). Asian flu occurred in 1957-1958 caused by H2N2 and 
was estimated at to have killed 1-2 million (Neumann and Kawaoka 2015). Hong Kong influenza 
arose in 1968-1969 as a result of H3N2 and was estimated to have been responsible of 0.75-1 
million deaths (Fauci 2006). Avian influenza H5N1 caused a minor human outbreak in 1996, often 
referred to as bird flu (Wan 2012). H1N1 re-emerged in 1977-1978 and was referred to as Russian 
flu (Donaldson, Rutter et al. 2009). Finally, in 2009-2010 there was a worldwide flu pandemic 
often referred to as swine flu caused by H1N1/09 (Cheng, To et al. 2012), a virus that still 
circulates today.  
 Vaccination 
Viral antigenic drift in influenza A means that the vaccine’s effectiveness can often become 
compromised. Accordingly, the vaccine requires updating, alongside revaccination of at-risk 
individuals (Gensheimer, Meltzer et al. 2003). WHO set up an influenza surveillance program in 
1947 to monitor and advise on relevant strains (Heymann and Rodier 2004). Vaccination against 
circulating strains of influenza A and B with inactivate or live attenuated vaccines are often used 
as a countermeasure against the disease; prophylactic or therapeutic drugs are also available 
(Couch 2000). There are a variety of influenza vaccine types shown in Table 17. Trivalent vaccines 
contain two subtypes of influenza A and one type B virus. Trivalent vaccines for use in 2019-2020 
have been recommended to contain B/Colorado/06/2017-like virus of the B/Victoria/2/87-
lineage as their influenza B component (WHO 2019). The 2019-2020 quadrivalent vaccine 
consists of an A/Brisbane/02/2018 (H1N1)pdm09-like virus; an A/Kansas/14/2017 (H3N2)-like 
virus; a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and a B/Phuket/3073/2013-







Supplier  Name of product  Vaccine type  Age indications 
AstraZeneca 
UK Ltd  
Fluenz Tetra Quadrivalent LAIV (live attenuated influenza vaccine) 
supplied as nasal spray suspension 
From 24 months to 
<18 years of age 
GSK  FluarixTM Tetra QIVe (standard egg grown quadrivalent 
influenza vaccine), split virion, 
inactivated 
From 6 months 
MASTA  Quadrivalent Influenza 
vaccine QIVe 
(standard egg grown quadrivalent 
influenza vaccine), split virion, 
inactivated 
From 6 months 
Mylan Quadrivalent Influenza 
vaccine Tetra MYL QIVe  
(standard egg grown quadrivalent 
influenza vaccine), supplied as surface 
antigen, inactivated 
From 3 years 
Quadrivalent Influvac 
sub-unit Tetra 
QIVe (standard egg grown quadrivalent 
influenza vaccine), supplied as surface 
antigen, inactivated 





vaccine QIVe  
(standard egg grown quadrivalent 
influenza vaccine), split virion, 
inactivated 
From 6 months 
Trivalent Influenza 
Vaccine, High-Dose 
TIV-HD (standard egg-grown trivalent 
influenza vaccine), split virion, 
inactivated 




Flucelvax® Tetra QIVc  (cell-grown quadrivalent influenza 
vaccine) supplied as surface antigen, 
inactivated, prepared in cell cultures 
From 9 years 
Fluad® aTIV  (adjuvanted trivalent influenza vaccine) 
supplied as surface antigen, inactivated, 
adjuvanted with MF59C.1 
65 years of age 
and over 
Table 17: Influenza vaccines for the 2019/20 influenza season. Table sourced from 
(PublicHealthEngland 2019) 
 
Table 17 summarises the 2019-2020 influenza vaccines available in the UK. Different age 
demographics are recommended different vaccine types, the micrograms per dose of ovalbumin 
content varies between vaccine type, some are therefore more suited to severe egg allergy suffers 
than others.                    
 
 Antiviral drugs 
Antiviral drugs should ideally be administered within 48 hours of symptom onset and fall into 
three categories. Firstly, matrix 2 ion channel blockers (amantadine and rimantadine) which are 
effective against influenza A viruses, but resistant viral strains develop rapidly. Secondly, 
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neuraminidase (NA) inhibitors, zanamivir and oseltamivir, which are effective against both 
influenza A and B viruses although resistance has again been noted (Monto, McKimm-Breschkin 
et al. 2006). Both classes of drugs are effective in preventing influenza when administered 
prophylactically (Monto, Robinson et al. 1999, Hayden 2006, Hayden and Pavia 2006). Finally the 
use of polymerase inhibitors, such as baloxavir marboxil, pimodivir and favipiravir are also being 
investigated (Naesens, Stevaert et al. 2016, Stevaert and Naesens 2016, Uyeki, Bernstein et al. 
2019). Baloxavir has already been approved in the US and Japan (Hayden and Shindo 2019). 
 
 Influenza and serology diagnosis  
Serological tests differ to those of genome detection, such as PCR, as they eliminate the need for 
live virus samples to be obtained, whilst also being able to detect prior infections where the 
antibody titre has remained high. Virus-specific antibodies against influenza can be identified in 
patient’s sera either as total antibody levels or by antibody sub-classes (IgA, IgM, IgG). An anti-
IgM response indicates a current or very recent infection whereas the IgG response includes 
immunological memory of previous infections. A variety of serological methods can be used in 
confirm current or prior infection including; complement-binding reaction (CBR), 
immunofluorescence test (IFT), haemagglutination inhibition test (HIT), the neutralisation test 
and, as used in this study, ELISAs (Arbeitskreis Blut 2009). Initially the use of ELISAs to detect 
influenza positive sera was thought of as having good specificity however a lower sensitivity than 
other methods which detect live virus or viral genome; this notion is being challenged more 
recently by a variety of studies all examining detection of avian influenza using ELISAs (Jensen, 
Andersen et al. 2017, Wibowo, Tarigan et al. 2017, Zhang, Hou et al. 2017).    
6.4.3 Influenza and Coronavirus experimental aim 
When gifted to the laboratory sera 1-11 were noted as being influenza virus negative and sera 12-
24 influenza sera positive. Influenza positive serum is assumed to be positive for either H1 or H3, 
to coincide with the circulating strains at the time. The sera was firstly used to ascertain an 
optimal sera dilution for distinguishing between the two subgroups, before it was used for 
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screening with the recombinant coronavirus N proteins. Primarily the set of sera is beneficial for 
its larger sample size and its wholly different geographical origin. Also although influenza viruses 
and CoVs differ in terms of replication, immune stimulation, and overall lethality (Ng, To et al. 
2006) in order to establish a successful respiratory infection, both viruses have been shown to 
overcome the effectors produced by interferon stimulated genes (ISGs) who’s functions are to 
impede viral pathogenesis (Menachery, Eisfeld et al. 2014). The signalling cascade produced by 
type I IFN provides a first line of defence against viral pathogens and initiates transcription of ISGs 
with antiviral, immune modulatory, and cell regulatory functions (Katze, He et al. 2002). A 2002 
study conducted by Katze et al used models of human airways, transcriptomics and proteomics 
datasets to compare ISG response after highly pathogen H5N1 avian influenza virus, 2009 H1N1 
pandemic influenza virus, SARS-CoV and MERS-CoV infections. It was noted that each virus 
antagonised the ISG response with distinct approaches, sharing some similarities and some 
differences. H5N1 actively manipulated the ISG response with both up and downregulation of ISG 
subsets and H1N1 produced a strong, uniform induction, whereas SARS-CoV and MERS-CoV both 
successfully delayed ISG expression until after viral titres had peaked. Similarities were seen 
between the highly virulent H5N1 and MERS-CoV, as both were able to downregulate ISG subset 
expression using altered histone modification. As a result, it may be hypothesised that having 
infection with influenza virus may increase likelihood of a coronavirus infection, or vice versa. The 
null hypothesis is that having prior infection with either has no result on the likelihood of infection 
with the other. 
6.4.4 Influenza materials and methods 
Sf9 cells were used to produce the recombinant H1 and H3 influenza proteins using the same 
method of BEV used in section 4.1. 
ELISAs were conducted in a similar manner to that described in chapters 6 and 7 however the 
wells were pre-coated with 50µL of snowdrop (Galanthus Nivalis) lectin from at a final 
concentration of 10µg/mL using sodium bicarbonate to dilute and left overnight at 4oC. Snowdrop 
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lectin is a mannose-specific lectin, mannose is the most common carbohydrate in insect cell 
expressed glycoproteins, including the HA (Dormitzer, Andrews et al. 2013). This eliminates the 
need for purification steps as once the recombinant HA proteins are expressed, the Sf9 cells simply 
need to be lysed and clarified to produce lysate suitable for use on the lectin coated 96-well plates.  
Cell pellets were resuspended in 4mLs PBS and lysed using sonication for 3 minutes on ice (pulse 
2 seconds on 2 seconds off, amplification 60%). Triton X100 was added to the final concentration 
of 0.1% and the lysate subjected to a clarifying spin at 13,000rpm for 15 minutes to remove the 
nuclei. The clear cell lysate was either stored in 1mL aliquots at -80oC for future use or diluted 
1:10 with PBS and used immediately for ELISA. After the snowdrop lectin had coated the plates 
overnight, they were washed three times with 1XTBST for 5 minutes each and then 200µL of lysate 
was added per well and left at RT for 1 hour before removal and washing. Thereafter the ELISA 
was conducted as described in section 2.2.7. ELISAs were conducted using varying dilutions of the 
sera in order to see which dilution would best differentiate between those deemed influenza virus 
negative (serum 1-11) and influenza positive (serum 12-24). The initial dilution tested was 1:10 
with a threefold dilution series.  
The cut-off value this time were drawn simply using the highest negative sera result (sera 1-11) 
although clearly if this were to be conducted for diagnostic purpose a more statistical method to 





6.4.5 H1 and H3 protein ELISAs 
 Overview 
 
Figure 64: ELISA results showing the comparison of influenza positive vs influenza negative sera 
screened against recombinant influenza H1 protein. Sera deemed influenza negative are 
coloured blue, sera deemed influenza positive are coloured red. The dilution series started with 
the stock sera being diluted 1:10 and followed a three-fold dilution series. Error bars not shown 































Figure 65: ELISA results showing the comparison of influenza positive vs influenza negative sera 
screened against recombinant influenza H3 protein. Sera deemed influenza negative are 
coloured blue, sera deemed influenza positive are coloured red. The dilution series started with 
the stock sera being diluted 1:10 and followed a three-fold dilution series. Error bars not shown 

































Both the graphs seen showing the ELISA results using recombinant H1 as the antigen, Figure 64, 
and using recombinant H3 as the diagnostic antigen, shown in Figure 65, show that the initial 
dilution of 1:10x30 provides a wide range of OD450 readings unlike to discriminate between 
influenza positive and negative sera and that readings from 1:10x35 onwards appear too dilute. 




 Determining optimal dilution factor for differentiating 
 
Figure 66: ELISA results obtained using a 1:10 sera dilution, conducted using negative and 
positive influenza sera and recombinant H1 and H3 proteins. Sera 1-11 deemed influenza 
negative and sera 12-24 deemed influenza positive. Figure a) results using recombinant H1 
protein in red b) results using recombinant H3 protein in blue. Error bars not shown due to lack 
of repeats. 
When the sera is used to conduct the ELISA at a 1:10 dilution, shown in Figure 66, none of the 
positive influenza sera are seen as being above the cut-off value for either H1 or H3. The 1:10 
dilution is clearly not effective at determining between influenza positive and negative sera.  
Graphs determining optimal detection dilution of human sera against recombinant H1 and 
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Figure 67: ELISA results obtained using a 1:30 sera dilution, conducted using negative and 
positive influenza sera and recombinant H1 and H3 proteins. Sera 1-11 deemed influenza 
negative and sera 12-24 deemed influenza positive. Figure a) results using recombinant H1 
protein in red b) results using recombinant H3 protein in blue. Error bars not shown due to lack 
of repeats.  
When the sera is used to conduct the ELISA at a 1:30 dilution, shown in Figure 67, none of the 
positive influenza sera are seen as being above the cut-off value for H1, however serum 17,22 and 
24 exceed the cut off line for H3. The 1:30 dilution is also clearly not effective at determining 
between influenza positive and negative sera as only 3 out of the 13 positive sera were detected.  
Graphs determining optimal detection dilution of human sera against recombinant H1 and 
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Figure 68: ELISA results obtained using a 1:90 sera dilution, conducted using negative and 
positive influenza sera and recombinant H1 and H3 proteins. Sera 1-11 deemed influenza 
negative and sera 12-24 deemed influenza positive. Figure a) results using recombinant H1 
protein in red b) results using recombinant H3 protein in blue. Error bars not shown due to lack 
of repeats. 
When the sera is used to conduct the ELISA at a 1:90 dilution, shown in Figure 68, only serum 19 
is above the cut-off value for H1. Sera 17, 22 and 24 again exceed the cut-off line for H3 this time 
in a more defined manner than that seen in the 1:30 dilution shown in Figure 67. The 1:90 dilution 
is not effective at determining between influenza positive and negative sera as again only 3 out of 
the 13 positive sera were detected.
Graphs determining optimal detection dilution of human sera against recombinant H1 and 






















































Figure 69: ELISA results obtained using a 1:270 sera dilution, conducted using negative and positive 
influenza sera and recombinant H1 and H3 proteins. Sera 1-11 deemed influenza negative and sera 
12-24 deemed influenza positive. Figure a) results using recombinant H1 protein in red b) results 
using recombinant H3 protein in blue. Error bars not shown due to lack of repeats. 
 
When the sera is used to conduct the ELISA at a 1:270 dilution, shown in Figure 69, for the first 
time positive influenza sera are seen as being above the cut-off value for H1, serum 16, 18 and 19. 
Sera 22 and 24 again exceed the cut off line for H3 however serum 17 this time does not. The 1:20 
dilution was deemed ineffective at determining between influenza positive and negative sera as 
only 5 out of the 13 positive sera were detected.  
Graphs determining optimal detection dilution of human sera against recombinant H1 and 























































Figure 70: ELISA results obtained using a 1:810 sera dilution, conducted using negative and positive 
influenza sera and recombinant H1 and H3 proteins. Sera 1-11 deemed influenza negative and sera 
12-24 deemed influenza positive. Figure a) results using recombinant H1 protein in red b) results 
using recombinant H3 protein in blue. Error bars not shown due to lack of repeats. 
 
Figure 70 shows the sera at a 1:810 dilution; positive influenza sera start becoming more defined 
in the H1 screening with sera 12, 13, 15, 16, 18,19 and 23 all surpassing the cut-off line. Sera 16, 
17, 22 and 24 exceed the cut-off line for H3. The 1:810 dilution shows a marked improvement on 
previous dilutions screened as 9 out of the 13 positive sera were detected. The only positive 
influenza sera that did not exceed the cut-off level for either H1 or H3 were 14, 20, 21 and 23. 
Graphs determining optimal detection dilution of human sera against recombinant H1 and 
H3 influenza proteins using sera dilution 1:810 
A)  
B)  




















































Figure 71: ELISA results obtained using a 1:2430 sera dilution, conducted using negative and positive 
influenza sera and recombinant H1 and H3 proteins. Sera 1-11 deemed influenza negative and sera 
12-24 deemed influenza positive. Figure a) results using recombinant H1 protein in red b) results 
using recombinant H3 protein in blue. Error bars not shown due to lack of repeats. 
 
When the sera is used to conduct the ELISA at a 1:2430 dilution, shown in Figure 71Figure 66, 
positive influenza sera are again detected in the H1 screening with sera 12, 13, 14, 15, 16, 18,19 
and 22 all surpassing the cut-off line. Sera 14, 17, 19, 22 and 24 exceed the cut-off line for H3. The 
1:2430 dilution detects 10 out of the 13 positive sera were detected. The only positive influenza 
sera that did not exceed the cut-off level for either H1 or H3 were 20, 21 and 23. 
Graphs determining optimal detection dilution of human sera against recombinant H1 and 
H3 influenza proteins using sera dilution 1:2430 
A)  
B)  



















































Figure 72: ELISA results obtained using a 1:7290 sera dilution, conducted using negative and 
positive influenza sera and recombinant H1 and H3 proteins. Sera 1-11 deemed influenza 
negative and sera 12-24 deemed influenza positive. Figure a) results using recombinant H1 
protein in red b) results using recombinant H3 protein in blue. Error bars not shown due to lack 
of repeats. 
When the sera is used to conduct the ELISA at a 1:7,290 dilution, shown in Figure 72, positive 
influenza sera deemed above the cut-off limit in the H1 screening were 13, 14, 15, 16, 17, 18,19 
and 22. Sera 12, 17, 22 and 24 exceed the cut-off line for H3. The 1:7,290 dilution detected 10 out 
of the 13 positive sera, similar to the results seen for the previous dilution of 1:2,430. The only 
positive influenza sera that did not exceed the cut-off level for either H1 or H3 were 20, 21 and 23. 
Graphs determining optimal detection dilution of human sera against recombinant H1 and 

























































Figure 73: ELISA results obtained using a 1:21,870 sera dilution, conducted using negative and 
positive influenza sera and recombinant H1 and H3 proteins. Sera 1-11 deemed influenza negative 
and sera 12-24 deemed influenza positive. Figure a) results using recombinant H1 protein in red b) 
results using recombinant H3 protein in blue. Error bars not shown due to lack of repeats. 
 
When the sera is used to conduct the ELISA at the highest dilution screened 1:21,870, shown in 
Figure 73, differentiation between positive and negative influenza serum reduces. The H1 
screening detects only sera 19, 20 and 22 above the cut-off limit and only sera 12, 22 and 24 
exceed the cut-off line for H3. The 1:21,870 dilution shows a clear reduction in efficiency on 
Graphs determining optimal detection dilution of human sera against recombinant H1 and 
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previous dilutions screened as only 5 out of the 13 positive sera were detected missing out sera 
13, 14, 15, 16, 17, 18, 21 and 23. 
 Summary of optimal ELISA protein dilution  
The graphs determining optimal detection dilution of human sera against recombinant H1 and H3 
influenza proteins using varying sera dilutions, shown in Figure 66-Figure 73, show that the 
dilutions with the fewest number of positive influenza sera missing were 1: 2,430 and 1: 7,290. If 
the purpose of this study was to truly use the recombinant H1 and H3 proteins in diagnostic 
testing then a more scientific cut-off value would need be to ascertained, for example the “mean + 
3 standard deviation of negative control” could be used (Lardeux, Torrico et al. 2016) and the 
test’s sensitivity and specificity could be ascertained.  
Going forward, the same set of 24 sera was used for ELISA screen this time using the CoV 








6.4.6 Coronavirus protein ELISAs 
 By individual sera 
 
Figure 74: ELISA results showing 4 human sera against recombinant CoV proteins (colour 
coded; SARS-CoV in red, MERS-CoV in blue, OC43-CoV in green, NL63-CoV in purple, 229E-CoV 
in yellow and IBV in grey). The dilution series started with the stock sera being diluted 1:50 and 
followed a two-fold dilution series. Figures a-d show sera 1-4 respectively. Error bars not shown 
due to lack of repeats. 
Figure 74 shows sera 1 and 3 as having suspected 229E-CoV and NL63-CoV positive, sera 4 as 





Figure 75: ELISA results showing 4 human sera against recombinant CoV proteins (SARS-CoV in 
red, MERS-CoV in blue, OC43-CoV in green, NL63-CoV in purple, 229E-CoV in yellow and IBV in 
grey). The dilution series started with the stock sera being diluted 1:50 and followed a two-fold 
dilution series. Figures a-d show sera 5-8 respectively. Error bars not shown due to lack of 
repeats. 
Figure 75 shows sera 5 and 6 as possible SARS-CoV reactivity although the high IBV levels also 
seen make this questionable, Sera 7 and 8 both show probably 229E-CoV reactivity with sera 7 
additionally having OC43-CoV reactivity. 
  
 
Graphs showing the ELISA results from sera 5-8 from the German cohort screened against 
recombinant Coronavirus N proteins 
A) B)  




Figure 76: ELISA results showing 4 human sera against recombinant CoV proteins (SARS-CoV in 
red, MERS-CoV in blue, OC43-CoV in green, NL63-CoV in purple, 229E-CoV in yellow and IBV in 
grey). The dilution series started with the stock sera being diluted 1:50 and followed a two-fold 
dilution series. Figures a-d show sera 9-12 respectively. Error bars not shown due to lack of 
repeats. 
Figure 76 shows sera 9-12 as all having suspected reactivity to 229E-CoV, they also all show 
possible reactivity to NL63-CoV except for sera 10 which does not. 
 
Graphs showing the ELISA results from sera 9-12 from the German cohort screened against 
recombinant Coronavirus N proteins 
A)  B)  




Figure 77: ELISA results showing 4 human sera against recombinant CoV proteins (SARS-CoV in 
red, MERS-CoV in blue, OC43-CoV in green, NL63-CoV in purple, 229E-CoV in yellow and IBV in 
grey). The dilution series started with the stock sera being diluted 1:50 and followed a two-fold 
dilution series. Figures a-d show sera 13-16 respectively. Error bars not shown due to lack of 
repeats. 
Figure 77 shows serum 13 with suspected 229E-CoV reactivity although a questionable IBV 
reactivity, serum 15 as having possible OC43-CoV, NL63-CoV and 229E-CoV reactivity and sera 14 
and 16 as having probably 229E-CoV reactivity. 
 
Graphs showing the ELISA results from sera 13-16 from the German cohort screened against 
recombinant Coronavirus N proteins 
A)  B)  




Figure 78: ELISA results showing 4 human sera against recombinant CoV proteins (SARS-CoV in 
red, MERS-CoV in blue, OC43-CoV in green, NL63-CoV in purple, 229E-CoV in yellow and IBV in 
grey). The dilution series started with the stock sera being diluted 1:50 and followed a two-fold 
dilution series. Figures a-d show sera 16-20 respectively. Error bars not shown due to lack of 
repeats. 
Figure 78 shows serum 17 as having possible OC43-CoV, NL63-CoV and 229E-CoV reactivity. 
Serum 18 as having NL63-CoV and 229E-CoV reactivity and sera 19 and 20 as having 229E-CoV 
reactivity. 
Graphs showing the ELISA results from sera 17-20 from the German cohort screened against 
recombinant Coronavirus N proteins 
A) B)  




Figure 79: ELISA results showing 4 human sera against recombinant CoV proteins (SARS-CoV in 
red, MERS-CoV in blue, OC43-CoV in green, NL63-CoV in purple, 229E-CoV in yellow and IBV in 
grey). The dilution series started with the stock sera being diluted 1:50 and followed a two-fold 
dilution series. Figures a-d show sera 21-24 respectively. Error bars not shown due to lack of 
repeats. 
Figure 79 shows sera 21-24 as all showing signs of 229E-CoV reactivity with serum 22 
additionally showing NL63-CoV reactivity. 
The following graphs show the ELISA results based on individual coronavirus recombinant N 
protein as opposed to sera. 
 
Graphs showing the ELISA results from sera 21-24 from the German cohort screened against 
recombinant Coronavirus N proteins 
A) B)   
C) D)   
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 By Coronavirus N protein 
 
Figure 80: ELISA results showing the comparison of influenza positive vs influenza negative sera screened against recombinant SARS-CoV N protein, 
with results seen when individual sera’s cut off values were implemented. Sera deemed influenza negative and positive are coloured blue and red 
respectively. The dilution series started with the stock sera being diluted 1:50 and followed a two-fold dilution series. Error bars not shown due to 
lack of repeats. 




Figure 81: ELISA results showing the comparison of influenza positive vs influenza negative sera screened against recombinant OC43-CoV N protein, 
with results seen when individual sera’s cut off values were implemented. Sera deemed influenza negative and positive are coloured blue and red 
respectively. The dilution series started with the stock sera being diluted 1:50 and followed a two-fold dilution series. Error bars not shown due to 
lack of repeats. 
Figure 81 shows that of the three sera deemed positive with cut off values two were influenza positive and one was influenza negative, more 




Figure 82: ELISA results showing the comparison of influenza positive vs influenza negative sera screened against recombinant NL63-CoV N protein, 
with results seen when individual sera’s cut off values were implemented. Sera deemed influenza negative and positive are coloured blue and red 
respectively. The dilution series started with the stock sera being diluted 1:50 and followed a two-fold dilution series. Error bars not shown due to 
lack of repeats. 
Figure 82 shows there to be a fairly even split between influenza positive and influenza negative sera showing reactivity to recombinant NL63-CoV N 
protein once cut-off levels were in place.  
 
Comparison of negative and positive influenza sera ELISA results screened against NL63 recombinant N protein with results seen when individual sera’s cut 
off values were implemented 








Figure 83: ELISA results showing the comparison of influenza positive vs influenza negative sera screened against recombinant 229E-CoV N protein, 
with results seen when individual sera’s cut off values were implemented. Sera deemed influenza negative and positive are coloured blue and red 
respectively. The dilution series started with the stock sera being diluted 1:50 and followed a two-fold dilution series. Error bars not shown due to 
lack of repeats. 
Figure 83 shows there to be a fairly even split between influenza positive and influenza negative sera showing reactivity to recombinant 229E-CoV N 
protein once cut-off levels were in place.
 
Comparison of negative and positive influenza sera ELISA results screened against 229E recombinant N protein with results seen when individual sera’s cut 
off values were implemented 








Figure 84: ELISA results showing the comparison of influenza positive vs influenza negative sera 
screened against recombinant MERS-CoV N protein. Sera deemed influenza negative and 
positive are coloured blue and red respectively. The dilution series started with the stock sera 
being diluted 1:50 and followed a two-fold dilution series. Error bars not shown due to lack of 
repeats. 
 
Figure 84 shows the colour coded results seen when influenza positive and negative sera was 
screened against recombinant MERS-CoV N proteins. Although it is highly unlikely that anybody 
screened would have true reactivity to MERS-CoV the data could be used as a negative control to 



























Negative and positive influenza sera ELISA 






Figure 85: ELISA results showing the comparison of influenza positive vs influenza negative sera 
screened against recombinant IBV N protein. Sera deemed influenza negative and positive are 
coloured blue and red respectively. The dilution series started with the stock sera being diluted 
1:50 and followed a two-fold dilution series. Error bars not shown due to lack of repeats. 
 
Figure 85 shows the colour coded results seen when influenza positive and negative sera was 
screened against recombinant IBV N proteins. Similar to the results seen during screening with 
diabetic positive and negative sera the MERS-CoV results are actually of a lower magnitude OD450 
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Influenza negative Influenza positive 
SARS-CoV 2 0 
MERS-CoV 0 0 
OC43-CoV 1 0 
NL63-CoV 1 3 
229E-CoV 8 13 
IBV 0 0 
Table 18: The number of positive reactions to HCoV N proteins using ELISAs with both influenza 
positive and negative sera 
Figures from Table 18 were used to create the contingency tables seen in Table 19 to allow 
Fisher’s exact test to take place, similar to section 6.3.5.10.2. 
6.4.6.3.1 2x2 contingency tables for each coronavirus recombinant N protein 
SARS-CoV  
Reactivity No Reactivity       Total 
Influenza positive 0 13 13 
Influenza negative 2 9 11 
Total 2 22 24 
MERS-CoV and IBV  
Reactivity No Reactivity       Total 
Influenza positive 0 13 13 
Influenza negative 0 11 11 
Total 0 24 24 
NL63-CoV  
Reactivity No Reactivity       Total 
Influenza positive 3 10 13 
Influenza negative 1 10 11 
Total 4 20 24 
OC43-CoV  
Reactivity No Reactivity       Total 
Influenza positive 0 13 13 
Influenza negative 1 10 11 
Total 1 23 24 
229E-CoV  
Reactivity No Reactivity       Total 
Influenza positive 13 0 13 
Influenza negative 8 3 11 
Total 20 4 24 
Table 19: The six 2x2 contingency tables for each recombinant coronavirus N protein using 
suspected influenza positive and negative sera 
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For the SARS-CoV, IBV, MERS-CoV, NL63-CoV, OC43-CoV results displayed in Table 19, the 
following outcome was observed “The two-tailed P value equals 1.0000, so the association between 
rows (groups) and columns (outcomes) is considered to be not statistically significant”. This allows 
the null hypothesis to be accepted and states that there is no association between influenza 
positive and negative status and coronavirus recombinant N protein reactivity seen in this study 
of a limited number of individual sera.  
The smallest P value was seen in the case of 229E-CoV and was 0.0815, this time “the association 
between rows (groups) and columns (outcomes) is considered to be not quite statistically 
significant”. Interestingly if the trend of 100% 229E-CoV reactivity in influenza positive and 73% 
229E-CoV reactivity in influenza negative sera were found in a higher population/sample number 
such as 100 the P value would be 0.0001 and the result would be considered to be “extremely 
statistically significant”. Showing the main downfall of this study to be the limited number of sera 
available to screen on.  
It has been reported that as many as 20% of patients with influenza also have additional viral 
infections (Esper, Spahlinger et al. 2011). This can be somewhat explained by the times at which 
viruses circulate within the year; predominantly winter in the Northern hemisphere. Influenza 
has been identified with co-existing viruses (Peng, Zhao et al. 2009). Whether coinfection effects 
patient morbidity remains controversial in literature making the clinical relevance of respiratory 
virus copathogens unclear (Esper, Spahlinger et al. 2011). A 2011 study by Esper et al argued that 
certain copathogen pairings had higher clinical relevance than others. The group used multiplex 
RT-PCR to identify prominent viral copathogens in the H1N1 influenza pandemic; they used 
respiratory samples from 229 patients identified without influenza and 267 samples from 
patients with influenza and screened for the presence of 13 seasonal respiratory viruses, including 
coronaviruses. The study found that 13.1% of influenza samples were positive for 31 viral 
copathogens, the most prominent being rhinovirus (61.3%) followed by coronaviruses (16.1%). 
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At no point does the data from the study distinguish between NL62, OC42 and 229E-CoV, the three 
they conducted screening for.   
 Further work will be needed on a larger data set to test the null hypothesis and see if there is a 




 Summary and future work 
 Purpose of investigation 
The emergence of SARS in 2003 highlighted an inadequacy in preparation for the first pandemic 
of the twenty-first century (de Wit, van Doremalen et al. 2016). Several months were needed 
before the causative agent was identified as SARS-CoV. Fortunately advances in next generation 
sequence technologies (NGST) paved the way for a quicker identification of MERS-CoV in 2012 
(Zaki, van Boheemen et al. 2012). Most emerging diseases, such as SARS, MERS and Covid19 are 
zoonotic (Jones, Patel et al. 2008) indicating that viral cross-species transmission is a significant 
threat to human health (Chan, To et al. 2013, de Wit, van Doremalen et al. 2016). The high 
mortality rates shown by SARS, Covid19 and MERS demonstrate the importance of studying 
Coronaviridae as emerging human pathogens.  
In 2015 it was suggested that a cluster of SARS-like CoV circulating in bat populations also show 
potential for human emergence (Menachery, Yount et al. 2015) (Drexler, Corman et al. 2014). It is 
also possible that there are additional CoVs circulating in other animal species that could go on to 
infect humans. A worldwide large-scale study screening samples from various wild animals would 
need to be conducted in order to investigate this further.  
There is still a need for broad-spectrum vaccinations or therapeutic strategies for both current 
and future emerging Coronaviruses to be established (Omrani, Saad et al.). The development of 
animal models closer to the natural host targets is an important part of research aims moving 
forward. Although there are effective vaccine prototypes for both SARS-CoV and MERS-CoV 
available (Haagmans, van den Brand et al. 2016) (Roper and Rehm 2009, Honda-Okubo, Barnard 
et al. 2015) none are yet licensed, nor are there any licensed therapeutic drugs to treat either 




In the case of MERS-CoV, vaccination of dromedary camels has been looked into (Haagmans, van 
den Brand et al. 2016) however there may be social complications by way of the reticence of camel 
owners to vaccinate their animals, although a dual vaccine against both  MERS-CoV and camelpox 
virus has been suggested as a solution (Haagmans, van den Brand et al. 2016) in a similar design 
to a dual MERS-CoV and rabis vaccine (Wirblich, Coleman et al. 2017). Issues surrounding political 
and intellectual property rights play roles in the lack of vaccine currently on the market as 
pharmaceutical companies are unlikely to invest in development unless  there is a current need 
(Simon, Claassen et al. 2005). 
Alongside developments in vaccinations and therapeutic strategies, diagnostic techniques also 
require further study. Speed is a crucial factor when it comes to the identification of a new virus 
outbreak, as appropriate treatment regimen for patients and disease containment are most 
advantageous when implemented swiftly. This study focuses on the diagnostic aspect of 
Coronaviruses, both in terms of serosurveillance to test for current disease as well as 
retrospective infections.  
The use of recombinant proteins as antigens may prove beneficial as they involve no biohazard 
risk, have the potential to be easily upscaled and the process can be readily automated for large-
scale screening. This study had two research objectives; to create purified soluble N proteins for 
MERS-CoV, SARS-CoV, OC43-CoV, NL63-CoV, 229E-CoV and IBV, and to use these recombinant N 




 Results  
7.2.1 A summary of the results and hypothesis 
The purpose of this investigation was to ascertain if recombinant nucleocapsid proteins could be 
used as diagnostic antigens when screening sera suspected of having prior human coronavirus 
infection. Sequences were cloned into a commercial PTriEx1.1 vector, modified with a 
polyhistidine tag at the N terminal domain and a stop coding to prevent translation of the pre-
existing polyhistine tag located at the C terminal domain of the vector, with the aim of producing 
soluble proteins. A variety of prokaryotic E. coli strains were investigated and SoluBL21 
subsequently proved the most viable for all Coronaviruses recombinant nucleocapsid proteins 
produced. Proteolytic degradation was observed, most noticeably in the IBV sample, and so 
eukaryotic expression was also examined without a marked increase in success. As a result, a 
truncated version of the protein, omitting the central disordered region, was created and shown 
to elicit similar antigenic properties to the full-length construct. All six recombinant nucleocapsid 
proteins (SARS-CoV, MERS-CoV, NL63-CoV, OC43-CoV, 229E-CoV, IBV and ΔIBV) were produced 
and purified using IMAC and subsequently used to conduct a variety of ELISA screenings; showing 
great promise for their use as diagnostic antigens. 
The individual hypotheses within this study were detailed in Chapter 6 and state that being a type 
one diabetic may predispose you to Coronavirus infection and secondly that showing signs of 
Coronavirus infection may correlate to an increased likelihood of an Influenza infection or vice 
versa. Due to the limited numbers of sera collected and screened neither hypothesis could be 
accepted, however the fact that 100% of influenza positive sera showed 229E-CoV reactivity 




7.2.2 Existing research 
 Recombinant protein production 
Although polyhistidine tags generally have no significant effect on the structure of the native 
protein (Carson, Johnson et al. 2007) a 2004 study compared four different vectors for expression 
of 20 human proteins with N- or C-terminal polyhistidine tags in E. coli, noting, among other 
things, the solubility of the target proteins (Woestenenk, Hammarstrom et al. 2004). The study 
showed that in general both N- and C-terminal polyhistine tags have a noticeable negative effect 
on protein solubility but found that the effect is target protein specific. Evidently in the case of the 
recombinant Coronavirus nucleocapsid proteins, the relocation from the C terminus to the N 
terminus elicited a positive effect in the proteins’ solubility, an issue that had proved problematic 
in previous studies (McCrory 2009). 
 The use of recombinant Coronavirus nucleocapsids as diagnostic antigens  
Similar studies using recombinant nucleocapsid proteins for diagnostic purposes have been 
implemented, some with an N terminus polyhistidine tag; screening SARS-CoV (Zuo, Mattern et al. 
2005) and NL63-CoV (Zuwała, Golda et al. 2015), others with a C terminus polyhistidine tag  
including SARS-CoV (Haynes, Miao et al. 2007) and MERS-CoV (Chen, Chan et al. 2015).  
This study is different to most in that it focuses on 5 HCoVs whereas predominantly studies chose 
to focus on one; mostly MERS-CoV or SARS-CoV. In examples whereby more than one Coronavirus 
is screened for RT-PCR appears the most common technique (Gaunt, Hardie et al. 2010) (Lau, Woo 
et al. 2006, Dominguez, Robinson et al. 2009, Mackay, Arden et al. 2012, Cabeca, Granato et al. 
2013). 
 The benefits of truncated nucleocapsid proteins 
Truncated proteins have similarly been examined and found to be beneficial. Blanchard et al 
divided the OC43-CoV N protein into three truncated proteins; N1 aa1-119, N2 aa120-332 and N3 
aa333-448 with molecular weights of 17kDa, 25kDa and 17.5kDa respectively (Blanchard, Miao 
et al. 2011). The proteins contained a C terminal polyhistidine tag and were expressed in BL21 
233 
 
cells. 11 convalescent OC43-CoV sera were used to evaluate antibody response to the truncated 
proteins, the predominant response was found when using N3 (11 out of 11), followed by N2 (4 
out of 11) then N1 (3 out of 11). As well as having the best response to OC43-CoV sera, N3 also 
had the least sequence homology to other HCoV N proteins. As a result, it was used to also screen 
sera from 229E-CoV and SARS-CoV positive patients to assess cross-reactivity. When the full-
length protein was used 74% (20 out of 27) of 229E-CoV and 100% (20 out of 20) of the SARS-
CoV sera showed cross reactivity. In contrast, when the truncated N3 protein was used, these 
figures reduced to 7.4% (2 out of 27) for 229E-CoV and 30% for SARS-CoV (6 out of 20). Similar 
studies have also been conducted using truncated SARS-CoV nucleocapsid proteins (Yu, Le et al. 
2007, Lee, Lee et al. 2008). These studies highlight the importance that truncated proteins may 
provide not only in terms of additional structural stability but also in their potential to decrease 
cross-reactivity. 
 Screening 
As previously mentioned, Coronaviruses that are potentially pathogenic towards humans may 
already be circulating in animal species, including bats, rodents and livestock. Viral surveillance 
studies are a crucial way of examining what strains exist in the environment that may be of 
concern (Coleman and Frieman 2014).  
7.2.2.4.1 Bats 
Small scale studies have highlighted the potential for a SARS-like virus, SHC014-CoV currently 
circulating in Chinese horseshoe bat populations, to emerge, as it was shown in vitro to be able to 
utilize ACE2 as a receptor and replicate in primary human airway cells as well as being shown to 
cause pathogenesis in vivo in mice (Menachery, Yount Jr et al. 2015). A novel MERS-like 
Coronavirus has also been reported in Pipistrellus hesperidus bats in Uganda giving further 
credence to MERS-CoV having a bat origin (Anthony, Gilardi et al. 2017). Evolution 
notwithstanding, the virus’ spike protein differs sufficiently that it is not deemed as being a threat 
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to human health. Recent suspected zoonotic spread includes that of a new bat-HKU2-like porcine 
Coronavirus found in piglets with diarrhoea in China (Gong, Li et al. 2017). 
7.2.2.4.2 Camels 
Similar work has been successfully conducted in order to screen camels (Song, Ha et al. 2015). 
Due to their role in infection transmission in the case of MERS-CoV, metagenomic sequence 
analysis on nasopharyngeal swabs of 108 MERS-CoV positive camels were studied to ascertain if 
there are any additional, currently unidentified, viruses in camels’ upper respiratory tracks, with 
a potential to infect humans (Li, Khalafalla et al. 2017). The study collected a total of 846.72 million 
high-quality reads from the samples, of which 2.88 million (0.34%) were related to viral 
sequences. 512.63 million (60.5%) and 50.87 million (6%) matched bacterial and eukaryotic 
sequences respectively. Sequences related to mammalian viruses from 13 genera in 10 viral 
families were identified, including Coronaviridae, Nairoviridae, Paramyxoviridae, Parvoviridae, 
Polyomaviridae, Papillomaviridae, Astroviridae, Picornaviridae, Poxviridae, and Genomoviridae. 
The study showed that although some viral sequence belonged to pre-known camel or human 
viruses, others were from potentially novel camel viruses with only limited sequence similarity to 
virus sequences found in GenBank. Five potentially novel virus species or strains were identified.  
7.2.2.4.3 Other animals  
Studies published in 2017 have also described serological evidence of Coronavirus infections in 
hamadryas baboons (Papio hamadryas hamadryas) in the Kingdom of Saudi Arabia (Olarinmoye, 
Olugasa et al. 2017). It is also thought that genetic recombination is responsible for the discovery 
of a novel canine respiratory Coronavirus (Lu, Wang et al. 2017) 
 Importance of the study 
Few studies have been conducted on multiple Coronavirus-detection in immunosurveillance 
studies, with most focusing on the two emerging viruses of SARS-CoV and MERS-CoV. Although 
the screening studies provided no statistically significant results due to a low sample number, the 
principle remains that recombinant nucleocapsid proteins can be used in future 
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immunosurveillance studies to ascertain the seroprevalence of human Coronaviruses amongst 
populations. 
7.3.1 Implications and practical applications of the study 
The results of this study could provide the foundation for a functional ELISA screening kit for 
multiple Coronavirus. Current ELISA kits available seem to only specify a positive/negative result 
for Coronaviruses in general as opposed to giving a detailed account of which may be present. Pre-
existing kits including a general Coronavirus ELISA kit to detect IgG  available from my Biosource 
(MyBioSource 2020) and a sandwich ELISA kit to detect MERS-CoV specifically (MyBioSource 
2020).  
7.3.2 Limitations of the study 
The study had several limitations, namely the limited number of sera collected and screened 
decreasing the statistical significance of any result.  
 KHU1-CoV omitted  
One limitation of the study was the incomplete set of HCoVs used, as human Coronavirus KHU1-
CoV (Drexler, Corman et al. 2014) was left out of this study due to lack of availability. 
 Cross-reactivity  
Betacoronaviruses have been found to cross-react, which can cause false positives and limit the 
use of the procedure in diagnostics (Corman, Muller et al. 2012) (Woo, Lau et al. 2012) (Qiu, Shi 
et al. 2005) (Maache, Komurian-Pradel et al. 2006) (Che, Qiu et al. 2005).  One way to compensate 
is to use an additional confirmation assay, such as a viral neutralization test (VNT), on any sera 
deemed positive by an ELISA. Although this is labour-intensive and would not be ideal in an 
outbreak situation. 
 Positive and negative sera 
As discussed in the Chapter 6 and 7, positive and negative sera would have been beneficial in order 
to establish a scientific cut-off limit; although this may have been possible for the influenza screens 
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there was no such sera available for the Coronavirus screening and so the recombinant IBV data 
was utilised as a negative control instead. 
 Sample size 
The small sample sizes screened hampered statistical analysis and did not enable any correlation 
for either hypothesis to be determined. 
 Analytical and statistical analysis 
The purpose of this study was to test out the practicality of using recombinant nucleocapsid 
proteins as diagnostic antigens in serosurveillance as opposed to drawing conclusions on 
prevalence of Coronaviruses in the population screened and so statistical analysis was limited.  
 Recommendations for further research 
Further work could be conducted in several areas in order to best improve this study, as detailed 
below.  
7.4.1 ELISA optimisation and performance 
Before the ELISA method could be expected to perform as a true diagnostic test it would need to 
be optimised and have the optimal N protein concentration, serum dilution and conjugate dilution 
assessed.  
The main flaw with the ELISAs conducted in the study is the lack of data corresponding to their 
sensitivity (measure of the proportion of positive results correctly identified) and specificity 
(measure of the proportion of negatives that are correctly identified) due to a lack of positive and 
negative control serum for the Coronavirus examples. This makes it impossible to truly compare 
the test’s validity against other methods, although the data would not be hard to generate with 
the necessary sera.  
True positives (TP), true negatives (TN), false positives (FP) and false negatives (FN) results could 
be looked at to evaluate the diagnostic test’s performance. 
237 
 
Accuracy/sensitivity =  
𝑇𝑃
𝑇𝑃+𝐹𝑁
  (To determine how good the assay picked up actual positive) 
Precision/specificity =  
𝑇𝑁
𝑇𝑁+𝐹𝑃
  (To determine how good the assay excluded actual negative) 
Positive Predictive Value (PPV) = 
𝑇𝑃
𝑇𝑃+𝐹𝑃
  (The probability of observed positive result) 
Negative Predictive Value (NPV) = 
𝑇𝑁
𝑇𝑁+𝐹𝑁
  (The probability of observed negative result) 
 
Where: TP = the number of tests correctly assigned as positive. 
TN = the number of tests correctly assigned as negative. 
FP = the number of tests incorrectly assigned as positive. 
FN = the number of tests incorrectly assigned negative 
 
Ideally diagnostic tests would have 100% sensitivity and specificity however realistically this is 
almost impossible to achieve and so values over 90% are deemed to have high credibility in 
differential diagnosis (Parikh, Mathai et al. 2008).  
In the case of the influenza sera screened against recombinant H1 and H3 proteins, sensitivity and 
specificity could be examined, however the cut-off point was merely set by the highest negative 
value, adding bias into equations as FP will automatically equal 0. That being said, using the 
current cut-off level and the optimum sera dilution of 1:2430 or 1:7290, only 10 out of the 13 
samples were detected as TP leaving 3 FN and 11 TN, giving the test a specificity of 1 and 
sensitivity of 0.77. 
A second use of positive and negative sera sets would be in validating assays. A positive control 
mean (PC) and negative control mean (NC) could be ascertained and OD boundaries set 
accordingly i.e.  assay is valid when PC–NC > x and NC ≤ y, the figures would be arbitrarily set by 
the test conductor but could remain constant throughout subsequent assays. 
7.4.2 Statistical analysis 
“There is no single statistic that can adequately represent the agreement between a diagnostic test 
and a reference standard” (Okeh and Okoro 2012). The cut-off points generated in this study were 
done crudely and could be improved upon again with the use of known negative and positive sera. 
Statistical analysis could also be improved with the use of statistical software and, perhaps more 
importantly, a larger data set. A variety of measures can be used to summarise and quantify the 
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diagnostic accuracy of a test including amongst others; sensitivity, specificity, ROC curve, 
likelihood ratio (LR) for positive/negative test, odds ratio (OR), error rates and confidence 
interval. Perhaps the one most likely to be beneficial in a study such as this is the ROC curve which 
could be created by plotting the true positive rate (TPR), equivalent to sensitivity, against the false 
positive rate (FPR), equal to 1- specificity, at various threshold settings in order to analyse cost 
(false positives) vs benefit (true positives) when it comes to diagnostic decision making. A 
diagonal line can be used to divide the ROC space whereby sensitivity=specificity and points above 
the diagonal represent results that are better than random and points below the line represent 
results worse than random. The perfect classification would be a test with no false negatives 
(100% sensitivity) and no false positives (100% specificity) this would like on the (0,1) point of 
the ROC space graph (Powers 2011). 
 
7.4.3 Further investigation into protein structure 
The truncated IBV protein provided similar ELISA results to that of the full-length protein, it 
would be interesting to apply the same truncation to the remaining recombinant nucleocapsid 
proteins to see if they too become more structurally stable without compromising their 
antigenicity. 
7.4.4 Other methodologies  
Once the sensitivity and specificity of the ELISA method using the recombinant Coronavirus 
nucleocapsid proteins is established using a larger sample set of both known positive and negative 
sera; the method can be compared with other diagnostic tests such as PCR, RT-PCR and IFA.  
Newer methods could also be compared against including a MassARRAY matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) which has already been 
used to screen Alphavoronavirus and Betacoronavirus in bat, rodent and human samples (Xiu, 
Zhang et al. 2017). The results of the Xiu et al study showed good agreement with the results of 
metagenomic analysis or PCR-sequencing and could also be used to provide phylogenetic 
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evidence about unknown CoVs. Quantitative polymerase chain reaction (qPCR) has been shown 
to be a sensitive detection method to detect HCoV sensitivity and has the additional benefit of 
being quantitative (Vijgen, Keyaerts et al. 2005, Gaunt, Hardie et al. 2010). The downside to qPCR-
based methods is that most target a single gene of a virus. Although a few studies have developed 
methods to target different genes of MERS-CoV such as upE, ORF1b and ORF1a (Corman, Eckerle 
et al. 2012, Corman, Muller et al. 2012) as well as the nucleocapsid gene (Lu, Whitaker et al. 2014). 
The MALDI-TOF method targets two or four genes and showed that using multiple targets was 
beneficial to avoid false negative results (Xiu, Zhang et al. 2017).  NGST have been widely used in 
pathogen detection (Wu, Yang et al. 2016) as they do not require prior knowledge of targets which 
is beneficial in the case of CoVs as they have a high frequency of mutation and recombination. 
However, NGST often come with a high cost, long turn-around time and require complex 
bioinforamatic analysis which can limit the number of samples that can be sequenced and the 
overall practicality of the method. Other methods such as MALDI-TOF could be used initially and 
then positive results further investigated using NGST. 
 
7.4.5 Large scale human screening 
Future larger studies with statistical analyses would be of interest. Sera could be examined both 
from cohorts suspected of having prior Coronavirus exposure, people from the Middle East who 
may have been exposed to MERS-CoV for example, as well as cohorts not suspected of having any 
exposure above that of common Coronaviruses. Statistical analysis could be conducted to see to 
what extent age, gender, season, socio-economic status, location and other factors, effect 
likelihood of each Coronavirus infection. One such study by Liljander, Meyer et al. focused on the 
detection of MERS-CoV antibodies in 1122 human sera collected as part of a household survey 
conducted during 2013–2014 in 2 eastern counties of Kenya, Garissa and Tana River (Liljander, 
Meyer et al. 2016). Where possible gender, age and occupation was recorded. The households of 
nearly all participants kept or owned livestock, including goats, sheep, cattle, and donkeys; 
although camels are not commonly kept, they are widespread in the region. The study used a 
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commercial anti-MERS-CoV recombinant ELISA, based on the viral spike protein. The study 
identified 16 samples as having positive results. Although the number of samples tested was 
approximately one tenth of the number of samples tested during a similar Saudi Arabia study 
conducted by Muller, Meyer et al., the proportion of seropositive specimens was shown to be 
similar (Müller, Meyer et al. 2015). Prior to the study autochthonous human MERS-CoV infections 
have not been recorded in Africa, resulting in the hypothesis that there is a difference in 
transmission between Africa and the Arabian Peninsula and raising doubts as to the involvement 
of camels in the disease spread. The study showed the presence of previously unrecorded human 
MERS-CoV infections in Kenya; the apparent lack of reported cases may therefore be down to 
either a lack of a well-developed public health system and lack of diagnoses or perhaps a less 
virulent strain. The recombinant nucleocapsid proteins produced in this study could be similarly 
used to conduct large scale human sera screens. 
7.4.6 Animal screening 
Following on from the paper highlighting the presence of CoV in European hedgehogs (Erinaceus 
europaeus) (Corman, Kallies et al. 2014) the recombinant nucleocapsid proteins produced in this 
study could be used to conduct ELISAs on animal sera too. Feral sera samples could be sourced 
from the Royal Society for the Protection of Animals (RSPCA) and/or Animal Health and 
Veterinary Laboratory Agency (AHVLA); who have a large selection of animal and bat sera as a 
result of their rabies screening program. 
7.4.7 Production of a functional screening kit  
As well as using the recombinant nucleocapsid proteins to produce ELISA kits to conduct 
serosurveillance, other styles of kits could also be manufactured such as an 
immunochromatographic test which is beneficial in that in can be used for diagnosis in remote 
areas where laboratory facilities are not available (Guan, Chen et al. 2004). Such kit has been 
produced using recombinant MERS-CoV nucleocapsid protein with a relative sensitivity and 
241 
 
specificity of 93.90% and 100%, respectively, compared to that of the UpE and Orf1A RT-PCR 
(Song, Ha et al. 2015) shown in Figure 86 . 
 
Figure 86: Two test strips showing the immunochromatographic screening of sera to MERS-CoV. 
C= control line; T= test line. A) shows a positive result and B) a negative result. Image taken from  
(Song, Ha et al. 2015). 
 
Other potential tests that could be produced as a result of this study include an antigen spot test 
(AST). This has been used previously to detect bovine Coronavirus (BCV) in bovine faecal samples 
(Gaber and Kapil 1999). The Gaber and Kapil study compared the sensitivity and specificity of AST 
for the detection of BCV antigen to those of a sandwich ELISA and a haemagglutination assay (HA). 
347 field samples were collected and screened using all three methods. 94.2% were deemed 
positive using AST, 91.4% by ELISA, and 86.7% by HA. The sensitivity of the AST was determined 
to be 100% however the test had a low specificity of 67% as a result of a lower limit of detection 
(104 viral particles per mL in a 10% faecal suspension). As mentioned in section 1.2.10.2 such kits 






Even before diagnostic methods come in to play healthcare providers play a crucial role in disease 
containment. During a six-month period (December 2015–May 2016) a series of unannounced 
“mystery patient drills” were carried out to assess New York City Emergency Departments’ (EDs) 
abilities to identify and respond to patients with communicable diseases of public health concern 
(Foote, Styles et al. 2017). The aim of the study was to highlight significant health care system 
vulnerabilities and stress the importance of rapid recognition and isolation of patients with 
potentially severe infectious diseases. The drill scenarios presented a patient reporting signs or 
symptoms and having a travel history consistent with possible measles or MERS. The expectation 
was that once the patient was identified as being at high risk for having a communicable disease 
with a potential for respiratory transmission, they would be asked to wear a mask and be placed 
into an airborne infection isolation room. The evaluators used a variety of infection control 
performance measures. The exercise was considered successful/passed if the patient was given a 
mask and isolated from other patients and staff members, and unsuccessful whereby waiting time 
exceeded 30 minutes before triage which was deemed as a fail. 
In total ninety-five drills (53 measles and 42 MERS) were conducted in 49 EDs with patients 
masked and isolated in 78% of drills. Median time from entry to masking was 1.5 minutes (range 
= 0–47 minutes) and from entry to isolation was 8.5 minutes (range = 1–57). Overall, 80% patients 
were asked about recent fevers, and 85% were asked about recent travel. In total 88% patients 
were given a mask; 85% patients in the measles scenarios and 93% patients in the MERS 
scenarios. Nineteen (39%) of 49 hospitals failed at least one drill.  
Other infection control practices found that only 36% of staff members performed personal hand 
hygiene. In the 76 (80%) drills that resulted in the patient being isolated, precaution signage was 
posted outside the patient’s airborne isolation room of 53 (70%), and staff members used 
recommended PPE when entering these rooms in 56 (74%) drills. 
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The results clearly show that hospitals varied in their ability to identify potentially infectious 
patients and implement recommended infection control measures in a timely manner. Drill 
findings were used to inform hospital improvement planning to more rapidly and consistently 
identify and isolate patients with a potentially highly infectious disease. Studies evaluating 
hospital emergency plans are important, as waiting areas have been shown to facilitate the 
transmission of infections, to patients and health care workers, leading to spread within hospitals 
and surrounding communities (McDonald, Simor et al. 2004, Adini, Goldberg et al. 2008) 
(Maltezou and Wicker 2013). The findings were used to set a performance goals of 1 minute from 
entry to masking and 10 minutes from entry to isolation. The overall median time from entry to 
isolation achieved in this study (8.5 minutes) was comparable to times achieved in an earlier 
Ebola drill analysis (9 minutes) (Foote, Daver et al. 2017). 
7.5.2 Diagnosis 
Clearly diagnostic testing remains a crucial element of disease monitoring and potential 
containment. This study has successfully shown that recombinant nucleocapsids proteins can be 
used as diagnostic antigens in regard to human coronavirus cases and refers to a variety of ways 
in which they could be commercialised into functional screening kits. Further work could be 
undertaken to see if truncating the N proteins could improve specificity and sensitivity.  
7.5.3 Current situation and concluding remarks 
The emergence of novel pathogens is a global cause for concern. A team at University College 
London has developed a computer-modelling program that uses data about societal impact on the 
environment, including climate and changes in animal habitat, to predict where future zoonotic 
pandemics might emerge (Hassell, Newbold et al. 2021). This approach successfully predicted the 
origins, but not the specific timing, of the Ebola outbreak (Gibb, Redding et al. 2020). As mentioned 
in the prologue the timing of the submission of this thesis coincides with an outbreak of SARS-
CoV-2. Whilst the pandemic was somewhat predictable given the nature of coronaviruses, globally 
the world seemed ill-prepared for disease treatment, diagnosis or containment.  
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Although RT-PCR is the standard method for diagnosing a SARS-CoV-2 infection high false 
negative rates have been reported (Li, Yi et al. 2020) (Guo, Ren et al. 2020). Scientists around the 
world are searching to find a diagnostic kit with a high enough sensitivity and specificity to be of 
use in clinical test to help with disease control. An accurate and rapid test could allow large 
number of infected and asymptomatic carriers to be identified and help prevent virus 
transmission as well as allowing for timely treatment of patients. Whilst figures for SARS-CoV-2 
infections and death seem large (at the time of writing, 17th August 2021, WHO reports Covid-19’s 
case numbers are estimated to be 207,784,507 resulting in 4,370,424 deaths) the fatality rate of 
SARS-CoV-2 remains lower than both that of MERS-CoV and SARS-CoV.  
It remains possible, if not probable, that novel coronaviruses may emerge in future, potentially 
leading to further pandemics. The ability to produce a rapid, sensitive, specific, cost-effective point 
of care test for the current and potential future epidemics and pandemics, whether coronavirus 
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Appendix one: A table showing the percentages of each 
symptom displayed during four SARS cohort studies 
 
SARS Clinical symptoms at presentation (in %) 





et al. 2003) 
n=50 
(A., Ghani et 
al. 2003) 





Fever 100 100 94 99 
Chills or rigors 73 74 65 28 
Cough 57 62 50 69 
Myalgia 61 54 51 49 
Malaise n/a 50 64 31 
Runny nose 23 24 25 2 
Sore throat 23. 20 23 12 
Shortness of breath n/a 20 31 n/a 
Diarrhoea 20 10 27 24 



























Appendix two: BLAST results 
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Appendix three: A table showing potential SARS-CoV-2 
therapeutic agents sourced from (Kaddoura, AlIbrahim et 
al. 2020)  
 
Compound/drug Mechanism of action In vitro studies Randomized clinical 
trials 
   
Ongoing Complete 
Virus targeting agents 
Remdesivir Inhibits RNA-dependent RNA 
polymerase 
Yes 
EC50 = 0.77 - 





Protease inhibitor with a CYP3A4 
inhibitory activity 
Yes 
EC50 = 26.63 μM 
Vero E6 cells 
Yes Yes 
Favipiravir Inhibits RNA-dependent RNA 
polymerase 
No Yes Yes 
Ribavirin Blocks viral RNA synthesis and 
viral mRNA capping 
No Yes Yes 
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Famotidine Histamine-2 (H2) receptor 
antagonist 
3CLpro targeting 
No Yes No 
EIED 2801 Impairs viral replication by 
incorporating into the genome of 
the newly formed virions 
Yes 
EC50 = 0.3 μM 
Vero E6 
Yes No 
Oseltamivir Inhibits neuraminidase enzyme No Yes No 
Sofosbuvir Inhibits RNA-dependent RNA 
polymerase 
No No No 




Azvudine Inhibiting nucleoside reverse-
transcriptase 
No Yes No 
Triazavirin Inhibits RNA synthesis No Yes No 






Azithromycin Stimulates the interferon pathway 
Interferes with virus internalization 
Yes Yes No 
Ivermectin Impairs nuclear import by 
interacting with importin (IMP) 
α/β1 heterodimer 
Yes 





Inhibits fusion-activation of the 
virus through inhibition of the host 
protease (TMPRSS2) 
Yes 
EC50 = 22.50 µM 
Vero E6 cells 
Yes No 
Teicoplanin Suppresses the entry by blocking 
the activity of cathepsin L in the 
late endosome/lysosome 
Yes 
EC50 = 1.66 µM 
Vero E6 cells 
No No 
Nitazoxanide Blocks viral entry and replication 




Vero E6 cells 
Yes No 
Drugs with mixed action 
Umifenovir -Inhibits membrane fusion through 
interacting with the viral 
glycoproteins 
- Elevate endosomal pH 
Yes 
EC50 = 4.11 μM 







-Hinders the auto-immune response 




CQ EC50 = 1.13–
5.74 μM 
HCQ EC50 = 0.72 
μM 




Fingolimod Targets sphingosine-1-phosphate 
(S1P) receptors and alters the 
signaling of the S1P pathway 
No Yes No 
Thymosin α1 Triggers lymphocyte maturation 
Enhances T cell activation 
No Yes No 
Tocilizumab Recombinant anti-human 
interleukin-6 receptor (IL-6R) 
monoclonal antibody 
No Yes No 
Bevacizumab Humanized monoclonal antibody 
against the angiogenic vascular 
endothelial growth factor (VEGF) 
No Yes No 
Colchicine Down-regulates multiple 
inflammatory pathways through 
tubulin disruption 




chemotaxis of neutrophils, 
generation of leukotrienes and 
cytokines, phagocytosis, and the 
(TNF-α)-induced NF-κB pathway 
Methylprednisolone Anti-inflammatory properties at 
high doses 
Not applicable Yes No 
Dexamethasone Anti-inflammatory properties Not applicable Yes Yes 






















Appendix four: Summary of COVID-19 therapeutics that have completed clinical trials, 
sourced from (Kaddoura, AlIbrahim et al. 2020)  
 
Compound Route Dosing regimen Study design Evidence 
type# 
Summary 
Remdesivir Intravenous 200 mg on day 1 followed by 
100 mg on days 2–10 in 




Moderate Aim: To evaluate the safety and efficacy of 
remdesivir in hospitalized adults infected with 
SARS-CoV-2. 
Key findings: No significant difference in 
improvement time. 
Adverse effects: Same as placebo. 
Remdesivir Intravenous 200 mg on the first day 
followed by a 100-mg once 
daily maintenance dose for 





Strong Aim: To evaluate the safety and efficacy of 
remdesivir in hospitalized adults infected with 
SARS-CoV-2. 
Key findings: Patients receiving remdesivir 
recovered faster than those treated with placebo 
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Compound Route Dosing regimen Study design Evidence 
type# 
Summary 
(median recovery time of 11 days and 15 days, 
respectively). The risk of death by 14 days was 
less in the remdesivir group compared with the 
placebo one; 7.1% and 11.9% respectively. 
Adverse effects: Same as placebo. 
Lopinavir/ritonavir oral 400 mg/100 mg twice daily 
for 14 days 
Randomized, controlled, 
open-label trial 
Moderate Aim: To study the efficacy of lopinavir/ritonavir 
in hospitalized adult patients with severe COVID-
19. 
Key findings: No clinical benefit. 
Adverse effects: Greater than placebo primarily 
gastrointestinal side effects. 
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Oral Favipiravir 1,600 mg twice 
daily 1st day then 600 mg 
twice daily for 10 days 
vs. umifenovir 200 mg three 
times daily for 10 days 
Prospective, randomized, 
controlled, open-label. 
Moderate Aim: To evaluate the clinical efficacy and safety of 
favipiravir versus umifenovir as a treatment for 
COVID-19. 
Key findings: No improvement in clinical 
recovery at day 7. Improved the time to relief for 
pyrexia and cough compared to umifenovir. 
Adverse effects: raised serum uric acid was more 
frequently observed in favipiravir group. 
Favipiravir Oral Favipiravir 1,600 mg twice 
daily 1st day then 600 mg 
twice daily for 14 days + 







Weak Aim: To examine the efficacy of favipiravir versus 
lopinavir/ritonavir for the treatment of COVID-
19. 
Key Findings: FPV showed better therapeutic 
responses than LPV/RTV. 
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Compound Route Dosing regimen Study design Evidence 
type# 
Summary 
mg/100 mg twice daily + 5 
mIU of IFN-α twice daily for 
14 days 
Adverse effects: Generally mild but less common 
in the favipiravir treated group. 
Ribavirin Oral 400mg twice daily for 14 
days 
Prospective, randomized, 
controlled, open-label trial 
Moderate Aim: To evaluate the safety and efficacy of IFN-ß-
1b, lopinavir/ritonavir, and ribavirin 
combination. 
Key findings: Recovery was accelerated, viral 
load was suppressed, hospitalization was 
shortened and mortality was reduced after the 
combination of lopinavir/ritonavir, ribavirin, 
and IFN-ß-1b compared with to 
lopinavir/ritonavir alone (control). 
Adverse effects: Same as placebo. 
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Oral Lopinavir 200 mg plus 
ritonavir 500mg twice daily 
for 7–14 days 
vs. 
umifenovir 200 mg three 
times daily for 7–14 days 
Open-label randomized 
controlled trial 
Moderate Aim: To explore the efficacy and safety of 
lopinavir/ritonavir or umifenovir monotherapy 
for the treatment of patients hospitalized with 
mild/moderate COVID-19. 
Key findings: lopinavir/ritonavir or umifenovir 
monotherapy offered minimal added benefit 
compared to standard of care. 
Adverse events: Greater than control with 
diarrhea being most common. 
HCQ/AZM Oral HCQ 200 mg three times 
daily for 10 days 
Azithromycin 500 mg on day 
Open-label non-
randomized clinical trial 
Weak Aim: To investigate the efficacy of HCQ in COVID-
19 patients and the role of adding AZM 
Key findings: Significant reduction in viral load in 
patients receiving HCQ alone. 100% recovery in 
patients receiving a combination of AZM and 
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Compound Route Dosing regimen Study design Evidence 
type# 
Summary 
1 followed by 250 mg daily 
for four consecutive days 
HCQ. 
Adverse effects: Not described. 
HCQ Oral 800 mg as a first dose, 
followed by 600 mg after 6 to 




Strong Aim: To assess HCQ as post-exposure (within 4 
days of exposure) prophylaxis for COVID-19 
Key findings: HCQ did not prevent laboratory 
confirmed infection or COVID-19 like illness 
compared to placebo 
Adverse effects: Greater than placebo but not 
serious 
HCQ Oral 800 mg on the first day, 
followed by 400 mg once 
daily for 6 days 
Multicenter, open label, 
randomized controlled trail 
Moderate Aim: To evaluate the efficacy of early 
administration of HCQ in non-hospitalized adults 
with mild COVID-19 
Key findings: No significant difference in viral 
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Compound Route Dosing regimen Study design Evidence 
type# 
Summary 
load reduction, risk of hospitalization, and 
clinical recovery compared to standard care. 
Adverse effects: Same as placebo 
HCQ Oral 800 mg as a first dose 
followed by 600 mg after 6 to 
8 h, then 600 mg daily for 4 
days 
Randomized, double 
blinded, placebo controlled 
trial 
Strong Aim: To assess the efficacy of HCQ in decreasing 
the disease severity in adult outpatients with 
early, mild COVID-19 
Key findings: No significant decrease in the 
severity of symptoms compared to placebo 
Adverse effects: Greater than placebo- none were 
serious 
Colchicine Oral 1.5-mg loading dose 
followed by 0.5 mg after 60 
min 
Prospective, open-label, 
randomized clinical trial 
Moderate Aim: To evaluate the effect of treatment with 
colchicine on cardiac and inflammatory 
biomarkers and clinical outcomes in COVID-19 
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Compound Route Dosing regimen Study design Evidence 
type# 
Summary 
and maintenance doses of 
0.5 mg twice daily for 3 
weeks 
hospitalized patients 
Key findings: Improved time to clinical 
deterioration. 
Adverse effects: Similar to the control group 
except for diarrhea being more frequent with 
colchicine. 
Dexamethasone Oral or 
intravenous 
6 mg once daily for 10 days Randomized, controlled, 
open-label, adaptive, 
platform trial 
Moderate Aim: To evaluate dexamethasone in hospitalized 
COVID-19 patients. 
Key findings: Dexamethasone reduced mortality 
among those receiving invasive mechanical 
ventilation or oxygen but not among milder 
cases. 
Adverse effects: Not described. 
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Compound Route Dosing regimen Study design Evidence 
type# 
Summary 
Convalescent Plasma Intravenous 200 – 500 mL Non-randomized Weak Aim: To investigate the safety of convalescent 
plasma treatment in hospitalized COVID-19 
patients 
Key findings: Transfusion of convalescent plasma 
is safe. 
Adverse effects: Frequency of <1% of all 
transfusions. Include transfusion-associated 
circulatory overload (TACO), transfusion-related 
acute lung injury (TRALI), severe allergic 
transfusion reaction, and death. 
Convalescent Plasma Intravenous 4 to 13 ml/kg Open-label, multicenter, 
randomized clinical trial 
Moderate Aim: To evaluate the efficacy and adverse effects 
of convalescent plasma therapy for patients with 
COVID-19. 
Key findings: No statistically significant 
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Compound Route Dosing regimen Study design Evidence 
type# 
Summary 
difference in clinical improvement within 28 
days. Negative viral PCR conversion rate was 
significantly higher in the convalescent plasma 
group. 
Adverse effects: Reported in two patients. 
Included chills and rashes in one patient and 
shortness of breath, cyanosis, and severe 
dyspnea within 6 h of transfusion in another one. 
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Appendix five: Mass spectrometry results 
 
MALDI mass fingerprint of tryptic digest on Micromass MALDImicroMX. Raw data, centred spectrum, externally calibrated 
Spectrum then lockmass-calibrated, de-isotoped and the resulting 




CHCA matrix 120pwr, 2080pv 
external calibration 
int lockmass calib to 2211.104 tryptic peptide 
03-Jul-2015 






T T = trypsin peptides 
2.51e4 


































Clear high level of keratin signals on this band 
 



























































































































MALDI mass fingerprint of tryptic digest on Micromass MALDImicroMX. Raw data, centred spectrum, externally calibrated 
Spectrum then lockmass-calibrated, de-isotoped and the resulting 




CHCA matrix 120pwr, 2080pv 
external calibration 
int lockmass calib to 2211.104 tryptic peptide 
03-Jul-2015 





















Note: IBV is clearly a closely-spaced, overlapping doublet. 













































































































































MALDI mass fingerprint of tryptic digest on Micromass MALDImicroMX. Raw data, centred spectrum, externally calibrated 
Spectrum then lockmass-calibrated, de-isotoped and the resulting 




CHCA matrix 120pwr, 2080pv 
external calibration 
int lockmass calib to 2211.104 tryptic peptide 
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T = trypsin peptides 
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No further matches found 
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IBVlower - relative signals 
 
 
 
 
 
